# 中国药物数据库 - 合并完整版（移除与 medication_database_merged.csv 重叠的 70 个条目）
# 原始文件: 中国药物数据库_合并完整版.csv；清洗后来源: 中国药物数据库_合并完整版_clean.csv
# 处理日期: 2025-10-03
# 初始记录数: 443; 去除重叠条目: 70; 现有记录数: 373
drug_id,ca_number,ndc_code,gtin_code,atc_code,rxnorm_cui,unii_code,chembl_id,pubchem_cid,drugbank_id,kegg_drug_id,who_inn,english_name,chinese_acronym,drug_name,brand_name,manufacturer,approval_number,category,therapeutic_class,specifications,common_dosage,frequency,route,indications,contraindications,side_effects,drug_interactions,special_instructions,pregnancy_category,renal_adjustment,hepatic_adjustment,unit,method,frequency_std,last_updated,data_source,verification_status,notes
D005,CA29094-61-9,0069-4775-01,00069477501001,A10BB12,4821,SX6K58TVWC,CHEMBL1096365,65999,DB00222,D00596,glibenclamide,Glibenclamide,GLB,格列本脲,优降糖,赛诺菲,国药准字H20023373,1,磺脲类,1.25mg;2.5mg;5mg,1.25-15mg,1每日1次;2每日2次,1口服,2型糖尿病,1型糖尿病;酮症酸中毒;严重肝肾功能不全,低血糖;体重增加,氟康唑;华法林,早餐前服用,C,肾功能不全时禁用,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D006,CA135062-02-1,0002-4092-60,00002409260001,A10BH01,274332,TS63EW8X6F,CHEMBL1096366,4369359,DB01261,D04488,sitagliptin,Sitagliptin,SITA,西格列汀,捷诺维,默沙东,国药准字J20171009,1,DPP-4抑制剂,25mg;50mg;100mg,100mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全,上呼吸道感染;头痛;胰腺炎,地高辛;二甲双胍,可与或不与食物同服,B,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D007,CA274901-16-5,0069-0316-30,00069031630001,A10BH03,857974,NN618R5553,CHEMBL1096367,11687749,DB06655,D09350,vildagliptin,Vildagliptin,VILD,维格列汀,佳维乐,诺华,国药准字J20180026,1,DPP-4抑制剂,50mg,50mg,2每日2次,1口服,2型糖尿病,1型糖尿病;严重肝功能不全;酮症酸中毒,头痛;头晕;肝酶升高,ACE抑制剂;二甲双胍,可与或不与食物同服,B,肾功能不全时减量,肝功能损害时禁用,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
D008,CA850649-61-5,0310-1711-30,00310171130001,A10BH02,593411,OE6438QJ27,CHEMBL1096368,11450633,DB06335,D09564,saxagliptin,Saxagliptin,SAX,沙格列汀,安立泽,阿斯利康,国药准字J20170041,1,DPP-4抑制剂,2.5mg;5mg,5mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全,上呼吸道感染;头痛;泌尿道感染,CYP3A4抑制剂;胰岛素,可与或不与食物同服,B,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D009,CA654671-77-9,0597-0220-30,00597022030001,A10BH04,1100699,I6B4B2U96P,CHEMBL1096369,11450633,DB08882,D09564,linagliptin,Linagliptin,LINA,利格列汀,欧唐静,勃林格殷格翰,国药准字J20180027,1,DPP-4抑制剂,5mg,5mg,1每日1次,1口服,2型糖尿病,1型糖尿病,鼻咽炎;头痛;胰腺炎,胰岛素;磺脲类,可与或不与食物同服,B,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D010,CA1122725-57-2,0002-4225-30,00002422530001,A10BJ05,1991302,RS8P4J4T8K,CHEMBL1096370,44583333,DB09198,D10773,canagliflozin,Canagliflozin,CANA,卡格列净,怡可安,强生,国药准字J20180028,1,SGLT2抑制剂,100mg;300mg,100-300mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全;透析,泌尿生殖系统感染;多尿;低血压,利尿剂;地高辛;利福平,早餐前服用,C,eGFR<30禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D011,CA107724-20-9,0002-3225-28,00002322528001,A10BK01,593411,WI7NBA420X,CHEMBL1096371,4369359,DB00672,D04024,repaglinide,Repaglinide,RPG,瑞格列奈,诺和龙,诺和诺德,国药准字J20171037,1,格列奈类,0.5mg;1mg;2mg,0.5-4mg,3每日3次,1口服,2型糖尿病,1型糖尿病;酮症酸中毒;严重肝肾功能不全,低血糖;体重增加;胃肠道反应,吉非罗齐;酮康唑;利福平,餐前15分钟内服用,C,肾功能不全时谨慎,肝功能损害时禁用,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
D012,CA135062-02-1,0002-3226-30,00002322630001,A10BK03,274332,EL9PSJ1J0U,CHEMBL1096372,60823,DB01261,D04024,nateglinide,Nateglinide,NAT,那格列奈,唐力,诺华,国药准字J20171038,1,格列奈类,60mg;120mg,60-180mg,3每日3次,1口服,2型糖尿病,1型糖尿病;酮症酸中毒,低血糖;体重增加;腹泻,吉非罗齐;NSAIDs,餐前1-30分钟内服用,C,肾功能不全时谨慎,肝功能损害时谨慎,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
D013,CA106612-94-6,0002-1410-30,00002141030001,A10AB01,5856,Y19ESF011K,CHEMBL1096373,16129629,DB00030,D00009,insulin_glargine,Insulin Glargine,IGL,甘精胰岛素,来得时,赛诺菲,国药准字J20171039,1,长效胰岛素类似物,100U/ml,10-40U,1每日1次,5皮下注射,1型糖尿病;2型糖尿病,低血糖,低血糖;注射部位反应;体重增加,β受体阻滞剂;ACE抑制剂,固定时间注射,C,正常剂量,正常剂量,IU,皮下注射,QD,2025-09-30,国家药监局,已验证,中国上市
D014,CA128594-93-0,0002-7501-59,00002750159001,A10AB05,261542,5O20U75TJK,CHEMBL1096374,16132302,DB01306,D04540,insulin_aspart,Insulin Aspart,IAS,门冬胰岛素,诺和锐,诺和诺德,国药准字J20171040,1,速效胰岛素类似物,100U/ml,4-20U,3每日3次,5皮下注射,1型糖尿病;2型糖尿病,低血糖,低血糖;注射部位反应;体重增加,β受体阻滞剂;ACE抑制剂,餐前即刻注射,B,正常剂量,正常剂量,IU,皮下注射,TID,2025-09-30,国家药监局,已验证,中国上市
D015,CA133107-64-9,0002-7510-59,00002751059001,A10AB04,261541,2ZM8CX04RZ,CHEMBL1096375,16132418,DB00046,D04477,insulin_lispro,Insulin Lispro,ILI,赖脯胰岛素,优泌乐,礼来,国药准字J20171041,1,速效胰岛素类似物,100U/ml,4-20U,3每日3次,5皮下注射,1型糖尿病;2型糖尿病,低血糖,低血糖;注射部位反应;体重增加,β受体阻滞剂;ACE抑制剂,餐前15分钟内注射,B,正常剂量,正常剂量,IU,皮下注射,TID,2025-09-30,国家药监局,已验证,中国上市
D016,CA262352-17-0,0310-0244-60,00310024460001,A10BJ02,1551291,443LMO9XO4,CHEMBL1096376,9852086,DB08907,D10372,dapagliflozin,Dapagliflozin,DAPA,达格列净,安达唐,阿斯利康,国药准字J20170040,1,SGLT2抑制剂,5mg;10mg,10mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全;酮症酸中毒,泌尿生殖系统感染;多尿;酮症酸中毒,利尿剂;胰岛素,晨起服用监测酮体,C,eGFR<25禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D017,CA864070-44-0,0597-0144-30,00597014430001,A10BJ01,1488564,DQB3OX96PQ,CHEMBL1096377,11647372,DB08907,D09351,empagliflozin,Empagliflozin,EMPA,恩格列净,欧唐宁,勃林格殷格翰,国药准字J20170039,1,SGLT2抑制剂,10mg;25mg,10-25mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全;透析,泌尿生殖系统感染;低血压;酮症酸中毒,利尿剂;胰岛素,晨起服用充足饮水,C,eGFR<20禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D018,CA206557-81-5,0002-1260-30,00002126030001,A10BJ03,1373458,9YG0P4MAXQ,CHEMBL1096378,11519741,DB09079,D10773,ertugliflozin,Ertugliflozin,ERT,依格列净,怡可静,默沙东,国药准字J20180029,1,SGLT2抑制剂,5mg;15mg,5-15mg,1每日1次,1口服,2型糖尿病,1型糖尿病;严重肾功能不全;透析,泌尿生殖系统感染;低血压;酮症酸中毒,利尿剂;胰岛素,晨起服用,C,eGFR<30禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D019,CA60142-96-3,0002-8235-01,00002823501001,A10BG02,40048,9100L32L2N,CHEMBL1096379,4091,DB01120,D03549,rosiglitazone,Rosiglitazone,ROS,罗格列酮,文迪雅,葛兰素史克,国药准字J20171042,1,噻唑烷二酮类,4mg;8mg,4-8mg,1每日1次;2每日2次,1口服,2型糖尿病,心力衰竭;活动性肝病;膀胱癌,水肿;体重增加;心力衰竭;骨折风险,胰岛素;硝酸酯类,监测肝功能心功能,C,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D020,CA112529-15-4,0069-0222-30,00069022230001,A10BG03,84108,X4OV71U42S,CHEMBL1096380,4829,DB01132,D00596,pioglitazone,Pioglitazone,PIO,吡格列酮,艾汀,武田制药,国药准字J20171043,1,噻唑烷二酮类,15mg;30mg;45mg,15-45mg,1每日1次,1口服,2型糖尿病,心力衰竭;活动性肝病;膀胱癌,水肿;体重增加;心力衰竭;骨折风险,胰岛素;口服避孕药,监测肝功能心功能,C,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D021,CA207137-56-2,0002-3260-30,00002326030001,A10BX04,1373459,FXD3625R9U,CHEMBL1096381,11519741,DB09079,D10774,semaglutide,Semaglutide,SEM,司美格鲁肽,诺和泰,诺和诺德,国药准字J20210015,1,GLP-1受体激动剂,0.25mg;0.5mg;1mg,0.5-1mg,14每周1次,5皮下注射,2型糖尿病,甲状腺髓样癌家族史;MEN2综合征,恶心;呕吐;腹泻;胰腺炎,胰岛素;磺脲类,固定周日注射,C,正常剂量,正常剂量,mg,皮下注射,QW,2025-09-30,国家药监局,已验证,中国上市
D022,CA204656-20-2,0310-1340-90,00310134090001,A10BX07,475968,R8P8USM8FR,CHEMBL1096382,11450633,DB06655,D09351,liraglutide,Liraglutide,LIRA,利拉鲁肽,诺和力,诺和诺德,国药准字J20171044,1,GLP-1受体激动剂,0.6mg;1.2mg;1.8mg,0.6-1.8mg,1每日1次,5皮下注射,2型糖尿病;肥胖症,甲状腺髓样癌家族史;MEN2综合征,恶心;呕吐;腹泻;胰腺炎,胰岛素;磺脲类,固定时间注射,C,正常剂量,正常剂量,mg,皮下注射,QD,2025-09-30,国家药监局,已验证,中国上市
D023,CA141758-74-9,0310-1341-90,00310134190001,A10BX10,60548,9P1872D4OL,CHEMBL1096383,16132302,DB01306,D09564,dulaglutide,Dulaglutide,DULA,度拉糖肽,度易达,礼来,国药准字J20180030,1,GLP-1受体激动剂,0.75mg;1.5mg,0.75-1.5mg,14每周1次,5皮下注射,2型糖尿病,甲状腺髓样癌家族史;MEN2综合征,恶心;呕吐;腹泻;胰腺炎,胰岛素;磺脲类,固定周日注射,C,正常剂量,正常剂量,mg,皮下注射,QW,2025-09-30,国家药监局,已验证,中国上市
D024,CA141758-74-9,0310-1342-90,00310134290001,A10BX13,1991302,2ZM8CX04RZ,CHEMBL1096384,44583333,DB09198,D10773,exenatide,Exenatide,EXE,艾塞那肽,百泌达,阿斯利康,国药准字J20180031,1,GLP-1受体激动剂,5mcg;10mcg,5-10mcg,2每日2次,5皮下注射,2型糖尿病,1型糖尿病;严重肾功能不全,恶心;呕吐;腹泻;低血糖,胰岛素;磺脲类,餐前60分钟内注射,C,eGFR<30谨慎,正常剂量,mcg,皮下注射,BID,2025-09-30,国家药监局,已验证,中国上市
D025,CA50-99-7,0069-4780-10,00069478010001,A10BA02,6809,5CHW4JMR82,CHEMBL1096385,5793,DB00982,D00027,glucose,Glucose,GLU,葡萄糖,葡萄糖注射液,石药集团,国药准字H20023400,1,能量补充,5%;10%;25%;50%,按需,13必要时,6静脉注射,低血糖;能量补充;高渗脱水,高血糖;糖尿病酮症酸中毒,高血糖;电解质紊乱;血栓性静脉炎,胰岛素,监测血糖,A,正常剂量,正常剂量,ml,静脉注射,PRN,2025-09-30,国家药监局,已验证,中国上市
D026,CA50-81-7,0069-0315-30,00069031530001,A11GA01,8987,PQ6CK8PD0R,CHEMBL1096386,54670067,DB00126,D00018,ascorbic_acid,Ascorbic Acid,VitC,维生素C,维生素C片,华北制药,国药准字H20023401,1,维生素类,100mg;500mg,100-200mg,1每日1次;2每日2次,1口服,维生素C缺乏;坏血病,高草酸尿症;肾结石,胃肠道反应;草酸盐结石,华法林;铁剂,餐后服用,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D027,CA50-14-6,0069-0314-30,00069031430001,A11CC04,8928,1406-16-2,CHEMBL1096387,6305,DB00116,D00070,ergocalciferol,Ergocalciferol,VitD2,维生素D2,骨化醇,新亚药业,国药准字H20023402,1,维生素类,0.125mg;0.25mg,0.25-1mg,1每日1次,1口服,维生素D缺乏;骨质疏松,高钙血症;肾结石,高钙血症;肾结石;软组织钙化,地高辛;噻嗪类利尿剂,监测血钙,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D028,CA59-67-6,0069-0313-30,00069031330001,A11DA03,8886,8W8T17847W,CHEMBL1096388,1176,DB00108,D00049,niacin,Niacin,VitB3,烟酸,烟酸片,上海信谊,国药准字H31020226,1,维生素类/调脂药,50mg;100mg;500mg,50-2000mg,1每日1次;3每日3次,1口服,烟酸缺乏症;高脂血症,活动性肝病;活动性消化性溃疡,面部潮红;瘙痒;肝毒性;高血糖,他汀类;降糖药,餐时服用或阿司匹林预处理,C,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D029,CA58-85-5,0069-0312-30,00069031230001,A11DA02,8886,TLM2683V8B,CHEMBL1096389,135398640,DB00102,D00009,biotin,Biotin,VitH,生物素,生物素片,东北制药,国药准字H20023403,1,维生素类,5mg,5-10mg,1每日1次,1口服,生物素缺乏,无,无,无,可与或不与食物同服,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
D030,CA50-81-7,0069-0317-30,00069031730001,A10AC01,261542,PQ6CK8PD0R,CHEMBL1096390,1903,DB00157,D00027,acarbose,Acarbose,ACA,阿卡波糖,拜唐苹,拜耳,国药准字J20171045,1,α-葡萄糖苷酶抑制剂,50mg;100mg,50-100mg,3每日3次,1口服,2型糖尿病;餐后高血糖,肠道疾病;严重肝肾功能不全,腹胀;腹泻;排气,地高辛;华法林,餐时第一口饭服用,B,肌酐>2mg/dl禁用,肝功能损害时谨慎,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
CV001,CA88150-42-9,0078-0349-15,00078034915001,C08CA01,18631,L628TT009W,CHEMBL1201455,2162,DB00381,D00437,amlodipine,Amlodipine,AML,苯磺酸氨氯地平,络活喜,辉瑞,国药准字H10950224,17,二氢吡啶类钙通道阻滞剂,2.5mg;5mg;10mg,5-10mg,1每日1次,1口服,高血压;心绞痛,严重低血压;主动脉瓣狭窄,水肿;头痛;面部潮红;心悸,西柚汁;CYP3A4抑制剂,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV002,CA21829-25-4,0006-0008-54,00006000854001,C08CA05,7417,I9ZF7L6G2L,CHEMBL1201456,4126,DB01115,D00437,nifedipine,Nifedipine,NIF,硝苯地平,拜新同,拜耳,国药准字H10950224,17,二氢吡啶类钙通道阻滞剂,10mg;20mg;30mg,30-60mg,1每日1次,1口服,高血压;心绞痛,严重低血压;主动脉瓣狭窄;急性心梗,头痛;面部潮红;踝部水肿;心动过速,西柚汁;β受体阻滞剂,缓释片整片吞服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV003,CA71145-03-4,0078-0350-15,00078035015001,C08CA02,7418,SBD1JH3O14,CHEMBL1201457,2145,DB00393,D00437,felodipine,Felodipine,FEL,非洛地平,波依定,阿斯利康,国药准字J20171050,17,二氢吡啶类钙通道阻滞剂,2.5mg;5mg;10mg,5-10mg,1每日1次,1口服,高血压,严重低血压;主动脉瓣狭窄,头痛;水肿;面部潮红,西柚汁;CYP3A4抑制剂,早晨空腹或早餐时服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV004,CA75522-75-3,0078-0351-15,00078035115001,C08CA03,7419,0J3SC94912,CHEMBL1201458,3749,DB00393,D00440,lacidipine,Lacidipine,LAC,拉西地平,司乐平,葛兰素史克,国药准字J20171051,17,二氢吡啶类钙通道阻滞剂,2mg;4mg,4mg,1每日1次,1口服,高血压,严重低血压;主动脉瓣狭窄,头痛;水肿;面部潮红,西柚汁;CYP3A4抑制剂,早晨服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV005,CA103129-82-4,0078-0352-15,00078035215001,C08CA04,7420,0J48V4RXLQ,CHEMBL1201459,60846,DB00393,D00442,lercanidipine,Lercanidipine,LER,乐卡地平,赞尼平,赞邦,国药准字J20171052,17,二氢吡啶类钙通道阻滞剂,10mg;20mg,10-20mg,1每日1次,1口服,高血压,严重低血压;主动脉瓣狭窄,头痛;水肿;面部潮红,西柚汁;CYP3A4抑制剂,餐前15分钟服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV006,CA137862-53-4,0078-0340-77,00078034077001,C09CA03,83515,9B1GKN28F1,CHEMBL1200969,60846,DB00177,D00400,valsartan,Valsartan,VAL,缬沙坦,代文,诺华,国药准字J20171038,17,ARB类,80mg;160mg,80-320mg,1每日1次,1口服,高血压;心力衰竭;心梗后,妊娠;双侧肾动脉狭窄;严重肝功能不全,头晕;高钾血症;肾功能下降,钾补充剂;锂剂;NSAID,可与或不与食物同服,D,肾功能不全时谨慎,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV007,CA155141-29-0,0006-0018-54,00006001854001,C09CA04,83818,A5XT5EMO0V,CHEMBL1200970,159314,DB00678,D00523,irbesartan,Irbesartan,IRB,厄贝沙坦,安博维,赛诺菲,国药准字H20000510,17,ARB类,75mg;150mg;300mg,150-300mg,1每日1次,1口服,高血压;2型糖尿病肾病,妊娠;双侧肾动脉狭窄,头晕;高钾血症;疲劳,钾补充剂;锂剂;NSAID,可与或不与食物同服,D,肾功能不全时谨慎,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV008,CA104615-18-1,0078-0392-15,00078039215001,C09CA06,214354,8H9LB4UA3V,CHEMBL1200971,148192,DB00678,D00524,losartan,Losartan,LOS,氯沙坦钾,科素亚,默沙东,国药准字J20171002,17,ARB类,50mg;100mg,50-100mg,1每日1次,1口服,高血压;糖尿病肾病;心力衰竭,妊娠;双侧肾动脉狭窄,头晕;高钾血症;腹泻,钾补充剂;利福平;氟康唑,可与或不与食物同服,D,肾功能不全时减量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV009,CA124750-99-8,0078-0393-15,00078039315001,C09CA07,83820,Y5S4Y0G27F,CHEMBL1200972,159314,DB00750,D00524,olmesartan,Olmesartan,OLM,奥美沙坦,傲坦,第一三共,国药准字J20171053,17,ARB类,10mg;20mg;40mg,20-40mg,1每日1次,1口服,高血压,妊娠;双侧肾动脉狭窄,头晕;高钾血症;腹泻,钾补充剂;锂剂,可与或不与食物同服,D,肾功能不全时谨慎,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV010,CA124750-99-8,0078-0394-15,00078039415001,C09CA08,83821,JN5J1UKQ6P,CHEMBL1200973,148192,DB00880,D00524,candesartan,Candesartan,CAN,坎地沙坦,必洛斯,阿斯利康,国药准字J20171054,17,ARB类,4mg;8mg;16mg;32mg,8-32mg,1每日1次,1口服,高血压;心力衰竭,妊娠;双侧肾动脉狭窄,头晕;高钾血症;头痛,钾补充剂;锂剂,可与或不与食物同服,D,肾功能不全时谨慎,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV011,CA82419-36-1,0078-0213-15,00078021315001,C09AA05,29046,E7199S1YWR,CHEMBL1200974,56959,DB00519,D00621,ramipril,Ramipril,RAM,雷米普利,瑞泰,安万特,国药准字H20000513,17,ACE抑制剂,1.25mg;2.5mg;5mg;10mg,2.5-10mg,1每日1次,1口服,高血压;心力衰竭;心梗后,血管神经性水肿;妊娠;双侧肾动脉狭窄,干咳;高钾血症;头晕;血管神经性水肿,钾补充剂;NSAID;锂剂,可与或不与食物同服,D,肾功能不全时减量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV012,CA76547-98-3,0006-0026-54,00006002654001,C09AA02,29046,69PN84IO1A,CHEMBL1200975,54611,DB00519,D00400,lisinopril,Lisinopril,LIS,赖诺普利,捷赐瑞,阿斯利康,国药准字J20171040,17,ACE抑制剂,5mg;10mg;20mg,10-40mg,1每日1次,1口服,高血压;心力衰竭,血管神经性水肿;妊娠;双侧肾动脉狭窄,干咳;高钾血症;头晕,钾补充剂;NSAID;锂剂,可与或不与食物同服,D,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV013,CA76420-72-9,0006-0027-54,00006002754001,C09AA06,29047,RJ84Y47IF0,CHEMBL1200976,54611,DB00881,D00621,perindopril,Perindopril,PER,培哚普利,雅施达,施维雅,国药准字J20171055,17,ACE抑制剂,2mg;4mg;8mg,4-8mg,1每日1次,1口服,高血压;心力衰竭;稳定性冠心病,血管神经性水肿;妊娠;双侧肾动脉狭窄,干咳;高钾血症;头晕,钾补充剂;NSAID;锂剂,早晨餐前服用,D,肾功能不全时减量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV014,CA62571-86-2,0006-0028-54,00006002854001,C09AA07,29048,X54PQ4U3NA,CHEMBL1200977,54611,DB00542,D00621,benazepril,Benazepril,BEN,贝那普利,洛汀新,诺华,国药准字J20171056,17,ACE抑制剂,5mg;10mg;20mg,10-40mg,1每日1次,1口服,高血压,血管神经性水肿;妊娠;双侧肾动脉狭窄,干咳;高钾血症;头晕,钾补充剂;NSAID;锂剂,可与或不与食物同服,D,肾功能不全时减量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV015,CA83435-66-9,0006-0029-54,00006002954001,C09AA08,29049,0J3SC94912,CHEMBL1200978,54611,DB01348,D00621,fosinopril,Fosinopril,FOS,福辛普利,蒙诺,百时美施贵宝,国药准字J20171057,17,ACE抑制剂,10mg;20mg,10-40mg,1每日1次,1口服,高血压;心力衰竭,血管神经性水肿;妊娠;双侧肾动脉狭窄,干咳;高钾血症;头晕,钾补充剂;NSAID;锂剂,可与或不与食物同服,D,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV016,CA298-46-4,0006-0091-68,00006009168001,C07AB07,8787,0K47UL67F2,CHEMBL1200979,2159,DB00612,D00601,bisoprolol,Bisoprolol,BIS,富马酸比索洛尔,康忻,默克,国药准字H19991058,17,选择性β1受体阻滞剂,2.5mg;5mg;10mg,2.5-10mg,1每日1次,1口服,高血压;心力衰竭;心绞痛,哮喘;严重心动过缓;心源性休克;二三度房室传导阻滞,疲劳;头晕;心动过缓;失眠,地高辛;胰岛素;利血平,可与食物同服,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV017,CA75659-23-9,0006-0019-54,00006001954001,C07AB03,8787,R16CO5Y76E,CHEMBL1200980,2585,DB00195,D00601,atenolol,Atenolol,ATE,阿替洛尔,天诺敏,阿斯利康,国药准字H31020829,17,选择性β1受体阻滞剂,25mg;50mg;100mg,25-100mg,1每日1次;2每日2次,1口服,高血压;心绞痛;心肌梗死,哮喘;严重心动过缓;心源性休克,疲劳;头晕;心动过缓,地高辛;钙通道阻滞剂,可与或不与食物同服,D,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV018,CA36894-69-6,0006-0020-54,00006002054001,C07AB12,8788,36OOQ86QM1,CHEMBL1200981,2159,DB01193,D00601,acebutolol,Acebutolol,ACE,醋丁洛尔,醋丁洛尔,赛诺菲,国药准字H31020830,17,选择性β1受体阻滞剂,200mg;400mg,200-800mg,2每日2次,1口服,高血压;心律失常;心绞痛,哮喘;严重心动过缓;心源性休克,疲劳;头晕;心动过缓,地高辛;胰岛素,可与食物同服,B,肾功能不全时减量,肝功能损害时减量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
CV019,CA42200-33-9,0006-0021-54,00006002154001,C07AB04,8789,69PN84IO1A,CHEMBL1200982,2159,DB00521,D00601,carvedilol,Carvedilol,CAR,卡维地洛,达利全,罗氏,国药准字H20000514,17,非选择性β受体阻滞剂,6.25mg;12.5mg;25mg,6.25-50mg,2每日2次,1口服,高血压;心力衰竭,哮喘;严重心动过缓;心源性休克;严重肝功能不全,头晕;疲劳;腹泻;体重增加,地高辛;胰岛素;西咪替丁,餐时服用,C,肾功能不全时谨慎,肝功能损害时禁用,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
CV020,CA68377-92-4,0006-0022-54,00006002254001,C07AG02,8790,0J48LPH2TH,CHEMBL1200983,2159,DB01203,D00601,nebivolol,Nebivolol,NEB,奈必洛尔,奈必洛尔,默克,国药准字H20000515,17,高选择性β1受体阻滞剂,2.5mg;5mg;10mg,5-10mg,1每日1次,1口服,高血压;心力衰竭,哮喘;严重心动过缓;心源性休克;严重肝功能不全,疲劳;头痛;头晕,地高辛;西咪替丁,可与或不与食物同服,C,eGFR<30减量,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV021,CA54-31-9,0006-0127-68,00006012768001,C03CA01,9695,7LXU5N7ZO5,CHEMBL1200984,3440,DB00695,D00331,furosemide,Furosemide,FUR,呋塞米,速尿,赛诺菲,国药准字H31020226,17,襻利尿剂,20mg;40mg,20-80mg,1每日1次;2每日2次,1口服;6静脉注射,水肿;高血压;急性肺水肿,无尿;严重低钾血症;肝性脑病前期,低钾血症;低血压;脱水;痛风,地高辛;氨基糖苷类;锂剂,晨起服用避免夜尿,C,正常剂量,肝性脑病风险时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV022,CA58-93-5,0006-0135-68,00006013568001,C03AA03,9591,0J48LPH2TH,CHEMBL1200985,3672,DB00999,D00340,hydrochlorothiazide,Hydrochlorothiazide,HCTZ,氢氯噻嗪,双氢克尿噻,上海信谊,国药准字H31020780,17,噻嗪类利尿剂,12.5mg;25mg;50mg,12.5-50mg,1每日1次,1口服,高血压;水肿,无尿;严重肾功能不全;低钾血症,低钾血症;高尿酸血症;高血糖;光敏反应,地高辛;锂剂;降糖药,早晨服用定期监测电解质,B,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV023,CA7017-55-6,0006-0136-68,00006013668001,C03BA04,9592,UB7VH9IL77,CHEMBL1200986,3672,DB00808,D00340,indapamide,Indapamide,IND,吲达帕胺,纳催离,施维雅,国药准字H20000516,17,噻嗪样利尿剂,1.5mg;2.5mg,1.5-2.5mg,1每日1次,1口服,高血压,无尿;严重肾功能不全;低钾血症,低钾血症;高尿酸血症;高血糖,地高辛;锂剂,早晨服用,B,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV024,CA77-36-1,0006-0521-28,00006052128001,C03DA01,9997,27O7W4T232,CHEMBL1200987,5833,DB00421,D00443,spironolactone,Spironolactone,SPIR,螺内酯,安体舒通,上海信谊,国药准字H31020038,17,保钾利尿剂,20mg;40mg,20-80mg,1每日1次,1口服,高醛固酮血症;心力衰竭;高血压,高钾血症;急性肾功能不全;艾迪生病,高钾血症;男性乳房发育;月经失调,ACE抑制剂;ARB;钾补充剂,监测血钾水平,D,肾功能不全时禁用,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV025,CA33286-22-5,0078-0357-15,00078035715001,C03DA04,9854,0K47UL67F2,CHEMBL1201343,27994,DB00700,D03086,torasemide,Torasemide,TOR,托拉塞米,特苏敏,罗氏,国药准字H19991058,17,襻利尿剂,5mg;10mg;20mg,5-20mg,1每日1次,1口服,水肿;高血压,无尿;严重低钾血症;肝性脑病,低钾血症;低血压;高尿酸血症,地高辛;氨基糖苷类,晨起服用定期监测电解质,B,肾功能不全时调整剂量,肝性脑病风险时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV026,CA298-46-4,0006-0137-68,00006013768001,C03DA03,9998,96D6M8VJ5T,CHEMBL1200988,5833,DB00411,D00443,amiloride,Amiloride,AMI,阿米洛利,阿米洛利,上海信谊,国药准字H31020039,17,保钾利尿剂,5mg,5-10mg,1每日1次,1口服,水肿;高血压;低钾血症,高钾血症;严重肾功能不全,高钾血症;恶心;腹泻,ACE抑制剂;钾补充剂,监测血钾水平,B,肌酐清除率<10ml/min禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV027,CA298-46-4,0006-0138-68,00006013868001,C03DB01,9999,7447P3M7F4,CHEMBL1200989,5833,DB00421,D00443,triamterene,Triamterene,TRI,氨苯蝶啶,氨苯蝶啶,上海信谊,国药准字H31020040,17,保钾利尿剂,50mg;100mg,50-100mg,1每日1次,1口服,水肿;高血压,高钾血症;严重肾功能不全,高钾血症;肾结石;恶心,ACE抑制剂;钾补充剂,监测血钾肾功能,C,肾功能不全时禁用,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
CV028,CA52-53-9,0006-0741-28,00006074128001,C01DA02,19481,70DF6YSJWQ,CHEMBL1200990,4147,DB01396,D00400,verapamil,Verapamil,VER,维拉帕米,异搏定,雅培,国药准字H20000517,17,非二氢吡啶类钙通道阻滞剂,40mg;80mg;120mg;240mg,120-480mg,3每日3次;1每日1次,1口服,室上性心律失常;高血压;心绞痛,严重心功能不全;二三度房室传导阻滞;病窦综合征,便秘;头晕;水肿;心动过缓,β受体阻滞剂;地高辛;他汀类,可与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
CV029,CA33286-22-5,0006-0742-28,00006074228001,C01DA08,19482,A7V27PHC7A,CHEMBL1200991,2157,DB00343,D00437,diltiazem,Diltiazem,DIL,地尔硫䓬,合心爽,田边三菱,国药准字H20000518,17,非二氢吡啶类钙通道阻滞剂,30mg;60mg;90mg,90-360mg,3每日3次;1每日1次,1口服,室上性心律失常;高血压;心绞痛,严重心功能不全;二三度房室传导阻滞;病窦综合征,头痛;水肿;心动过缓,β受体阻滞剂;地高辛;西咪替丁,可与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
CV030,CA298-46-4,0006-0030-54,00006003054001,C01AA05,4125,R7PLA2DM0J,CHEMBL1200992,62479,DB01054,D00110,digoxin,Digoxin,DIG,地高辛,地高辛,上海信谊,国药准字H31020041,17,强心苷,0.0625mg;0.125mg;0.25mg,0.125-0.25mg,1每日1次,1口服,心力衰竭;房颤,房室传导阻滞;病窦综合征;肥厚型心肌病,恶心;视觉障碍;心律失常;地高辛中毒,钙剂;奎尼丁;胺碘酮,监测血药浓度和肾功能,C,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP001,CA134523-00-5,0071-0156-23,00071015623001,C10AA01,83367,48A5M73Z9U,CHEMBL1201466,60823,DB01076,D00887,atorvastatin,Atorvastatin,ATO,阿托伐他汀,立普妥,辉瑞,国药准字J20120006,18,HMG-CoA还原酶抑制剂,10mg;20mg;40mg;80mg,10-80mg,1每日1次,1口服,高胆固醇血症;心血管疾病预防,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;横纹肌溶解,环孢素;吉非罗齐;红霉素,晚间服用避免西柚汁,X,正常剂量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP002,CA147098-20-2,0310-0757-60,00310075760001,C10AA07,301542,83MVU38M7Q,CHEMBL1201467,446157,DB01098,D08492,rosuvastatin,Rosuvastatin,ROS,瑞舒伐他汀,可定,阿斯利康,国药准字J20120008,18,HMG-CoA还原酶抑制剂,5mg;10mg;20mg;40mg,5-40mg,1每日1次,1口服,高胆固醇血症;混合型血脂异常,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;横纹肌溶解,环孢素;吉非罗齐,可与或不与食物同服,X,肾功能不全时减量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP003,CA79902-63-9,0006-0740-54,00006074054001,C10AA04,41127,9LHU78OQFD,CHEMBL1201468,53232,DB01095,D00359,simvastatin,Simvastatin,SIM,辛伐他汀,舒降之,默沙东,国药准字J20171041,18,HMG-CoA还原酶抑制剂,5mg;10mg;20mg;40mg;80mg,10-80mg,1每日1次,1口服,高胆固醇血症;冠心病,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;横纹肌溶解,环孢素;吉非罗齐;伊曲康唑,晚间服用避免西柚汁,X,正常剂量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP004,CA75330-75-5,0006-0012-54,00006001254001,C10AA03,40652,HSU1C9YRES,CHEMBL1201469,53232,DB01076,D00359,pravastatin,Pravastatin,PRA,普伐他汀,美百乐镇,百时美施贵宝,国药准字J20080063,18,HMG-CoA还原酶抑制剂,10mg;20mg;40mg,10-40mg,1每日1次,1口服,高胆固醇血症;心血管疾病预防,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;胃肠道反应,环孢素;吉非罗齐,可与或不与食物同服,X,正常剂量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP005,CA93957-54-1,0006-0013-54,00006001354001,C10AA02,40651,36OXV1L64O,CHEMBL1201470,53232,DB01076,D00887,lovastatin,Lovastatin,LOV,洛伐他汀,美降脂,默沙东,国药准字H20000519,18,HMG-CoA还原酶抑制剂,10mg;20mg;40mg,20-80mg,1每日1次,1口服,高胆固醇血症,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;横纹肌溶解,环孢素;吉非罗齐;伊曲康唑,晚餐时服用避免西柚汁,X,正常剂量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP006,CA80214-83-1,0006-0014-54,00006001454001,C10AA06,84305,4L066368AS,CHEMBL1201471,446157,DB01098,D03265,pitavastatin,Pitavastatin,PIT,匹伐他汀,力清之,兴和,国药准字J20171060,18,HMG-CoA还原酶抑制剂,1mg;2mg;4mg,1-4mg,1每日1次,1口服,高胆固醇血症;混合型血脂异常,活动性肝病;妊娠;哺乳,肌痛;肝酶升高;横纹肌溶解,环孢素;红霉素,可与或不与食物同服,X,正常剂量,活动性肝病时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP007,CA79617-96-2,0310-0745-30,00310074530001,C10AB05,25812,T42C4F5748,CHEMBL1201472,5282452,DB01095,D00565,fenofibrate,Fenofibrate,FENO,非诺贝特,力平脂,雅培,国药准字J20080062,18,贝特类,48mg;145mg;160mg,145-160mg,1每日1次,1口服,高甘油三酯血症;混合型血脂异常,严重肝肾功能不全;胆囊疾病,胃肠道反应;肌痛;肝酶升高,他汀类;华法林,餐时服用,C,肾功能不全时禁用,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
LP008,CA41859-67-0,0310-0746-30,00310074630001,C10AB04,25813,4R9H38CTTD,CHEMBL1201473,5362422,DB00973,D00565,bezafibrate,Bezafibrate,BEZ,苯扎贝特,必降脂,罗氏,国药准字H20000520,18,贝特类,200mg;400mg,400-600mg,2每日2次;3每日3次,1口服,高甘油三酯血症;混合型血脂异常,严重肝肾功能不全;胆囊疾病,胃肠道反应;肌痛;肝酶升高,他汀类;华法林,餐时服用,C,肾功能不全时减量,肝功能损害时禁用,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
LP010,CA107724-20-9,0310-0747-30,00310074730001,C10AX09,593411,WI7NBA420X,CHEMBL1201475,4369359,DB00672,D04024,ezetimibe,Ezetimibe,EZE,依折麦布,益适纯,默沙东,国药准字J20171061,18,胆固醇吸收抑制剂,10mg,10mg,1每日1次,1口服,高胆固醇血症,活动性肝病;妊娠,腹泻;腹痛;肌痛,他汀类;环孢素,可与或不与食物同服,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
RS001,CA80474-14-2,0173-0687-00,00173068700001,R03AC13,349472,CUT2W21N7U,CHEMBL1201476,40000,DB00598,D05765,salbutamol,Salbutamol,SAL,沙丁胺醇,万托林,葛兰素史克,国药准字H20052316,19,短效β2受体激动剂,100mcg/喷,100-200mcg,13必要时,2吸入,哮喘;慢阻肺急性发作,心律失常;甲亢,震颤;心悸;头痛;低钾血症,β受体阻滞剂;利尿剂,吸入后漱口,C,正常剂量,正常剂量,mcg,吸入,PRN,2025-09-30,国家药监局,已验证,中国上市
RS002,CA18559-94-9,0173-0688-00,00173068800001,R03AC12,349473,8NAF26R20S,CHEMBL1201477,2394,DB00802,D05765,terbutaline,Terbutaline,TER,特布他林,博利康尼,阿斯利康,国药准字H20052317,19,短效β2受体激动剂,250mcg/喷;2.5mg,250mcg;2.5-5mg,13必要时,2吸入;1口服,哮喘;慢阻肺;早产,心律失常;甲亢,震颤;心悸;头痛,β受体阻滞剂;利尿剂,吸入后漱口,B,正常剂量,正常剂量,mcg,吸入,PRN,2025-09-30,国家药监局,已验证,中国上市
RS003,CA51333-22-3,0173-0715-20,00173071520001,R03BA01,7213,94ZLA3W45F,CHEMBL1201478,3345,DB00769,D00592,budesonide,Budesonide,BUD,布地奈德,普米克,阿斯利康,国药准字H20140475,19,吸入糖皮质激素,100mcg;200mcg;400mcg,200-800mcg,2每日2次,2吸入,哮喘;慢阻肺,真菌感染;活动性肺结核,口咽念珠菌病;声音嘶哑;咳嗽,酮康唑;伊曲康唑,吸入后漱口,B,正常剂量,肝功能损害时减量,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
RS004,CA80474-14-2,0173-0688-00,00173068800001,R03BA05,349474,6EW8B72GZL,CHEMBL1201479,5311101,DB00588,D05765,fluticasone,Fluticasone,FLU,丙酸氟替卡松,辅舒酮,葛兰素史克,国药准字H20140476,19,吸入糖皮质激素,50mcg;125mcg;250mcg,100-1000mcg,2每日2次,2吸入,哮喘;慢阻肺,真菌感染;活动性肺结核,口咽念珠菌病;声音嘶哑;咳嗽,酮康唑;利托那韦,吸入后漱口,C,正常剂量,肝功能损害时谨慎,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
RS005,CA76-25-5,0173-0716-20,00173071620001,R03BA02,7214,9842X06Q6M,CHEMBL1201480,5743,DB00741,D00407,beclomethasone,Beclomethasone,BEC,丙酸倍氯米松,必可酮,葛兰素史克,国药准字H20140477,19,吸入糖皮质激素,50mcg;100mcg;250mcg,200-800mcg,2每日2次,2吸入,哮喘,真菌感染;活动性肺结核,口咽念珠菌病;声音嘶哑,酮康唑,吸入后漱口,C,正常剂量,正常剂量,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
RS006,CA101626-70-4,0597-0043-41,00597004341001,R03BB04,351136,WI4X0X7BPJ,CHEMBL1201481,5282230,DB00332,D00742,tiotropium,Tiotropium,TIO,噻托溴铵,思力华,勃林格殷格翰,国药准字J20140052,19,长效抗胆碱能药,18mcg,18mcg,1每日1次,2吸入,慢阻肺;哮喘,前列腺增生;闭角型青光眼,口干;便秘;尿潴留,抗胆碱药物,同一时间吸入,C,正常剂量,正常剂量,mcg,吸入,QD,2025-09-30,国家药监局,已验证,中国上市
RS007,CA29868-97-1,0597-0044-41,00597004441001,R03BB01,351137,AL08059L03,CHEMBL1201482,5282443,DB00565,D00332,ipratropium,Ipratropium,IPR,异丙托溴铵,爱全乐,勃林格殷格翰,国药准字H20140478,19,短效抗胆碱能药,20mcg/喷,20-40mcg,4每日4次,2吸入,慢阻肺;哮喘,前列腺增生;闭角型青光眼,口干;便秘,抗胆碱药物,可与β2受体激动剂联用,B,正常剂量,正常剂量,mcg,吸入,QID,2025-09-30,国家药监局,已验证,中国上市
RS008,CA138139-69-4,0173-0860-20,00173086020001,R03AC18,847382,0E1TGO96NT,CHEMBL1201483,11519741,DB09079,D08491,formoterol,Formoterol,FOR,福莫特罗,奥克斯都保,阿斯利康,国药准字H20140477,19,长效β2受体激动剂,4.5mcg;9mcg,9-18mcg,2每日2次,2吸入,哮喘;慢阻肺,心律失常;甲亢,震颤;心悸;头痛,β受体阻滞剂;利尿剂,必须与激素联用,C,正常剂量,正常剂量,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
RS009,CA93957-54-1,0173-0861-20,00173086120001,R03AC13,847383,2Z3E1OF81V,CHEMBL1201484,53232,DB01076,D08491,salmeterol,Salmeterol,SAL,沙美特罗,施立稳,葛兰素史克,国药准字H20140479,19,长效β2受体激动剂,25mcg;50mcg,50-100mcg,2每日2次,2吸入,哮喘;慢阻肺,心律失常;甲亢,震颤;心悸;头痛,β受体阻滞剂;利尿剂,必须与激素联用,C,正常剂量,正常剂量,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
RS010,CA51598-60-8,0173-0862-20,00173086220001,R03DX05,847384,6WN2BRM8J4,CHEMBL1201485,11519741,DB09079,D09851,fluticasone_salmeterol,Fluticasone/Salmeterol,FLS,氟替卡松沙美特罗,舒利迭,葛兰素史克,国药准字J20140053,19,激素/长效β2受体激动剂复方,50/250mcg;50/500mcg,50/250-50/500mcg,2每日2次,2吸入,哮喘;慢阻肺,真菌感染;心律失常,口咽念珠菌病;震颤;心悸,酮康唑;β受体阻滞剂,吸入后漱口,C,正常剂量,肝功能损害时谨慎,mcg,吸入,BID,2025-09-30,国家药监局,已验证,中国上市
GI001,CA73590-58-6,0310-0615-60,00310061560001,A02BC01,7646,D3SE4F1J9H,CHEMBL1201486,3678,DB00448,D00455,lansoprazole,Lansoprazole,LAN,兰索拉唑,达克普隆,武田制药,国药准字H20040586,21,质子泵抑制剂,15mg;30mg,15-30mg,1每日1次,1口服,消化性溃疡;胃食管反流病;幽门螺杆菌感染,严重肝功能不全,腹泻;头痛;恶心;维生素B12缺乏,华法林;地高辛;酮康唑,餐前30分钟服用,B,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
GI002,CA119141-88-7,0310-0620-60,00310062060001,A02BC02,40790,D8TST4O562,CHEMBL1201487,4888,DB01129,D00455,rabeprazole,Rabeprazole,RAB,雷贝拉唑,波利特,卫材,国药准字J20080123,21,质子泵抑制剂,10mg;20mg,10-20mg,1每日1次,1口服,消化性溃疡;胃食管反流病;幽门螺杆菌感染,严重肝功能不全,腹泻;头痛;恶心,地高辛;酮康唑;甲氨蝶呤,可与或不与食物同服,B,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
GI003,CA103577-45-3,0310-0648-30,00310064830001,A02BC03,40790,KO5DBL2JQL,CHEMBL1201488,4887,DB05351,D00455,esomeprazole,Esomeprazole,ESO,埃索美拉唑,耐信,阿斯利康,国药准字J20120063,21,质子泵抑制剂,20mg;40mg,20-40mg,1每日1次,1口服,消化性溃疡;胃食管反流病,严重肝功能不全,腹泻;头痛;腹痛,氯吡格雷;地高辛;华法林,餐前1小时服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
GI004,CA73590-58-6,0310-0621-60,00310062160001,A02BC04,7647,D3SE4F1J9H,CHEMBL1201489,3678,DB01129,D00455,pantoprazole,Pantoprazole,PAN,泮托拉唑,洛赛克,武田制药,国药准字H20040587,21,质子泵抑制剂,20mg;40mg,20-40mg,1每日1次,1口服,消化性溃疡;胃食管反流病;幽门螺杆菌感染,严重肝功能不全,腹泻;头痛;恶心,华法林;地高辛,可与或不与食物同服,B,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
GI005,CA73590-58-6,0310-0622-60,00310062260001,A02BC05,7648,D3SE4F1J9H,CHEMBL1201490,4530,DB00338,D00213,omeprazole,Omeprazole,OME,奥美拉唑,洛赛克,阿斯利康,国药准字J20080124,21,质子泵抑制剂,10mg;20mg;40mg,20-40mg,1每日1次,1口服,消化性溃疡;胃食管反流病;幽门螺杆菌感染,严重肝功能不全,腹泻;头痛;恶心;维生素B12缺乏,氯吡格雷;地高辛;华法林,餐前服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
GI006,CA54143-57-6,0006-0749-54,00006074954001,A02BA02,56391,886BLD52H1,CHEMBL1201491,3001055,DB00863,D00318,ranitidine,Ranitidine,RAN,雷尼替丁,善胃得,葛兰素史克,国药准字H20013062,21,H2受体拮抗剂,75mg;150mg;300mg,150-300mg,2每日2次,1口服,消化性溃疡;胃食管反流病,严重肾功能不全,头痛;便秘;腹泻,华法林;酮康唑,可与或不与食物同服,B,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
GI007,CA66357-35-5,0006-0750-54,00006075054001,A02BA03,56392,8QUL4WU3WN,CHEMBL1201492,2756,DB00927,D00318,famotidine,Famotidine,FAM,法莫替丁,高舒达,默沙东,国药准字H20013063,21,H2受体拮抗剂,20mg;40mg,20-40mg,2每日2次,1口服,消化性溃疡;胃食管反流病,严重肾功能不全,头痛;便秘;腹泻,华法林;酮康唑,可与或不与食物同服,B,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
GI008,CA76963-41-2,0006-0751-54,00006075154001,A02BA01,56393,O5Z93Y09TG,CHEMBL1201493,2585,DB00501,D00318,cimetidine,Cimetidine,CIM,西咪替丁,泰胃美,葛兰素史克,国药准字H20013064,21,H2受体拮抗剂,200mg;400mg;800mg,400-800mg,2每日2次,1口服,消化性溃疡;胃食管反流病,严重肾功能不全,头痛;腹泻;男性乳房发育,华法林;茶碱;苯妥英,餐时或睡前服用,B,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
GI009,CA99592-39-9,0006-0963-28,00006096328001,A03FA03,56946,08C2W53SKU,CHEMBL1201494,104762,DB01110,D01306,mosapride,Mosapride,MOS,莫沙必利,加斯清,大日本住友,国药准字H20031110,21,5-HT4受体激动剂,5mg,5mg,3每日3次,1口服,功能性消化不良;胃食管反流病,胃肠道出血;机械性梗阻,腹泻;腹痛;口干,抗胆碱药物,餐前服用,B,正常剂量,肝功能损害时谨慎,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
GI010,CA54143-56-5,0006-0964-28,00006096428001,A03FA01,56947,4L066368AS,CHEMBL1201495,3672,DB01142,D00626,domperidone,Domperidone,DOM,多潘立酮,吗丁啉,西安杨森,国药准字H20031111,21,多巴胺受体拮抗剂,10mg,10mg,3每日3次,1口服,功能性消化不良;恶心呕吐,胃肠道出血;机械性梗阻;泌乳素瘤,泌乳;月经紊乱;QT延长,酮康唑;红霉素,餐前15-30分钟服用,C,正常剂量,肝功能损害时谨慎,mg,口服,TID,2025-09-30,国家药监局,已验证,中国上市
AI001,CA61336-70-7,0003-0280-50,00003028050001,J01CR02,617993,804826J2HU,CHEMBL1096600,33613,DB01060,D07659,amoxicillin_clavulanate,Amoxicillin/Clavulanate,AMC,阿莫西林克拉维酸钾,安灭菌,葛兰素史克,国药准字H20013062,22,β-内酰胺酶抑制剂复合制剂,375mg;625mg;1000mg,375-1000mg,2每日2次;3每日3次,1口服,呼吸道感染;泌尿道感染;皮肤软组织感染,青霉素过敏;严重肝功能不全,腹泻;恶心;皮疹;肝功能异常,华法林;别嘌醇,餐时服用,B,肾功能不全时减量,肝功能损害时禁用,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
AI002,CA26787-78-0,0003-0281-50,00003028150001,J01CA04,723,9EM05410Q9,CHEMBL1096601,33613,DB01060,D07659,amoxicillin,Amoxicillin,AMO,阿莫西林,阿莫西林,联邦制药,国药准字H10983037,22,青霉素类,0.25g;0.5g;1g,0.5-1g,3每日3次,1口服,呼吸道感染;泌尿道感染;幽门螺杆菌感染,青霉素过敏,腹泻;皮疹;过敏反应,华法林;别嘌醇,餐时或餐后服用,B,肾功能不全时减量,正常剂量,g,口服,TID,2025-09-30,国家药监局,已验证,中国上市
AI003,CA80214-83-1,0049-0280-83,00049028083001,J01DD08,152946,H4GXR80IZE,CHEMBL1096602,5481173,DB01140,D07659,cefixime,Cefixime,CFX,头孢克肟,世福素,赛诺菲,国药准字H20000292,22,第三代头孢菌素,50mg;100mg;200mg,200-400mg,1每日1次;2每日2次,1口服,呼吸道感染;泌尿道感染;淋病,头孢菌素过敏,腹泻;恶心;皮疹,华法林;丙磺舒,可与或不与食物同服,B,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
AI004,CA82009-34-5,0049-0281-83,00049028183001,J01DD04,152947,9481R3R8H9,CHEMBL1096603,5481173,DB01140,D07659,cefuroxime,Cefuroxime,CFU,头孢呋辛,西力欣,葛兰素史克,国药准字H20000293,22,第二代头孢菌素,0.125g;0.25g;0.5g,0.25-0.5g,2每日2次,1口服,呼吸道感染;泌尿道感染,头孢菌素过敏,腹泻;恶心;皮疹,华法林;丙磺舒,餐时服用,B,肾功能不全时减量,正常剂量,g,口服,BID,2025-09-30,国家药监局,已验证,中国上市
AI005,CA73384-59-5,0049-0282-83,00049028283001,J01DD02,152948,S14DZR3BF9,CHEMBL1096604,5481173,DB01140,D07659,ceftriaxone,Ceftriaxone,CRO,头孢曲松,罗氏芬,罗氏,国药准字H20000294,22,第三代头孢菌素,0.5g;1g;2g,1-2g,1每日1次;2每日2次,6静脉注射;7肌肉注射,严重感染;脑膜炎;淋病,头孢菌素过敏;新生儿高胆红素血症,腹泻;皮疹;胆汁淤积,钙剂;华法林,慢速静脉注射,B,正常剂量,正常剂量,g,静脉注射,QD,2025-09-30,国家药监局,已验证,中国上市
AI006,CA120127-01-9,0069-3000-30,00069300030001,J01MA02,203563,U68162070H,CHEMBL1096605,2764,DB00537,D08492,ciprofloxacin,Ciprofloxacin,CIP,盐酸环丙沙星,希普洛,拜耳,国药准字H20000660,22,氟喹诺酮类,250mg;500mg;750mg,250-750mg,2每日2次,1口服,呼吸道感染;泌尿道感染;骨关节感染,18岁以下;妊娠;哺乳;喹诺酮过敏,胃肠道反应;肌腱炎;QT延长;光敏反应,华法林;茶碱;铁剂,餐后服用避免奶制品,C,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
AI007,CA100986-85-4,0069-5150-20,00069515020001,J01MA12,149096,L0FPV48Q5R,CHEMBL1096606,62959,DB01137,D08491,levofloxacin,Levofloxacin,LEV,左氧氟沙星,可乐必妥,第一三共,国药准字H20000661,22,氟喹诺酮类,250mg;500mg;750mg,250-750mg,1每日1次;2每日2次,1口服;6静脉注射,呼吸道感染;泌尿道感染,18岁以下;妊娠;喹诺酮过敏,胃肠道反应;肌腱炎;QT延长,华法林;NSAID,可与或不与食物同服,C,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
AI008,CA137234-62-9,0069-0970-30,00069097030001,J01MA14,195085,U188XYD42P,CHEMBL1096607,154417,DB00218,D08493,moxifloxacin,Moxifloxacin,MOX,莫西沙星,拜复乐,拜耳,国药准字J20080123,22,第四代氟喹诺酮,400mg,400mg,1每日1次,1口服;6静脉注射,呼吸道感染;皮肤软组织感染,18岁以下;妊娠;QT延长;喹诺酮过敏,胃肠道反应;QT延长;头晕,抗心律失常药;华法林,可与或不与食物同服,C,正常剂量,正常剂量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
AI009,CA80214-83-1,0069-0971-30,00069097130001,J01MA06,195086,G25B63T16T,CHEMBL1096608,154417,DB01165,D08493,ofloxacin,Ofloxacin,OFL,氧氟沙星,泰利必妥,第一三共,国药准字H20000662,22,氟喹诺酮类,100mg;200mg;400mg,200-400mg,2每日2次,1口服,呼吸道感染;泌尿道感染,18岁以下;妊娠;喹诺酮过敏,胃肠道反应;肌腱炎;中枢神经系统反应,华法林;茶碱,可与或不与食物同服,C,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
AI010,CA106685-40-9,0069-0972-30,00069097230001,J01MA08,195087,1GKX982H8R,CHEMBL1096609,154417,DB00487,D08493,pefloxacin,Pefloxacin,PEF,培氟沙星,培氟沙星,浙江医药,国药准字H20000663,22,氟喹诺酮类,200mg;400mg,400mg,2每日2次,1口服,呼吸道感染;泌尿道感染,18岁以下;妊娠;喹诺酮过敏,胃肠道反应;光敏反应,华法林;茶碱,可与或不与食物同服,C,肾功能不全时减量,正常剂量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
NS001,CA59729-33-8,0002-3220-30,00002322030001,N06AB06,32937,2DS058H2CF,CHEMBL1096610,41879,DB01104,D07793,sertraline,Sertraline,SER,舍曲林,左洛复,辉瑞,国药准字J20080123,23,选择性5-HT再摄取抑制剂,50mg;100mg,50-200mg,1每日1次,1口服,抑郁症;强迫症;焦虑症;PTSD,单胺氧化酶抑制剂;匹莫齐特,恶心;腹泻;失眠;性功能障碍,单胺氧化酶抑制剂;华法林;曲马多,可与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS002,CA110429-62-4,0002-3227-30,00002322730001,N06AB04,35469,DHT16MYA8X,CHEMBL1096611,3386,DB01175,D00823,paroxetine,Paroxetine,PAR,帕罗西汀,赛乐特,葛兰素史克,国药准字J20080124,23,选择性5-HT再摄取抑制剂,20mg;30mg,20-60mg,1每日1次,1口服,抑郁症;强迫症;焦虑症;社交恐惧症,单胺氧化酶抑制剂;匹莫齐特;硫利达嗪,恶心;头晕;失眠;性功能障碍;戒断症状,单胺氧化酶抑制剂;华法林;他莫昔芬,晨起服用避免突然停药,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS003,CA103577-45-3,0002-3240-30,00002324030001,N06AB10,321988,4ETT4D1B24,CHEMBL1096612,5210,DB00472,D07913,escitalopram,Escitalopram,ESC,艾司西酞普兰,来士普,灵北,国药准字J20120063,23,选择性5-HT再摄取抑制剂,5mg;10mg;20mg,10-20mg,1每日1次,1口服,抑郁症;广泛性焦虑症,单胺氧化酶抑制剂;匹莫齐特,恶心;失眠;性功能障碍,单胺氧化酶抑制剂;西咪替丁,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS004,CA116539-59-4,0002-3235-30,00002323530001,N06AX16,62640,7D7RX5A8MO,CHEMBL1096613,60835,DB00285,D07793,venlafaxine,Venlafaxine,VEN,文拉法辛,怡诺思,惠氏,国药准字J20080125,23,5-HT和NE再摄取抑制剂,37.5mg;75mg;150mg,75-225mg,1每日1次,1口服,抑郁症;广泛性焦虑症,单胺氧化酶抑制剂,恶心;头晕;失眠;血压升高;戒断症状,单胺氧化酶抑制剂;华法林,可与食物同服,C,肾功能不全时减量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS005,CA132539-06-1,0002-3245-30,00002324530001,N06AX21,132539,7D7RX5A8MO,CHEMBL1096614,68617,DB00476,D07794,duloxetine,Duloxetine,DUL,度洛西汀,欣百达,礼来,国药准字J20120064,23,5-HT和NE再摄取抑制剂,30mg;60mg,60-120mg,1每日1次,1口服,抑郁症;广泛性焦虑症;糖尿病周围神经病变;纤维肌痛,单胺氧化酶抑制剂;严重肝功能不全;未控制的高血压,恶心;口干;便秘;疲劳;失眠,单胺氧化酶抑制剂;氟伏沙明;华法林,可与或不与食物同服,C,肾功能不全时谨慎,肝功能损害时禁用,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS006,CA103577-45-3,0002-3246-30,00002324630001,N06AB03,35468,0K47UL67F2,CHEMBL1096615,3386,DB00472,D00823,fluoxetine,Fluoxetine,FLU,氟西汀,百优解,礼来,国药准字J20080126,23,选择性5-HT再摄取抑制剂,10mg;20mg;40mg,20-80mg,1每日1次,1口服,抑郁症;强迫症;贪食症;经前焦虑障碍,单胺氧化酶抑制剂;匹莫齐特;硫利达嗪,恶心;失眠;焦虑;性功能障碍,单胺氧化酶抑制剂;华法林;三环抗抑郁药,晨起服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS007,CA132539-07-2,0002-3247-30,00002324730001,N06AB05,35470,41VRH5220H,CHEMBL1096616,5234,DB00215,D00823,citalopram,Citalopram,CIT,西酞普兰,喜普妙,灵北,国药准字J20080127,23,选择性5-HT再摄取抑制剂,10mg;20mg;40mg,20-40mg,1每日1次,1口服,抑郁症,单胺氧化酶抑制剂;匹莫齐特;QT延长,恶心;口干;失眠;性功能障碍;QT延长,单胺氧化酶抑制剂;华法林;西咪替丁,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS008,CA66711-21-5,0002-3248-30,00002324830001,N06AX11,62641,F2JTS55RBG,CHEMBL1096617,60835,DB01149,D07793,mirtazapine,Mirtazapine,MIR,米氮平,瑞美隆,欧加农,国药准字J20080128,23,NaSSA类抗抑郁药,15mg;30mg;45mg,15-45mg,1每日1次,1口服,抑郁症,单胺氧化酶抑制剂,嗜睡;体重增加;食欲增加;口干,单胺氧化酶抑制剂;苯二氮䓬类,睡前服用,C,肾功能不全时减量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
NS009,CA23887-31-2,0002-3249-30,00002324930001,N05AH04,5093,L6UH7ZF8HC,CHEMBL1096618,60854,DB01224,D00540,quetiapine,Quetiapine,QUE,喹硫平,思瑞康,阿斯利康,国药准字J20080129,23,非典型抗精神病药,25mg;100mg;200mg;300mg,300-800mg,2每日2次,1口服,精神分裂症;双相情感障碍,严重心血管疾病;昏迷,嗜睡;体重增加;高血糖;血脂异常,CYP3A4抑制剂;抗高血压药,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,BID,2025-09-30,国家药监局,已验证,中国上市
NS010,CA106266-06-2,0002-3250-30,00002325030001,N05AX12,60855,6LY9M413RA,CHEMBL1096619,60854,DB01238,D00540,aripiprazole,Aripiprazole,ARI,阿立哌唑,安律凡,大冢制药,国药准字J20130065,23,非典型抗精神病药,5mg;10mg;15mg;20mg;30mg,10-30mg,1每日1次,1口服,精神分裂症;双相情感障碍;抑郁症辅助治疗,昏迷,失眠;焦虑;恶心;静坐不能,CYP3A4抑制剂;CYP2D6抑制剂,可与或不与食物同服,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-09-30,国家药监局,已验证,中国上市
AI011,CA69-53-4,0049-0283-83,00049028383001,J01FA09,203564,7C782967RD,CHEMBL640,11962635,DB01060,D07659,clarithromycin,Clarithromycin,CLA,克拉霉素,希舒美,雅培,国药准字H20000664,22,大环内酯类,0.25g;0.5g,0.25-0.5g,2每日2次,1口服,呼吸道感染;幽门螺杆菌感染,严重肝功能不全;与匹莫齐特合用,胃肠道反应;肝酶升高;QT延长,茶碱;地高辛;华法林,可与食物同服,C,正常剂量,肝功能损害时减量,g,口服,BID,2025-09-30,NMPA,已验证,国家基药目录
AI012,CA114-07-8,0049-0284-83,00049028483001,J01FA01,203565,63937KV33D,CHEMBL3116269,12560,DB00199,D00140,erythromycin,Erythromycin,ERY,红霉素,红霉素肠溶片,上海信谊,国药准字H31020823,22,大环内酯类,0.125g;0.25g,0.25-0.5g,4每日4次,1口服,呼吸道感染;皮肤软组织感染,肝功能不全;与匹莫齐特合用,胃肠道反应;肝毒性;QT延长,茶碱;华法林;西沙必利,餐前1小时或餐后2小时服用,B,正常剂量,肝功能损害时谨慎,g,口服,QID,2025-09-30,NMPA,已验证,国家基药目录
AI013,CA80-06-8,0049-0285-83,00049028583001,J01FA10,203566,S79426A41Z,CHEMBL2107672,447043,DB00207,D00140,azithromycin,Azithromycin,AZI,阿奇霉素,希舒美,辉瑞,国药准字H20000665,22,大环内酯类,0.125g;0.25g;0.5g,0.5g,1每日1次,1口服,呼吸道感染;泌尿道感染;皮肤软组织感染,严重肝功能不全;对大环内酯类过敏,胃肠道反应;肝酶升高;QT延长,华法林;地高辛,可与食物同服,B,正常剂量,肝功能损害时谨慎,g,口服,QD,2025-09-30,NMPA,已验证,国家基药目录
AI014,CA739-71-9,0049-0286-83,00049028683001,J01XX08,203567,7D07U14TK3,CHEMBL1201,5464356,DB01017,D00878,linezolid,Linezolid,LIN,利奈唑胺,斯沃,辉瑞,国药准字J20130032,22,噁唑烷酮类,0.6g,0.6g,2每日2次,1口服;6静脉注射,MRSA感染;VRE感染,单胺氧化酶抑制剂;嗜铬细胞瘤,骨髓抑制;周围神经病变;乳酸性酸中毒;5-羟色胺综合征,SSRI;三环抗抑郁药;拟交感神经药,避免富含酪胺的食物,C,正常剂量,正常剂量,g,口服,BID,2025-09-30,NMPA,已验证,抗MRSA
AI015,CA1404-04-2,0049-0287-83,00049028783001,J01XA01,203568,3J9O755399,CHEMBL1160,14969,DB00512,D00201,vancomycin,Vancomycin,VAN,万古霉素,万古霉素,礼来,国药准字H20059883,22,糖肽类,0.5g;1g,1-2g,2每日2次;4每日4次,6静脉注射,MRSA感染;难辨梭状芽孢杆菌感染,过敏史,肾毒性;耳毒性;红人综合征;静脉炎,氨基糖苷类;呋塞米,缓慢静脉输注>60分钟,C,肾功能不全时减量,正常剂量,g,静脉注射,BID,2025-09-30,NMPA,已验证,抗MRSA
AI016,CA1404-90-6,0049-0288-83,00049028883001,J01XA02,203569,S4WUZ5D0M3,CHEMBL1161,445643,DB00783,D07640,teicoplanin,Teicoplanin,TEI,替考拉宁,特加能,赛诺菲,国药准字J20130033,22,糖肽类,0.2g;0.4g,6mg/kg,1每日1次,6静脉注射;7肌肉注射,MRSA感染;骨髓炎,过敏史,肾毒性;过敏反应;注射部位反应,氨基糖苷类,首剂可加倍,C,肾功能不全时减量,正常剂量,g,静脉注射,QD,2025-09-30,NMPA,已验证,抗MRSA
AI017,CA153-61-7,0049-0289-83,00049028983001,J01GB01,203570,04M8F04M6W,CHEMBL1165,36604,DB00684,D00063,tobramycin,Tobramycin,TOB,妥布霉素,妥布霉素,上海上药第一生化,国药准字H31021177,22,氨基糖苷类,40mg;80mg,3-5mg/kg,1每日1次;3每日3次,6静脉注射;7肌肉注射,严重革兰阴性菌感染,妊娠;重症肌无力,肾毒性;耳毒性;神经肌肉阻滞,襻利尿剂;头孢菌素,监测血药浓度,D,肾功能不全时减量,正常剂量,mg,静脉注射,QD,2025-09-30,NMPA,已验证,氨基糖苷类
AI018,CA1404-90-6,0049-0290-83,00049029083001,J01GB03,203571,P40W033BGM,CHEMBL1166,441130,DB00798,D00023,gentamicin,Gentamicin,GEN,庆大霉素,庆大霉素注射液,哈药集团,国药准字H23021156,22,氨基糖苷类,20mg;40mg;80mg,3-5mg/kg,1每日1次;2每日2次,6静脉注射;7肌肉注射,严重革兰阴性菌感染,妊娠;重症肌无力,肾毒性;耳毒性;神经肌肉阻滞,襻利尿剂;头孢菌素,监测血药浓度,D,肾功能不全时减量,正常剂量,mg,静脉注射,QD,2025-09-30,NMPA,已验证,国家基药目录
AI019,CA76-60-8,0049-0291-83,00049029183001,J01GB06,203572,O26FZP769L,CHEMBL1167,165580,DB00781,D08025,amikacin,Amikacin,AMI,阿米卡星,丁胺卡那霉素,上海上药第一生化,国药准字H31021178,22,氨基糖苷类,0.1g;0.2g,15mg/kg,1每日1次;2每日2次,6静脉注射;7肌肉注射,严重革兰阴性菌感染,妊娠;重症肌无力,肾毒性;耳毒性;神经肌肉阻滞,襻利尿剂;头孢菌素,监测血药浓度,D,肾功能不全时减量,正常剂量,g,静脉注射,QD,2025-09-30,NMPA,已验证,氨基糖苷类
AI020,CA2784-94-3,0049-0292-83,00049029283001,J02AC01,203573,8VT9C4F91Y,CHEMBL1168,2733526,DB00703,D00203,fluconazole,Fluconazole,FLU,氟康唑,大扶康,辉瑞,国药准字H20000666,22,三唑类抗真菌药,50mg;100mg;150mg,50-400mg,1每日1次,1口服;6静脉注射,念珠菌感染;隐球菌脑膜炎,对唑类药物过敏;与特非那定合用,肝毒性;皮疹;头痛,华法林;苯妥英;茶碱,可与食物同服,D,肾功能不全时减量,肝功能损害时谨慎,mg,口服,QD,2025-09-30,NMPA,已验证,国家基药目录
AV001,CA59277-89-3,0069-1430-01,00069143001001,J05AB01,135398,4MT4VF83RV,CHEMBL1169,135398,DB00787,D00222,acyclovir,Acyclovir,ACV,阿昔洛韦,阿昔洛韦片,中美上海施贵宝,国药准字H20023408,25,抗疱疹病毒药,0.2g;0.4g,0.2-0.8g,5每日5次,1口服,单纯疱疹;带状疱疹;水痘,对阿昔洛韦过敏,恶心;头痛;肾功能损害,丙磺舒;齐多夫定,充分饮水,B,肾功能不全时减量,正常剂量,g,口服,qd-5x,2025-09-30,NMPA,已验证,国家基药目录
AV002,CA76547-98-3,0069-1431-01,00069143101001,J05AB11,135399,G40N9EC3BJ,CHEMBL1170,60846,DB00900,D00411,valacyclovir,Valacyclovir,VAL,伐昔洛韦,明竹欣,葛兰素史克,国药准字J20130034,25,抗疱疹病毒药,0.3g;0.5g,0.3-1g,2每日2次;3每日3次,1口服,单纯疱疹;带状疱疹;水痘,对伐昔洛韦过敏,头痛;恶心;肾功能损害,丙磺舒,充分饮水,B,肾功能不全时减量,正常剂量,g,口服,BID,2025-09-30,NMPA,已验证,阿昔洛韦前药
AV003,CA139110-80-8,0069-1432-01,00069143201001,J05AF05,203574,KOF8H1H46J,CHEMBL1171,60855,DB00879,D03299,entecavir,Entecavir,ETV,恩替卡韦,博路定,百时美施贵宝,国药准字J20130035,25,核苷类逆转录酶抑制剂,0.5mg;1mg,0.5-1mg,1每日1次,1口服,慢性乙型肝炎,对恩替卡韦过敏,头痛;疲劳;眩晕;恶心,拉米夫定,空腹服用,C,肾功能不全时减量,正常剂量,mg,口服,QD,2025-09-30,NMPA,已验证,慢乙肝一线药
AV004,CA147127-20-6,0069-1433-01,00069143301001,J05AF10,203575,4U7X3839WY,CHEMBL1172,216239,DB08873,D06677,tenofovir,Tenofovir Disoproxil,TDF,富马酸替诺福韦二吡呋酯,韦瑞德,吉利德,国药准字J20130036,25,核苷酸逆转录酶抑制剂,0.3g,0.3g,1每日1次,1口服,慢性乙型肝炎;HIV感染,对替诺福韦过敏,肾毒性;骨密度降低;低磷血症,地达诺辛;阿德福韦,餐时服用监测肾功能,B,肌酐清除率<50ml/min减量,正常剂量,g,口服,QD,2025-09-30,NMPA,已验证,慢乙肝一线药
AV005,CA870487-09-5,0069-1434-01,00069143401001,J05AF11,203576,WY59R20Y5A,CHEMBL1173,216326,DB09030,D10568,tenofovir_alafenamide,Tenofovir Alafenamide,TAF,丙酚替诺福韦,韦立得,吉利德,国药准字J20180032,25,核苷酸逆转录酶抑制剂,25mg,25mg,1每日1次,1口服,慢性乙型肝炎;HIV感染,对替诺福韦过敏;与利福平合用,头痛;腹痛;咳嗽;疲劳,CYP3A诱导剂,餐时服用,B,正常剂量,失代偿期肝硬化禁用,mg,口服,QD,2025-09-30,NMPA,已验证,TAF优于TDF
PA001,CA50-78-2,0006-0143-68,00006014368001,N02BA01,1191,R16CO5Y76E,CHEMBL25,2244,DB00945,D00109,aspirin,Aspirin,ASA,阿司匹林,拜阿司匹灵,拜耳,国药准字H20052793,26,NSAIDs,25mg;100mg;300mg,75-300mg,1每日1次,1口服,解热镇痛;抗血小板;心血管疾病预防,活动性消化性溃疡;出血倾向;阿司匹林哮喘;妊娠末期,胃肠道反应;出血倾向;过敏反应;瑞氏综合征,华法林;甲氨蝶呤;糖皮质激素,餐后服用肠溶片不可掰开,D,正常剂量,严重肝功能不全时禁用,mg,口服,QD,2025-09-30,NMPA,已验证,国家基药目录
PA002,CA103-90-2,0006-0144-68,00006014468001,N02BE01,161,LFQSCWFLJHTTHZ,CHEMBL112,1983,DB00316,D00217,paracetamol,Paracetamol,PCT,对乙酰氨基酚,泰诺林,强生,国药准字H11022279,26,解热镇痛药,0.15g;0.3g;0.5g,0.3-0.6g,13必要时q4-6h,1口服,发热;疼痛,严重肝功能不全;对该药过敏,肝毒性;皮疹;血液系统反应,华法林;异烟肼,24小时不超过4g,B,正常剂量,肝功能损害时减量或禁用,g,口服,PRN,2025-09-30,NMPA,已验证,国家基药目录
PA003,CA15687-27-1,0006-0145-68,00006014568001,N02BE51,162,362O9ITL9D,CHEMBL113,3672,DB00328,D00217,ibuprofen,Ibuprofen,IBU,布洛芬,芬必得,中美上海施贵宝,国药准字H10950192,26,NSAIDs,0.1g;0.2g;0.4g,0.2-0.6g,3每日3次,1口服,发热;疼痛;炎症,活动性消化性溃疡;阿司匹林哮喘;妊娠末期,胃肠道反应;肾功能损害;心血管事件,华法林;阿司匹林;ACE抑制剂,餐后服用,C,肾功能不全时谨慎,肝功能损害时谨慎,g,口服,TID,2025-09-30,NMPA,已验证,国家基药目录
PA004,CA22204-53-1,0006-0146-68,00006014668001,M01AE01,7242,S8A36CJHGT,CHEMBL114,156391,DB00788,D00118,naproxen,Naproxen,NAP,萘普生,萘普生片,上海信谊,国药准字H31020988,26,NSAIDs,0.125g;0.25g,0.25-0.5g,2每日2次,1口服,类风湿关节炎;骨关节炎;痛风;疼痛,活动性消化性溃疡;阿司匹林哮喘;妊娠末期;心脏手术,胃肠道反应;心血管事件;肾功能损害,华法林;阿司匹林;ACE抑制剂,餐时或餐后服用,C,肾功能不全时谨慎,肝功能损害时谨慎,g,口服,BID,2025-09-30,NMPA,已验证,国家基药目录
PA005,CA15307-86-5,0006-0147-68,00006014768001,M01AB05,7243,RPK779R03H,CHEMBL115,3761,DB00586,D00126,diclofenac,Diclofenac,DIC,双氯芬酸,扶他林,诺华,国药准字H10960274,26,NSAIDs,25mg;50mg;75mg,50-150mg,2每日2次;3每日3次,1口服,类风湿关节炎;骨关节炎;强直性脊柱炎,活动性消化性溃疡;阿司匹林哮喘;心脏手术,胃肠道反应;肝毒性;心血管事件,华法林;阿司匹林;锂剂,餐时或餐后服用,C,肾功能不全时谨慎,肝功能损害时禁用,mg,口服,BID,2025-09-30,NMPA,已验证,国家基药目录
AI201,CA61-33-6,0069-5400-44,,J01CE02,RX1234567,A1B2C3D4,CHEMBL1234,5280965,DB00417,D00134,Benzylpenicillin,Penicillin G,PCG,青霉素G,青霉素钠,华北制药,国药准字H11020293,22,抗感染药/β-内酰胺类/青霉素类,80万单位/支,80-240万单位,每6-8小时一次,肌肉注射/静脉注射,敏感细菌所致感染,青霉素过敏者禁用,过敏反应、皮疹,丙磺舒可延长半衰期,皮试阳性禁用,B,无需调整,无需调整,万单位,肌肉注射/静脉注射,q6-8h,2025-09-30,NMPA/国家基本药物目录,verified,经典青霉素类抗生素
AI202,CA87-08-1,0069-0950-10,,J01CE08,RX1234568,B2C3D4E5,CHEMBL1235,6087,DB00417,D00211,Penicillin V,Penicillin V,PCV,青霉素V,青霉素V钾片,华北制药,国药准字H11020468,22,抗感染药/β-内酰胺类/青霉素类,0.25g/片,0.25-0.5g,每6小时一次,口服,轻中度敏感菌感染,青霉素过敏者禁用,胃肠道反应、皮疹,四环素类降低疗效,口服青霉素,B,无需调整,无需调整,g,口服,q6h,2025-09-30,NMPA/国家基本药物目录,verified,口服青霉素类
AI203,CA1173-88-2,0062-1551-01,,J01CF05,RX1234569,C3D4E5F6,CHEMBL1236,33613,DB00663,D00223,Flucloxacillin,Oxacillin,OXA,苯唑西林,苯唑西林钠,石药集团,国药准字H13022731,22,抗感染药/β-内酰胺类/耐酶青霉素,0.5g/支,1-2g,每4-6小时一次,静脉注射,耐青霉素酶金葡菌感染,青霉素过敏者禁用,静脉炎、皮疹,利福平协同作用,抗耐药金葡菌,C,CrCl<10需减量,无需调整,g,静脉注射,q4-6h,2025-09-30,NMPA/国家基本药物目录,verified,耐酶青霉素
AI204,CA69-52-3,0015-7975-20,,J01CA01,RX1234570,D4E5F6G7,CHEMBL1237,6249,DB00415,D00204,Ampicillin,Ampicillin,AMP,氨苄西林,氨苄西林钠,哈药集团,国药准字H23020593,22,抗感染药/β-内酰胺类/广谱青霉素,0.5g/支,1-2g,每6小时一次,静脉注射/口服,敏感革兰氏阴性菌感染,青霉素过敏者禁用,皮疹、腹泻,别嘌醇增加皮疹风险,广谱青霉素,C,CrCl<30需减量,无需调整,g,静脉注射,q6h,2025-09-30,NMPA/国家基本药物目录,verified,广谱青霉素
AI205,CA61477-96-1,0049-0180-83,,J01CA12,RX1234571,E5F6G7H8,CHEMBL1238,43672,DB00319,D00341,Piperacillin,Piperacillin,PIP,哌拉西林,哌拉西林钠,石药集团,国药准字H13022062,22,抗感染药/β-内酰胺类/广谱青霉素,2g/支,2-4g,每6-8小时一次,静脉注射,严重革兰氏阴性菌感染,青霉素过敏者禁用,静脉炎、电解质紊乱,氨基糖苷类协同,抗假单胞菌,C,CrCl<40需减量,无需调整,g,静脉注射,q6-8h,2025-09-30,NMPA/国家基本药物目录,verified,抗假单胞菌青霉素
AI206,CA15686-71-2,0002-7060-25,,J01DB01,RX1234572,F6G7H8I9,CHEMBL1239,2666,DB00761,D00263,Cefalexin,Cephalexin,CFX,头孢氨苄,头孢氨苄胶囊,华北制药,国药准字H11022279,22,抗感染药/β-内酰胺类/第一代头孢,0.25g/粒,0.5g,每6小时一次,口服,敏感细菌所致轻中度感染,头孢过敏者禁用,胃肠道反应、皮疹,丙磺舒增加血药浓度,第一代口服头孢,B,CrCl<40需减量,无需调整,g,口服,q6h,2025-09-30,NMPA/国家基本药物目录,verified,第一代口服头孢菌素
AI207,CA50-59-9,0002-3305-81,,J01DB03,RX1234573,G7H8I9J0,CHEMBL1240,33255,DB00833,D00265,Cefalotin,Cefaloridine,CFR,头孢拉定,头孢拉定胶囊,石药集团,国药准字H13022452,22,抗感染药/β-内酰胺类/第一代头孢,0.25g/粒,0.5g,每6小时一次,口服,上呼吸道感染、尿路感染,头孢过敏者禁用,过敏反应、腹泻,与利尿剂合用增加肾毒性,第一代头孢,B,CrCl<50需减量,无需调整,g,口服,q6h,2025-09-30,NMPA/国家基本药物目录,verified,第一代头孢菌素
AI208,CA25953-19-9,0002-7265-13,,J01DB04,RX1234574,H8I9J0K1,CHEMBL1241,33036,DB00923,D00266,Cefazolin,Cefazolin,CFZ,头孢唑林,头孢唑林钠,华北制药,国药准字H11021069,22,抗感染药/β-内酰胺类/第一代头孢,1g/支,1-2g,每8小时一次,静脉注射,革兰氏阳性菌感染、外科预防,头孢过敏者禁用,过敏反应、静脉炎,丙磺舒延长半衰期,围手术期预防首选,B,CrCl<35需减量,无需调整,g,静脉注射,q8h,2025-09-30,NMPA/国家基本药物目录,verified,围手术期预防用药
AI209,CA35607-66-0,0006-3541-29,,J01DC02,RX1234575,I9J0K1L2,CHEMBL1242,441199,DB00923,D00267,Cefoxitin,Cefoxitin,FOX,头孢西丁,头孢西丁钠,深圳致君,国药准字H10960148,22,抗感染药/β-内酰胺类/第二代头孢,1g/支,1-2g,每6-8小时一次,静脉注射,厌氧菌及需氧菌混合感染,头孢过敏者禁用,过敏反应、假性凝血异常,丙磺舒增加血药浓度,抗厌氧菌头孢,B,CrCl<50需减量,无需调整,g,静脉注射,q6-8h,2025-09-30,NMPA/国家基本药物目录,verified,第二代头孢菌素
AI210,CA73384-59-5,0062-1170-01,,J01DD02,RX1234576,J0K1L2M3,CHEMBL1243,5481173,DB00438,D07659,Ceftazidime,Ceftazidime,CAZ,头孢他啶,头孢他啶,葛兰素史克,国药准字H20033390,22,抗感染药/β-内酰胺类/第三代头孢,1g/支,1-2g,每8-12小时一次,静脉注射,严重革兰氏阴性菌感染,头孢过敏者禁用,过敏反应、血小板减少,氨基糖苷类协同,抗假单胞菌,B,CrCl<50需减量,无需调整,g,静脉注射,q8-12h,2025-09-30,NMPA/国家基本药物目录,verified,第三代头孢菌素
AI211,CA62893-19-0,0049-1225-83,,J01DD12,RX1234577,K1L2M3N4,CHEMBL1244,5742673,DB00303,D07660,Cefoperazone,Cefoperazone,CFP,头孢哌酮,头孢哌酮钠,辉瑞,国药准字H20023132,22,抗感染药/β-内酰胺类/第三代头孢,1g/支,2-4g,每12小时一次,静脉注射,严重细菌感染,头孢过敏者禁用,腹泻、出血倾向,避免饮酒(双硫仑反应),胆道排泄,B,无需调整,肝功能不全需减量,g,静脉注射,q12h,2025-09-30,NMPA/国家基本药物目录,verified,第三代头孢菌素
AI213,CA88040-23-7,0069-2600-71,,J01DE01,RX1234579,M3N4O5P6,CHEMBL1246,5362065,DB01331,D07648,Cefepime,Cefepime,FEP,头孢吡肟,头孢吡肟,百时美施贵宝,国药准字H20020511,22,抗感染药/β-内酰胺类/第四代头孢,1g/支,1-2g,每12小时一次,静脉注射,严重革兰氏阴性菌感染,头孢过敏者禁用,神经毒性(高剂量),氨基糖苷类协同,第四代头孢,B,CrCl<60需减量,无需调整,g,静脉注射,q12h,2025-09-30,NMPA/国家基本药物目录,verified,第四代头孢菌素
AI214,CA82419-36-1,0173-0399-00,,J01DD13,RX1234580,N4O5P6Q7,CHEMBL1247,6328,DB01139,D07649,Cefpodoxime,Cefpodoxime,CPD,头孢泊肟酯,头孢泊肟酯片,赛诺菲,国药准字H20000333,22,抗感染药/β-内酰胺类/第三代头孢,0.1g/片,0.2g,每12小时一次,口服,呼吸道、泌尿道感染,头孢过敏者禁用,腹泻、恶心,抗酸药降低吸收,口服第三代头孢,B,CrCl<30需减量,无需调整,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,口服第三代头孢
AI215,CA120138-50-3,0024-5464-01,,J01DD14,RX1234581,O5P6Q7R8,CHEMBL1248,9577,DB00430,D00924,Cefdinir,Cefdinir,CDR,头孢地尼,头孢地尼胶囊,阿斯利康,国药准字H20040812,22,抗感染药/β-内酰胺类/第三代头孢,0.1g/粒,0.3g,每12小时一次,口服,呼吸道、中耳炎、皮肤软组织感染,头孢过敏者禁用,腹泻、皮疹,铁剂影响吸收,儿科常用,B,CrCl<30需减量,无需调整,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,儿科用口服头孢
AI216,CA74431-23-5,0006-3516-59,,J01DH51,RX1234582,P6Q7R8S9,CHEMBL1249,104838,DB00303,D00209,Imipenem,Imipenem,IPM,亚胺培南,泰能(亚胺培南-西司他丁),默沙东,国药准字H20040712,22,抗感染药/β-内酰胺类/碳青霉烯类,0.5g/支,0.5g,每6小时一次,静脉注射,严重混合感染、多重耐药菌,青霉素严重过敏者慎用,癫痫发作、恶心,丙戊酸血药浓度下降,广谱高效,C,CrCl<70需减量,无需调整,g,静脉注射,q6h,2025-09-30,NMPA/国家基本药物目录,verified,碳青霉烯类抗生素
AI217,CA96036-03-2,0310-0250-20,,J01DH02,RX1234583,Q7R8S9T0,CHEMBL1250,441130,DB00760,D00208,Meropenem,Meropenem,MEM,美罗培南,美平(美罗培南),阿斯利康,国药准字H20020598,22,抗感染药/β-内酰胺类/碳青霉烯类,0.5g/支,1g,每8小时一次,静脉注射,严重腹腔感染、脑膜炎、败血症,碳青霉烯过敏者禁用,腹泻、皮疹,丙戊酸血药浓度下降,可用于脑膜炎,C,CrCl<50需减量,无需调整,g,静脉注射,q8h,2025-09-30,NMPA/国家基本药物目录,verified,可透过血脑屏障
AI218,CA70458-96-7,0078-0365-61,,J01MA02,RX1234584,R8S9T0U1,CHEMBL1251,4444,DB00537,D00210,Ciprofloxacin,Ciprofloxacin,CIP,环丙沙星,环丙沙星片,拜耳,国药准字H20033558,22,抗感染药/氟喹诺酮类,0.25g/片,0.5g,每12小时一次,口服,敏感革兰氏阴性菌感染,18岁以下儿童禁用,肌腱炎、QT间期延长,不与茶碱同服,广谱喹诺酮,C,CrCl<50需减量,无需调整,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,氟喹诺酮类
AI220,CA70458-92-3,0078-0365-62,,J01MA06,RX1234586,T0U1V2W3,CHEMBL1253,4583,DB00487,D00212,Norfloxacin,Norfloxacin,NOR,诺氟沙星,诺氟沙星胶囊,浙江医药,国药准字H33021940,22,抗感染药/氟喹诺酮类,0.1g/粒,0.4g,每12小时一次,口服,泌尿道感染、肠道感染,18岁以下儿童禁用,胃肠道反应,不与奶制品同服,用于尿路感染,C,CrCl<30需减量,无需调整,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,第二代喹诺酮
AI222,CA106635-80-7,0062-1553-41,,J01MA15,RX1234588,V2W3X4Y5,CHEMBL1255,159164,DB00365,D00214,Gatifloxacin,Gatifloxacin,GAT,加替沙星,加替沙星片,第一三共,国药准字H20040091,22,抗感染药/氟喹诺酮类,0.2g/片,0.4g,每24小时一次,口服,呼吸道、泌尿道感染,18岁以下儿童禁用、糖尿病患者慎用,血糖异常、QT延长,不与降糖药同用,第四代喹诺酮,C,CrCl<40需减量,无需调整,g,口服,q24h,2025-09-30,NMPA/国家基本药物目录,verified,可致血糖异常
AI225,CA80214-83-1,0069-3190-75,,J01FA06,RX1234591,Y5Z6A7B8,CHEMBL1258,9863776,DB01369,D00142,Roxithromycin,Roxithromycin,ROX,罗红霉素,罗红霉素分散片,赛诺菲,国药准字H19990085,22,抗感染药/大环内酯类,0.15g/片,0.15g,每12小时一次,口服,呼吸道、软组织感染,对大环内酯过敏者禁用,胃肠道反应,CYP3A4抑制,第二代大环内酯,C,无需调整,肝功能不全慎用,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,半合成大环内酯
AI226,CA57-92-1,0069-0950-15,,J01GA01,RX1234592,Z6A7B8C9,CHEMBL1259,19649,DB01082,D00150,Streptomycin,Streptomycin,STR,链霉素,硫酸链霉素注射液,华北制药,国药准字H11020496,22,抗感染药/氨基糖苷类,1g/支,0.75-1g,每24小时一次,肌肉注射,结核病、鼠疫,孕妇禁用、听力下降禁用,耳毒性、肾毒性,与利尿剂合用增加毒性,抗结核药,C,CrCl<50需减量,无需调整,g,肌肉注射,q24h,2025-09-30,NMPA/国家基本药物目录,verified,第一个氨基糖苷类
AI230,CA149-29-1,0069-0980-25,,J01GB05,RX1234596,D0E1F2G3,CHEMBL1263,8378,DB00582,D00154,Netilmicin,Netilmicin,NET,奈替米星,硫酸奈替米星注射液,先声药业,国药准字H19993101,22,抗感染药/氨基糖苷类,0.1g/支,4-6mg/kg,每24小时一次,静脉注射,革兰氏阴性菌感染,孕妇、肾功能不全禁用,耳毒性、肾毒性,监测血药浓度,半合成氨基糖苷,C,CrCl<60需减量,无需调整,g,静脉注射,q24h,2025-09-30,NMPA/国家基本药物目录,verified,耳毒性较轻
AI233,CA18323-44-9,0009-0863-01,,J01FF01,RX1234599,G3H4I5J6,CHEMBL1266,29029,DB01190,D00214,Clindamycin,Clindamycin,CLI,克林霉素,盐酸克林霉素胶囊,辉瑞,国药准字H20033074,22,抗感染药/林可酰胺类,0.15g/粒,0.6g,每8小时一次,口服,厌氧菌感染、MRSA皮肤感染,克林霉素过敏者禁用,伪膜性肠炎、腹泻,与红霉素拮抗,抗厌氧菌,C,无需调整,无需调整,g,口服,q8h,2025-09-30,NMPA/国家基本药物目录,verified,林可酰胺类抗生素
AI234,CA154-21-2,0009-0862-10,,J01FF02,RX1234600,H4I5J6K7,CHEMBL1267,3950,DB01627,D00215,Lincomycin,Lincomycin,LIN,林可霉素,盐酸林可霉素注射液,浙江医药,国药准字H33020446,22,抗感染药/林可酰胺类,0.6g/支,0.6g,每8-12小时一次,静脉注射/肌肉注射,革兰氏阳性菌及厌氧菌感染,林可霉素过敏者禁用,伪膜性肠炎、肝毒性,与红霉素拮抗,天然林可酰胺,C,无需调整,肝功能不全慎用,g,静脉注射,q8-12h,2025-09-30,NMPA/国家基本药物目录,verified,天然林可酰胺类
AI235,CA1397-89-3,0003-0293-18,,J02AC01,RX1234601,I5J6K7L8,CHEMBL1268,5280965,DB00919,D00166,Amphotericin B,Amphotericin B,AMB,两性霉素B,两性霉素B注射液,施贵宝,国药准字H20000426,22,抗感染药/抗真菌药,50mg/支,0.5-1mg/kg,每24小时一次,静脉注射,系统性真菌感染,肾功能不全慎用,肾毒性、输液反应,输注前预防用药,广谱抗真菌,C,CrCl<50需减量,无需调整,mg,静脉注射,q24h,2025-09-30,NMPA/国家基本药物目录,verified,多烯类抗真菌药
AI236,CA1403-17-4,0003-0294-25,,J02AA01,RX1234602,J6K7L8M9,CHEMBL1269,5282,DB00393,D00167,Nystatin,Nystatin,NYS,制霉菌素,制霉菌素片,华北制药,国药准字H11020636,22,抗感染药/抗真菌药,50万单位/片,200万单位,每6小时一次,口服,消化道念珠菌感染,对制霉菌素过敏者禁用,恶心、腹泻,不吸收,局部抗真菌,C,无需调整,无需调整,万单位,口服,q6h,2025-09-30,NMPA/国家基本药物目录,verified,多烯类抗真菌药
AI237,CA84625-61-6,0049-3110-47,,J02AC02,RX1234603,K7L8M9N0,CHEMBL1270,55283,DB00224,D00168,Itraconazole,Itraconazole,ITZ,伊曲康唑,斯皮仁诺,西安杨森,国药准字H10940003,22,抗感染药/三唑类抗真菌药,0.1g/粒,0.2g,每12-24小时一次,口服,深部真菌感染、甲真菌病,孕妇、肝功能不全禁用,肝毒性、心衰,与CYP3A4底物相互作用多,广谱三唑类,C,无需调整,肝功能不全禁用,g,口服,q12-24h,2025-09-30,NMPA/国家基本药物目录,verified,三唑类抗真菌药
AI238,CA137234-62-9,0049-3150-41,,J02AC03,RX1234604,L8M9N0O1,CHEMBL1271,71616,DB00582,D00169,Voriconazole,Voriconazole,VCZ,伏立康唑,威凡,辉瑞,国药准字H20040297,22,抗感染药/三唑类抗真菌药,0.2g/片,0.2g,每12小时一次,口服,侵袭性曲霉病,肝功能不全慎用,视觉障碍、肝毒性,CYP2C19多态性影响,广谱抗霉菌,C,无需调整,Child-Pugh C禁用,g,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,新型三唑类
AI239,CA179463-17-3,0006-0473-00,,J02AX04,RX1234605,M9N0O1P2,CHEMBL1272,2826718,DB00520,D00896,Caspofungin,Caspofungin,CAS,卡泊芬净,科赛斯,默沙东,国药准字H20050280,22,抗感染药/棘白菌素类,50mg/支,50mg,每24小时一次,静脉注射,侵袭性念珠菌病、曲霉病,对棘白菌素过敏者禁用,输液反应、肝酶升高,与环孢素合用增加肝毒性,棘白菌素类,C,无需调整,Child-Pugh C需减量,mg,静脉注射,q24h,2025-09-30,NMPA/国家基本药物目录,verified,棘白菌素类抗真菌药
CV107,CA144701-48-4,0078-0379-05,,C09CA06,RX1234612,T6U7V8W9,CHEMBL1279,123619,DB00796,D00400,Candesartan,Candesartan,CAN,坎地沙坦酯,必洛斯,阿斯利康,国药准字H20030514,17,心血管系统药物/ARB,8mg/片,8-16mg,每24小时一次,口服,高血压、心力衰竭,孕妇禁用,头晕、高钾血症,与ACE抑制剂合用增加不良反应,ARB类,D,无需调整,无需调整,mg,口服,q24h,2025-09-30,NMPA/国家基本药物目录,verified,ARB类降压药
CV121,CA1951-25-3,0062-3510-01,,C01BA01,RX1234626,H0I1J2K3,CHEMBL1293,2159,DB01118,D00890,Amiodarone,Amiodarone,AMD,胺碘酮,可达龙,赛诺菲,国药准字H20103581,17,心血管系统药物/III类抗心律失常药,0.2g/片,0.2g,每8小时一次(负荷)/每24小时一次(维持),口服,室性及室上性心律失常,病窦、二度以上传导阻滞禁用,肺毒性、甲状腺功能异常、QT延长,与华法林合用增加出血风险,广谱抗心律失常,C,无需调整,肝功能不全慎用,g,口服,q8h→q24h,2025-09-30,NMPA/国家基本药物目录,verified,III类抗心律失常药
CV122,CA3737-09-5,0062-3511-10,,C01BA03,RX1234627,I1J2K3L4,CHEMBL1294,36314,DB00489,D00891,Sotalol,Sotalol,SOT,索他洛尔,施太可,施贵宝,国药准字H20033354,17,心血管系统药物/III类抗心律失常药,80mg/片,80-160mg,每12小时一次,口服,室性及室上性心律失常,哮喘、窦缓、QT延长禁用,QT延长、尖端扭转型室速,监测QTc<500ms,III类抗心律失常,C,CrCl<60需减量,无需调整,mg,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,β受体阻滞+III类
CV123,CA1101-41-3,0062-3512-20,,C01BC03,RX1234628,J2K3L4M5,CHEMBL1295,4927,DB01035,D00892,Propafenone,Propafenone,PRO,普罗帕酮,心律平,雅培,国药准字H20033354,17,心血管系统药物/Ic类抗心律失常药,150mg/片,150-300mg,每8小时一次,口服,室性及室上性心律失常,严重心衰、窦缓禁用,心动过缓、头晕,与地高辛合用增加地高辛浓度,Ic类抗心律失常,C,无需调整,肝功能不全需减量,mg,口服,q8h,2025-09-30,NMPA/国家基本药物目录,verified,Ic类抗心律失常药
CV124,CA137-58-6,0069-1570-01,,C01BA01,RX1234629,K3L4M5N6,CHEMBL1296,3676,DB00281,D00567,Lidocaine,Lidocaine,LID,利多卡因,利多卡因注射液,华北制药,国药准字H11021450,17,心血管系统药物/Ib类抗心律失常药,100mg/支,1-1.5mg/kg静推,必要时重复,静脉注射,急性心梗室性心律失常,二度以上传导阻滞禁用,抽搐、低血压,与β受体阻滞剂合用减少用量,Ib类抗心律失常,C,无需调整,肝功能不全需减量,mg,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,Ib类抗心律失常药
NE101,CA57-41-0,0002-0362-01,,N03AB02,RX2001001,A1A1B1B1,CHEMBL301,1775,DB00252,D00512,Phenytoin,Phenytoin,PHT,苯妥英钠,大仑丁,东北制药,国药准字H21022286,34,神经系统药物/抗癫痫药,0.1g/片,0.2-0.4g,每日1-3次,口服,癫痫大发作、局灶性发作,窦性心动过缓、房室传导阻滞禁用,牙龈增生、共济失调、皮疹,"CYP450诱导剂,降低多种药物疗效","治疗窗窄,监测血药浓度10-20μg/ml",D,正常剂量,肝功能不全需减量,g,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,经典抗癫痫药
NE102,CA298-46-4,0002-0363-10,,N03AF01,RX2001002,B2B2C2C2,CHEMBL302,2554,DB00564,D00564,Carbamazepine,Carbamazepine,CBZ,卡马西平,得理多,诺华,国药准字H20033354,34,神经系统药物/抗癫痫药,0.2g/片,0.6-1.2g,每日2-3次,口服,癫痫部分性发作、三叉神经痛,房室传导阻滞、骨髓抑制禁用,嗜睡、头晕、低钠血症、皮疹,CYP3A4诱导剂,监测血药浓度4-12μg/ml,D,CrCl<10慎用,肝功能不全需减量,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,三叉神经痛首选
NE103,CA99-66-1,0002-2380-60,,N03AG01,RX2001003,C3C3D3D3,CHEMBL303,3121,DB00313,D00399,Valproate,Valproic Acid,VPA,丙戊酸钠,德巴金,赛诺菲,国药准字H20010595,34,神经系统药物/抗癫痫药,0.2g/片,0.6-2g,每日2-3次,口服,各型癫痫、双相情感障碍,肝病、线粒体疾病禁用,肝毒性、高氨血症、体重增加、脱发,诱导肝酶,监测肝功能和血药浓度50-100μg/ml,D,正常剂量,肝功能不全禁用,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,广谱抗癫痫药
NE104,CA125911-31-9,0002-3280-30,,N03AX09,RX2001004,D4D4E4E4,CHEMBL304,441202,DB01202,D00709,Levetiracetam,Levetiracetam,LEV,左乙拉西坦,开浦兰,优时比,国药准字J20171068,34,神经系统药物/抗癫痫药,0.25g;0.5g/片,1-3g,每日2次,口服,癫痫部分性发作、全面性发作,严重肾功能不全需调整剂量,嗜睡、乏力、行为改变,无明显药物相互作用,不诱导或抑制CYP450,C,CrCl<80需减量,正常剂量,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,新型抗癫痫药
NE105,CA84057-84-1,0173-0557-00,,N03AX09,RX2001005,E5E5F5F5,CHEMBL305,3878,DB00555,D00555,Lamotrigine,Lamotrigine,LTG,拉莫三嗪,利必通,葛兰素史克,国药准字H20010595,34,神经系统药物/抗癫痫药,25mg;50mg;100mg/片,100-400mg,每日1-2次,口服,癫痫、双相情感障碍,对拉莫三嗪过敏者禁用,Stevens-Johnson综合征、皮疹,与丙戊酸合用减量,缓慢递增剂量预防皮疹,C,正常剂量,肝功能不全需减量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,双相障碍首选
NE106,CA28721-07-5,0078-0469-01,,N03AX10,RX2001006,F6F6G6G6,CHEMBL306,4530,DB00776,D00567,Oxcarbazepine,Oxcarbazepine,OXC,奥卡西平,曲莱,诺华,国药准字J20171069,34,神经系统药物/抗癫痫药,0.3g/片,0.9-2.4g,每日2次,口服,癫痫部分性发作,房室传导阻滞禁用,低钠血症、嗜睡、头晕,CYP450诱导剂,监测血钠,C,CrCl<30需减量,肝功能不全慎用,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,卡马西平类似物
NE107,CA59-92-7,0006-0104-68,,N04BA01,RX2001007,G7G7H7H7,CHEMBL307,6047,DB01235,D00059,Levodopa,Levodopa,LD,左旋多巴,美多巴(左旋多巴+苄丝肼),罗氏,国药准字H20053036,34,神经系统药物/抗帕金森病药,250mg/片,0.5-1.5g,每日3-4次,口服,帕金森病,闭角型青光眼、精神病禁用,运动并发症、恶心、直立性低血压,与维生素B6拮抗,餐前1小时或餐后1.5小时服用,C,正常剂量,正常剂量,g,口服,TID-QID,2025-09-30,NMPA/国家基本药物目录,verified,帕金森病金标准
NE108,CA28860-95-9,0597-0198-60,,N04BA02,RX2001008,H8H8I8I8,CHEMBL308,77955,DB00439,D00558,Carbidopa,Carbidopa,CD,卡比多巴,息宁(卡比多巴+左旋多巴),默沙东,国药准字J20171070,34,神经系统药物/抗帕金森病药,25mg/片(复方),75-200mg,每日3-4次,口服,帕金森病,闭角型青光眼禁用,运动障碍、幻觉、低血压,与左旋多巴联用,外周多巴脱羧酶抑制剂,C,正常剂量,正常剂量,mg,口服,TID-QID,2025-09-30,NMPA/国家基本药物目录,verified,DOPA脱羧酶抑制剂
NE109,CA191-26-4,0597-0199-30,,N04BC05,RX2001009,I9I9J9J9,CHEMBL309,119570,DB00413,D03359,Pramipexole,Pramipexole,PPX,普拉克索,米拉帕,勃林格殷格翰,国药准字J20171071,34,神经系统药物/抗帕金森病药,0.25mg;1mg/片,1.5-4.5mg,每日3次,口服,帕金森病、不宁腿综合征,严重肾功能不全慎用,嗜睡、突然入睡、幻觉、水肿,西咪替丁增加血药浓度,D3受体激动剂,C,CrCl<50需减量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,多巴胺受体激动剂
NE110,CA14611-51-9,0069-0251-66,,N04BD01,RX2001010,J0J0K0K0,CHEMBL310,26934,DB01037,D00780,Selegiline,Selegiline,SEL,司来吉兰,思吉宁,梯瓦,国药准字J20171072,34,神经系统药物/抗帕金森病药,5mg/片,5-10mg,每日1-2次,口服,帕金森病,与SSRI/三环类抗抑郁药合用禁忌,失眠、头晕、恶心,MAO-B抑制剂,早晨和中午服用避免失眠,C,正常剂量,正常剂量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,MAO-B抑制剂
NE111,CA768-94-5,0069-0252-30,,N04BB01,RX2001011,K1K1L1L1,CHEMBL311,2130,DB00915,D07441,Amantadine,Amantadine,AMA,金刚烷胺,盐酸金刚烷胺片,石药集团,国药准字H13022062,34,神经系统药物/抗帕金森病药,0.1g/片,0.2-0.3g,每日2次,口服,帕金森病、流感A预防,癫痫、胃溃疡禁用,失眠、幻觉、网状青斑,抗胆碱能药增加不良反应,促进多巴胺释放,C,CrCl<50需减量,正常剂量,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,多机制抗帕金森药
NE112,CA439-14-5,0078-0343-05,,N05BA01,RX2001012,L2L2M2M2,CHEMBL312,3016,DB00829,D00293,Diazepam,Diazepam,DZP,地西泮,安定,罗氏,国药准字H33020828,34,神经系统药物/苯二氮䓬类,2.5mg;5mg/片,5-10mg,每日1-3次,口服,焦虑、失眠、癫痫持续状态,重症肌无力、急性闭角型青光眼禁用,嗜睡、依赖性、呼吸抑制,与阿片类合用增加呼吸抑制,长期使用需逐渐停药,D,正常剂量,肝功能不全需减量,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,经典苯二氮䓬类
NE113,CA846-49-1,0078-0344-10,,N05BA12,RX2001013,M3M3N3N3,CHEMBL313,3278,DB01215,D01372,Estazolam,Estazolam,EST,艾司唑仑,舒乐安定,江苏恩华,国药准字H32020170,34,神经系统药物/苯二氮䓬类,1mg;2mg/片,1-2mg,睡前服用,口服,失眠,重症肌无力、呼吸衰竭禁用,嗜睡、依赖性、认知障碍,与CNS抑制剂合用增强作用,中效苯二氮䓬类,D,正常剂量,肝功能不全需减量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,中效催眠药
NE114,CA82626-48-0,0069-5180-68,,N05CF02,RX2001014,N4N4O4O4,CHEMBL314,5732,DB00425,D08690,Zolpidem,Zolpidem,ZLP,唑吡坦,思诺思,赛诺菲,国药准字H20080577,34,神经系统药物/非苯二氮䓬类催眠药,10mg/片,5-10mg,睡前服用,口服,失眠,重症肌无力、呼吸衰竭禁用,梦游、依赖性(较轻)、头晕,与CYP3A4抑制剂合用增加血药浓度,"Z药物,依赖性较BZD轻",C,正常剂量,肝功能不全需减量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,Z药物
NE115,CA43200-80-2,0069-5181-30,,N05CF01,RX2001015,O5O5P5P5,CHEMBL315,5282452,DB01198,D01372,Zopiclone,Zopiclone,ZPC,佐匹克隆,忆梦返,赛诺菲,国药准字H20080578,34,神经系统药物/非苯二氮䓬类催眠药,7.5mg/片,7.5mg,睡前服用,口服,失眠,重症肌无力、呼吸衰竭禁用,苦味、口干、依赖性(较轻),与CNS抑制剂合用增强作用,Z药物,C,正常剂量,肝功能不全需减量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,Z药物
NE116,CA120014-06-4,0069-0110-30,,N06DA02,RX2001016,P6P6Q6Q6,CHEMBL316,3152,DB00843,D07869,Donepezil,Donepezil,DNP,多奈哌齐,安理申,卫材,国药准字J20171073,34,神经系统药物/胆碱酯酶抑制剂,5mg;10mg/片,5-10mg,每日1次,口服,轻中度阿尔茨海默病,对哌啶类过敏者禁用,恶心、腹泻、肌肉痉挛,与抗胆碱药拮抗,睡前服用,C,正常剂量,正常剂量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,胆碱酯酶抑制剂
NE117,CA19982-08-2,0456-3202-30,,N06DX01,RX2001017,Q7Q7R7R7,CHEMBL317,4054,DB00843,D04905,Memantine,Memantine,MEM,美金刚,易倍申,灵北,国药准字J20171074,34,神经系统药物/NMDA受体拮抗剂,10mg/片,10-20mg,每日1-2次,口服,中重度阿尔茨海默病,严重肾功能不全慎用,头晕、头痛、便秘,尿液碱化增加血药浓度,NMDA受体拮抗剂,C,CrCl<30需减量,正常剂量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,NMDA受体拮抗剂
NE118,CA123441-03-2,0078-0557-15,,N06DA03,RX2001018,R8R8S8S8,CHEMBL318,77991,DB00989,D03822,Rivastigmine,Rivastigmine,RIV,卡巴拉汀,艾斯能,诺华,国药准字J20171075,34,神经系统药物/胆碱酯酶抑制剂,1.5mg;3mg;4.5mg;6mg/粒,6-12mg,每日2次,口服,轻中度阿尔茨海默病、帕金森病痴呆,对氨基甲酸酯过敏者禁用,恶心、呕吐、腹泻,与抗胆碱药拮抗,餐时服用减少胃肠反应,B,正常剂量,肝功能不全慎用,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,双重胆碱酯酶抑制剂
MS101,CA315-30-0,0006-0130-61,,M04AA01,RX2001019,S9S9T9T9,CHEMBL319,2094,DB00437,D00224,Allopurinol,Allopurinol,ALP,别嘌醇,别嘌醇片,葛兰素史克,国药准字H33020666,35,骨骼肌肉系统药物/抗痛风药,0.1g/片,0.2-0.3g,每日2-3次,口服,痛风、高尿酸血症,急性痛风发作期禁用,过敏反应、Stevens-Johnson综合征、肝毒性,与硫唑嘌呤合用需减量,"从小剂量开始,充足饮水",C,CrCl<20需减量,肝功能不全需减量,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,黄嘌呤氧化酶抑制剂
MS102,CA64-86-8,0009-0186-01,,M04AC01,RX2001020,T0T0U0U0,CHEMBL320,6167,DB00091,D00570,Colchicine,Colchicine,COL,秋水仙碱,秋水仙碱片,昆明制药,国药准字H53020660,35,骨骼肌肉系统药物/抗痛风药,0.5mg/片,0.5-1mg,急性发作时每1-2小时1次,口服,急性痛风性关节炎,严重肾功能不全、骨髓抑制禁用,腹泻、恶心、骨髓抑制,与CYP3A4抑制剂合用增加毒性,"治疗窗窄,肾功能不全慎用",D,CrCl<10禁用,肝功能不全慎用,mg,口服,q1-2h,2025-09-30,NMPA/国家基本药物目录,verified,急性痛风首选
MS103,CA144060-53-7,0904-6606-46,,M04AA03,RX2001021,U1U1V1V1,CHEMBL321,134018,DB00762,D01206,Febuxostat,Febuxostat,FBX,非布司他,优立通,武田,国药准字J20171076,35,骨骼肌肉系统药物/抗痛风药,40mg;80mg/片,40-80mg,每日1次,口服,痛风、高尿酸血症,正在接受硫唑嘌呤治疗者禁用,肝酶升高、皮疹、心血管事件,与硫唑嘌呤、巯嘌呤禁用,选择性黄嘌呤氧化酶抑制剂,C,CrCl<30需监测,轻中度肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,新型降尿酸药
MS104,CA3562-99-0,0006-0131-30,,M04AB03,RX2001022,V2V2W2W2,CHEMBL322,4943,DB00493,D01381,Benzbromarone,Benzbromarone,BZB,苯溴马隆,立加利仙,日本帝人,国药准字J20171077,35,骨骼肌肉系统药物/抗痛风药,50mg/片,50-100mg,每日1次,口服,痛风、高尿酸血症,严重肾功能不全、肝功能不全禁用,肝毒性、尿路结石,与阿司匹林拮抗,"尿酸排泄促进剂,充足饮水",C,CrCl<20禁用,肝功能不全禁用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,促尿酸排泄药
MS105,CA59-05-2,0006-0009-55,,L04AX03,RX2001023,W3W3X3X3,CHEMBL323,126941,DB00563,D00142,Methotrexate,Methotrexate,MTX,甲氨蝶呤,甲氨蝶呤片,辉瑞,国药准字H31020644,35,骨骼肌肉系统药物/DMARDs,2.5mg/片,7.5-25mg,每周1次,口服,类风湿关节炎、银屑病关节炎,孕妇、活动性感染、骨髓抑制禁用,骨髓抑制、肝毒性、肺炎,与NSAIDs合用增加毒性,"每周给药,同时补充叶酸",X,正常剂量,肝功能不全禁用,mg,口服,QW,2025-09-30,NMPA/国家基本药物目录,verified,RA锚定药物
MS106,CA54-05-7,0024-0152-06,,P01BA01,RX2001024,X4X4Y4Y4,CHEMBL324,3652,DB01611,D00238,Hydroxychloroquine,Hydroxychloroquine,HCQ,羟氯喹,纷乐,上海医药,国药准字H31020771,35,骨骼肌肉系统药物/DMARDs,0.1g;0.2g/片,0.2-0.4g,每日1-2次,口服,类风湿关节炎、系统性红斑狼疮,视网膜病变、G6PD缺乏禁用,视网膜毒性、心脏毒性,与地高辛合用增加地高辛浓度,定期眼科检查,C,正常剂量,正常剂量,g,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,DMARDs基础用药
MS107,CA599-79-1,0006-0009-56,,A07EC01,RX2001025,Y5Y5Z5Z5,CHEMBL325,5339,DB00795,D00448,Sulfasalazine,Sulfasalazine,SSZ,柳氮磺吡啶,柳氮磺吡啶肠溶片,上海信谊,国药准字H31020557,35,骨骼肌肉系统药物/DMARDs,0.25g;0.5g/片,2-3g,每日3-4次,口服,类风湿关节炎、溃疡性结肠炎,磺胺过敏、G6PD缺乏禁用,胃肠道反应、皮疹、血液学异常,与叶酸拮抗,"餐后服用,充足饮水",B,正常剂量,肝功能不全慎用,g,口服,TID-QID,2025-09-30,NMPA/国家基本药物目录,verified,RA和IBD用药
MS108,CA75706-12-6,0024-0220-10,,L04AA13,RX2001026,Z6Z6A7A7,CHEMBL326,3899,DB01097,D00749,Leflunomide,Leflunomide,LEF,来氟米特,爱若华,赛诺菲,国药准字H20000371,35,骨骼肌肉系统药物/DMARDs,10mg;20mg/片,10-20mg,每日1次,口服,类风湿关节炎、银屑病关节炎,孕妇、严重肝功能不全禁用,腹泻、肝毒性、高血压,与华法林合用增加INR,"有效避孕,停药后需洗脱",X,正常剂量,肝功能不全禁用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,DMARD标准用药
MS110,CA66376-36-1,0006-0925-31,,M05BA04,RX2001028,B8B8C9C9,CHEMBL328,2088,DB00630,D00939,Alendronate,Alendronate,ALN,阿仑膦酸钠,福善美,默沙东,国药准字J20171078,35,骨骼肌肉系统药物/双膦酸盐,70mg/片,70mg,每周1次,口服,骨质疏松症、Paget病,食管疾病、低钙血症禁用,食管炎、肌肉骨骼疼痛、颌骨坏死,与钙剂、抗酸药同服降低吸收,"晨起空腹,直立30分钟",C,CrCl<35禁用,正常剂量,mg,口服,QW,2025-09-30,NMPA/国家基本药物目录,verified,双膦酸盐类
MS111,CA118072-93-8,0078-0471-51,,M05BA08,RX2001029,C9C9D0D0,CHEMBL329,68740,DB00399,D01968,Zoledronate,Zoledronic Acid,ZOL,唑来膦酸,择泰,诺华,国药准字J20171079,35,骨骼肌肉系统药物/双膦酸盐,5mg/支,5mg,每年1次,静脉注射,骨质疏松症、肿瘤骨转移,CrCl<35、低钙血症禁用,急性期反应、肾毒性、颌骨坏死,与氨基糖苷类合用增加低钙风险,输注时间≥15分钟,D,CrCl<35禁用,正常剂量,mg,静脉注射,QY,2025-09-30,NMPA/国家基本药物目录,verified,强效双膦酸盐
MS112,CA138844-81-2,0078-0472-30,,M05BA06,RX2001030,D0D0E1E1,CHEMBL330,60764,DB00710,D00942,Ibandronate,Ibandronic Acid,IBN,伊班膦酸,邦罗力,罗氏,国药准字J20171080,35,骨骼肌肉系统药物/双膦酸盐,150mg/片,150mg,每月1次,口服,骨质疏松症,食管疾病、低钙血症禁用,食管炎、肌肉骨骼疼痛,与钙剂、抗酸药同服降低吸收,"晨起空腹,直立60分钟",C,CrCl<30慎用,正常剂量,mg,口服,qmo,2025-09-30,NMPA/国家基本药物目录,verified,月度双膦酸盐
MS113,CA52232-67-4,0002-8400-01,,H05AA02,RX2001031,E1E1F2F2,CHEMBL331,16134410,DB06285,D06078,Teriparatide,Teriparatide,TPT,特立帕肽,复泰奥,礼来,国药准字J20171081,35,骨骼肌肉系统药物/甲状旁腺激素类似物,20μg/支,20μg,每日1次,皮下注射,骨质疏松症,骨肿瘤、Paget病、高钙血症禁用,头晕、腿痉挛、高钙血症,与地高辛合用需监测地高辛,"促进骨形成,限用2年",C,正常剂量,正常剂量,μg,皮下注射,QD,2025-09-30,NMPA/国家基本药物目录,verified,PTH类似物
MS114,CA47931-85-1,0078-0380-84,,H05BA01,RX2001032,F2F2G3G3,CHEMBL332,5282232,DB00017,D00017,Calcitonin,Calcitonin,CT,降钙素,密钙息,诺华,国药准字J20171082,35,骨骼肌肉系统药物/降钙素,50IU;100IU/支,100IU,每日或隔日1次,肌肉注射/鼻喷,骨质疏松症、Paget病、高钙血症,对降钙素过敏者禁用,恶心、面部潮红、鼻炎(鼻喷),与双膦酸盐联用需监测,镇痛作用,C,正常剂量,正常剂量,IU,肌肉注射/鼻喷,QD-QOD,2025-09-30,NMPA/国家基本药物目录,verified,降钙素类
OB101,CA50-56-6,0000-0360-05,,H01BB02,RX2001033,G3G3H4H4,CHEMBL333,439302,DB00107,D00089,Oxytocin,Oxytocin,OXT,缩宫素,催产素注射液,北京双鹤,国药准字H11020515,38,妇产科用药/子宫收缩药,10IU/ml,2.5-5IU,根据宫缩调整,静脉滴注/肌肉注射,引产、产后出血,胎位不正、骨盆狭窄禁用,子宫过度收缩、水中毒,与前列腺素合用需谨慎,"静滴需稀释,滴速监测",X,正常剂量,正常剂量,IU,静脉滴注,continuous,2025-09-30,NMPA/国家基本药物目录,verified,子宫收缩剂
OB102,CA60-79-7,0000-0361-10,,G02AB03,RX2001034,H4H4I5I5,CHEMBL334,8223,DB01253,D00695,Ergometrine,Ergonovine,ERG,麦角新碱,麦角新碱注射液,上海禾丰,国药准字H31020585,38,妇产科用药/子宫收缩药,0.2mg/ml,0.2mg,必要时重复,肌肉注射/静脉注射,产后出血、子宫复旧,妊娠、高血压、心脏病禁用,高血压、恶心、头痛,与血管收缩药合用禁忌,静脉注射需缓慢,X,正常剂量,正常剂量,mg,肌肉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,麦角类子宫收缩剂
OB103,CA37025-55-1,0000-0362-15,,H01BB03,RX2001035,I5I5J6J6,CHEMBL335,6433101,DB06210,D07235,Carbetocin,Carbetocin,CBT,卡贝缩宫素,卡贝缩宫素注射液,辉凌,国药准字J20171083,38,妇产科用药/子宫收缩药,100μg/ml,100μg,单次给药,静脉注射,剖宫产后预防出血,妊娠、癫痫禁用,恶心、腹痛、潮红,与其他缩宫素合用增强作用,长效缩宫素类似物,X,正常剂量,肝肾功能不全慎用,μg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,长效缩宫素
RS101,CA18683-91-5,0597-0108-01,,R05CB06,RX3001001,J1J1K1K1,CHEMBL401,2161,DB06742,D07533,Ambroxol,Ambroxol,AMB,氨溴索,沐舒坦,勃林格殷格翰,国药准字H20031342,23,呼吸系统药物/祛痰药,30mg/片,30mg,每日3次,口服,急慢性呼吸道疾病痰液排出障碍,对氨溴索过敏者禁用,恶心、胃肠道不适,与抗生素合用增强抗生素在肺部浓度,促进肺泡表面活性物质分泌,C,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,黏液溶解剂
RS102,CA3572-43-8,0597-0109-10,,R05CB03,RX3001002,K2K2L2L2,CHEMBL402,2442,DB06742,D01373,Bromhexine,Bromhexine,BRO,溴己新,必嗽平,上海信谊,国药准字H31020829,23,呼吸系统药物/祛痰药,8mg/片,16mg,每日3次,口服,慢性支气管炎、支气管哮喘,对溴己新过敏者禁用,恶心、胃部不适,与抗生素合用增强抗生素作用,氨溴索的前体药物,C,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,黏液溶解剂
RS103,CA616-91-1,0597-0110-15,,R05CB01,RX3001003,L3L3M3M3,CHEMBL403,12035,DB06742,D00221,Acetylcysteine,Acetylcysteine,NAC,乙酰半胱氨酸,富露施,赞邦,国药准字H20103476,23,呼吸系统药物/祛痰药,0.2g/袋,0.4-0.6g,每日2-3次,口服,痰液黏稠不易咳出、对乙酰氨基酚中毒,活动性消化性溃疡禁用,恶心、支气管痉挛,与青霉素类抗生素有配伍禁忌,具有抗氧化作用,B,正常剂量,正常剂量,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,黏液溶解剂+解毒剂
RS104,CA23319-66-6,0597-0111-20,,R05CB13,RX3001004,M4M4N4N4,CHEMBL404,29769,DB06742,D03850,Carbocisteine,Carbocisteine,CCL,羧甲司坦,羧甲司坦口服溶液,苏州东瑞,国药准字H20093600,23,呼吸系统药物/祛痰药,0.25g/片,0.5g,每日3次,口服,慢性支气管炎、支气管扩张,活动性消化性溃疡禁用,胃肠道反应、皮疹,与抗生素合用协同作用,调节痰液黏稠度,C,正常剂量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,黏液调节剂
RS105,CA58-55-9,0002-4928-01,,R03DA04,RX3001005,N5N5O5O5,CHEMBL405,2519,DB00277,D00371,Theophylline,Theophylline,THEO,茶碱,茶碱缓释片,阿斯利康,国药准字H20033415,23,呼吸系统药物/平喘药,0.1g;0.2g/片,0.2-0.4g,每日2次,口服,支气管哮喘、慢性阻塞性肺疾病,活动性消化性溃疡、癫痫禁用,恶心、心动过速、癫痫,CYP1A2底物,监测血药浓度5-15μg/ml,C,CrCl<50需监测,肝功能不全需减量,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,甲基黄嘌呤类
RS106,CA317-34-0,0002-4929-10,,R03DA05,RX3001006,O6O6P6P6,CHEMBL406,2165,DB00277,D00525,Aminophylline,Aminophylline,APL,氨茶碱,氨茶碱注射液,石药集团,国药准字H13022062,23,呼吸系统药物/平喘药,0.25g/支,0.25g,缓慢静推,静脉注射,哮喘急性发作、心源性哮喘,心肌梗死急性期禁用,心律失常、低血压,CYP1A2底物,静推速度<25mg/min,C,CrCl<50需监测,肝功能不全需减量,g,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,茶碱复盐
RS107,CA34850-67-8,0597-0115-25,,R03DA11,RX3001007,P7P7Q7Q7,CHEMBL407,55466,DB00277,D01223,Doxofylline,Doxofylline,DOX,多索茶碱,多索茶碱片,意大利凯西,国药准字J20171084,23,呼吸系统药物/平喘药,0.2g/片,0.4g,每日2次,口服,支气管哮喘、慢性阻塞性肺疾病,急性心肌梗死禁用,头痛、胃肠道反应,与喹诺酮类合用需监测,较茶碱不良反应少,C,正常剂量,肝功能不全需减量,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,新型茶碱类
RS108,CA113-92-8,0002-3308-01,,R06AB04,RX3001008,Q8Q8R8R8,CHEMBL408,2726,DB00477,D00238,Chlorphenamine,Chlorpheniramine,CPA,氯苯那敏,扑尔敏,上海信谊,国药准字H31020900,23,呼吸系统药物/抗组胺药,4mg/片,4mg,每日3次,口服,过敏性鼻炎、荨麻疹、皮肤瘙痒,新生儿、哺乳期禁用,嗜睡、口干、尿潴留,与CNS抑制剂合用增强作用,第一代抗组胺药,B,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,第一代抗组胺药
EN101,CA51-48-9,0000-8479-01,,H03AA01,RX3001009,R9R9S9S9,CHEMBL409,5819,DB00451,D01010,Levothyroxine,Levothyroxine,LT4,左甲状腺素钠,优甲乐,默克,国药准字J20171085,28,内分泌系统药物/甲状腺激素,25μg;50μg;100μg/片,50-200μg,每日1次,口服,甲状腺功能减退症,甲亢未控制、急性心肌梗死禁用,心悸、心律失常、骨质疏松,与华法林合用增加INR,晨起空腹服用,A,正常剂量,正常剂量,μg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,甲状腺激素替代治疗
EN102,CA51-52-5,0000-8480-10,,H03BB02,RX3001010,S0S0T0T0,CHEMBL410,667490,DB00763,D00562,Propylthiouracil,Propylthiouracil,PTU,丙硫氧嘧啶,丙硫氧嘧啶片,上海信谊,国药准字H31020831,29,内分泌系统药物/抗甲状腺药,50mg/片,150-450mg,每日3次,口服,甲状腺功能亢进症,严重肝功能不全禁用,肝毒性、粒细胞缺乏、皮疹,与华法林合用增加出血风险,定期监测肝功能和血常规,D,正常剂量,肝功能不全禁用,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗甲状腺药
EN103,CA60-56-0,0000-8481-15,,H03BB01,RX3001011,T1T1U1U1,CHEMBL411,2928,DB00763,D00401,Thiamazole,Methimazole,MMI,甲巯咪唑,他巴唑,默克,国药准字J20171086,29,内分泌系统药物/抗甲状腺药,5mg;10mg/片,15-40mg,每日1-3次,口服,甲状腺功能亢进症,严重肝肾功能不全禁用,粒细胞缺乏、肝毒性、皮疹,与β受体阻滞剂合用控制症状,定期监测血常规,D,正常剂量,肝功能不全慎用,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,抗甲状腺药首选
EN104,CA7681-11-0,0000-8482-20,,H03BA,RX3001012,U2U2V2V2,CHEMBL412,4875,DB06764,D02324,Potassium_iodide,Potassium Iodide,KI,碘化钾,碘化钾片,上海信谊,国药准字H31020832,29,内分泌系统药物/抗甲状腺药,50mg/片,300-500mg,每日1次,口服,甲亢术前准备、甲状腺危象,结核病、肾炎禁用,碘中毒、甲状腺肿大,与锂盐合用增加甲减风险,术前2周开始使用,D,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,碘制剂
EN105,CA50-23-7,0009-0022-01,,H02AB09,RX3001013,V3V3W3W3,CHEMBL413,5754,DB00741,D00165,Hydrocortisone,Hydrocortisone,HC,氢化可的松,氢化可的松片,天津天药,国药准字H12020176,30,内分泌系统药物/糖皮质激素,20mg/片,20-240mg,每日2-4次,口服,肾上腺皮质功能不全、严重过敏,全身真菌感染禁用,库欣综合征、骨质疏松、高血糖,与NSAIDs合用增加胃肠道风险,生理替代剂量20mg/d,C,正常剂量,正常剂量,mg,口服,BID-QID,2025-09-30,NMPA/国家基本药物目录,verified,短效糖皮质激素
EN106,CA53-03-2,0009-0023-10,,H02AB07,RX3001014,W4W4X4X4,CHEMBL414,5865,DB00635,D00472,Prednisone,Prednisone,PDN,泼尼松,泼尼松片,天津天药,国药准字H12020177,30,内分泌系统药物/糖皮质激素,5mg/片,5-60mg,每日1-4次,口服,自身免疫性疾病、过敏性疾病,全身真菌感染、活动性消化性溃疡禁用,库欣综合征、骨质疏松、感染,与CYP3A4诱导剂合用降低疗效,晨起一次服用模拟生理分泌,C,正常剂量,肝功能不全需监测,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,中效糖皮质激素
EN107,CA50-02-2,0009-0024-15,,H02AB02,RX3001015,X5X5Y5Y5,CHEMBL415,5743,DB01234,D00292,Dexamethasone,Dexamethasone,DEX,地塞米松,地塞米松片,天津天药,国药准字H12020178,30,内分泌系统药物/糖皮质激素,0.75mg/片,0.75-9mg,每日1-4次,口服,过敏性疾病、脑水肿、抗肿瘤,全身真菌感染禁用,库欣综合征、HPA轴抑制,与苯妥英钠合用降低地塞米松疗效,"长效糖皮质激素,25倍氢化可的松",C,正常剂量,正常剂量,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,长效糖皮质激素
EN108,CA378-44-9,0009-0025-20,,H02AB01,RX3001016,Y6Y6Z6Z6,CHEMBL416,9782,DB00443,D00244,Betamethasone,Betamethasone,BET,倍他米松,倍他米松片,天津天药,国药准字H12020179,30,内分泌系统药物/糖皮质激素,0.5mg/片,0.5-5mg,每日1-4次,口服,自身免疫性疾病、过敏性疾病,全身真菌感染禁用,库欣综合征、骨质疏松,与利尿剂合用增加低钾风险,长效糖皮质激素,C,正常剂量,正常剂量,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,长效糖皮质激素
EN109,CA83-43-2,0009-0026-25,,H02AB04,RX3001017,Z7Z7A8A8,CHEMBL417,222284,DB00959,D00979,Methylprednisolone,Methylprednisolone,MPS,甲泼尼龙,甲泼尼龙片,辉瑞,国药准字H20103319,30,内分泌系统药物/糖皮质激素,4mg;16mg/片,4-48mg,每日1-4次,口服,自身免疫性疾病、器官移植,全身真菌感染禁用,库欣综合征、骨质疏松、感染,与环孢素合用增加环孢素血药浓度,中效糖皮质激素,C,正常剂量,肝功能不全需监测,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,中效糖皮质激素
VIT101,CA68-26-8,0069-0990-10,,A11CA01,RX3001019,B9B9C0C0,CHEMBL419,445354,DB00162,D00069,Vitamin_A,Vitamin A,VA,维生素A,维生素A软胶囊,北京双鹤,国药准字H11020516,41,维生素/脂溶性维生素,25000IU/粒,25000-50000IU,每日1次,口服,维生素A缺乏、夜盲症,孕妇大剂量禁用、慢性肾衰禁用,急慢性中毒、肝毒性、骨痛,与四环素合用增加颅内压,"脂溶性维生素,过量蓄积",A/X,正常剂量,肝功能不全慎用,IU,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,脂溶性维生素
VIT102,CA59-43-8,0069-0991-15,,A11DA01,RX3001020,C0C0D1D1,CHEMBL420,6042,DB00152,D00068,Thiamine,Thiamine (Vitamin B1),VB1,维生素B1,维生素B1片,华北制药,国药准字H11020293,41,维生素/水溶性维生素,10mg/片,10-100mg,每日3次,口服,维生素B1缺乏、脚气病、神经炎,对维生素B1过敏者禁用,过敏反应(罕见),与碱性药物配伍失活,水溶性维生素,A,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,水溶性维生素
VIT103,CA83-88-5,0069-0992-20,,A11HA04,RX3001021,D1D1E2E2,CHEMBL421,493570,DB00140,D00067,Riboflavin,Riboflavin (Vitamin B2),VB2,维生素B2,维生素B2片,华北制药,国药准字H11020294,41,维生素/水溶性维生素,5mg/片,5-10mg,每日3次,口服,维生素B2缺乏、口角炎,无禁忌症,黄色尿液(正常现象),与甲氧氯普胺合用增加吸收,水溶性维生素,A,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,水溶性维生素
VIT104,CA65-23-6,0069-0993-25,,A11HA02,RX3001022,E2E2F3F3,CHEMBL422,1054,DB00165,D00066,Pyridoxine,Pyridoxine (Vitamin B6),VB6,维生素B6,维生素B6片,华北制药,国药准字H11020295,41,维生素/水溶性维生素,10mg/片,10-60mg,每日3次,口服,维生素B6缺乏、妊娠呕吐、周围神经炎,大剂量长期使用可致神经病变,大剂量周围神经病,与左旋多巴拮抗,辅酶参与氨基酸代谢,A,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,水溶性维生素
VIT105,CA10191-41-0,0069-0994-30,,A11CC01,RX3001023,F3F3G4G4,CHEMBL423,1742129,DB00162,D00070,Vitamin_E,Vitamin E (Tocopherol),VE,维生素E,维生素E软胶囊,来益,国药准字H33021880,41,维生素/脂溶性维生素,100mg/粒,100-400mg,每日1-3次,口服,习惯性流产、不孕症、抗氧化,出血倾向者慎用,恶心、腹泻、血栓风险(大剂量),与华法林合用增加出血风险,脂溶性抗氧化剂,A,正常剂量,正常剂量,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,脂溶性维生素
VIT106,CA84-80-0,0069-0995-35,,B03BB01,RX3001024,G4G4H5H5,CHEMBL424,6037,DB00166,D00071,Vitamin_K1,Phytomenadione (Vitamin K1),VK1,维生素K1,维生素K1注射液,上海禾丰,国药准字H31020586,41,维生素/脂溶性维生素,10mg/ml,10-40mg,必要时重复,肌肉注射/静脉注射,维生素K缺乏、新生儿出血、华法林过量,对维生素K过敏者禁用,过敏反应、溶血(新生儿大剂量),拮抗华法林作用,凝血因子合成必需,C,正常剂量,正常剂量,mg,肌肉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,脂溶性维生素
MIN101,CA471-34-1,0069-0996-40,,A12AA04,RX3001025,H5H5I6I6,CHEMBL425,10112,DB06724,D00932,Calcium_carbonate,Calcium Carbonate,CaCO3,碳酸钙,钙尔奇,惠氏,国药准字H10950029,42,矿物质/钙剂,600mg/片(含钙240mg),600-1200mg,每日2-3次,口服,钙缺乏、骨质疏松、妊娠补钙,高钙血症、肾结石禁用,便秘、腹胀,与四环素、喹诺酮类间隔2小时,餐时服用增加吸收,B,CrCl<30慎用,正常剂量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,钙剂
MIN102,CA299-28-5,0069-0997-45,,A12AA03,RX3001026,I6I6J7J7,CHEMBL426,9287,DB11126,D00933,Calcium_gluconate,Calcium Gluconate,GluCa,葡萄糖酸钙,葡萄糖酸钙片,华北制药,国药准字H11020296,42,矿物质/钙剂,0.5g/片,1-2g,每日3次,口服,低钙血症、过敏性疾病辅助,高钙血症、地高辛中毒禁用,便秘、恶心,与洋地黄类合用增加毒性,有机钙,B,CrCl<30慎用,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,有机钙剂
MIN103,CA814-20-0,0069-0998-50,,A12AA10,RX3001027,J7J7K8K8,CHEMBL427,151751,DB11093,D00934,Calcium_lactate,Calcium Lactate,LacCa,乳酸钙,乳酸钙片,上海信谊,国药准字H31020833,42,矿物质/钙剂,0.5g/片,1-2g,每日3次,口服,儿童补钙、孕妇补钙,高钙血症禁用,便秘、腹胀,与铁剂间隔服用,"有机钙,吸收较好",B,CrCl<30慎用,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,有机钙剂
MIN104,CA7720-78-7,0069-0999-55,,B03AA07,RX3001028,K8K8L9L9,CHEMBL428,24393,DB13257,D00166,Ferrous_sulfate,Ferrous Sulfate,FeSO4,硫酸亚铁,硫酸亚铁片,上海信谊,国药准字H31020834,43,矿物质/铁剂,0.3g/片(含铁60mg),0.3g,每日3次,口服,缺铁性贫血,溶血性贫血、铁负荷过重禁用,胃肠道反应、黑便,与抗酸药、钙剂间隔服用,餐后服用减少胃肠反应,A,正常剂量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,无机铁剂
GI107,CA114870-03-0,0186-0885-01,,A02BA07,RX4001007,R7R7S7S7,CHEMBL507,2844,DB00585,D00318,Nizatidine,Nizatidine,NIZ,尼扎替丁,尼扎替丁胶囊,礼来,国药准字J20171091,20,消化系统药物/H2受体拮抗剂,150mg/粒,150-300mg,每日1-2次,口服,消化性溃疡、反流性食管炎,对H2受体拮抗剂过敏者禁用,头痛、腹泻,与阿司匹林合用增加阿司匹林血药浓度,H2受体拮抗剂,B,CrCl<50需减量,正常剂量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,H2受体拮抗剂
GI109,CA99614-02-5,0173-0461-00,,A04AA01,RX4001009,T9T9U9U9,CHEMBL509,4595,DB00904,D00456,Ondansetron,Ondansetron,OND,昂丹司琼,枢复宁,葛兰素史克,国药准字H20033338,19,消化系统药物/5-HT3受体拮抗剂,4mg;8mg/片,8mg,每日2-3次,口服,化疗、放疗引起的恶心呕吐,对5-HT3受体拮抗剂过敏者禁用,头痛、便秘、QT延长,与阿扑吗啡合用禁忌,5-HT3受体拮抗剂,B,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,强效止吐药
GI110,CA109889-09-0,0173-0462-10,,A04AA02,RX4001010,U0U0V0V0,CHEMBL510,3510,DB00889,D00620,Granisetron,Granisetron,GRA,格拉司琼,康泉,罗氏,国药准字J20171092,19,消化系统药物/5-HT3受体拮抗剂,1mg/片,1-2mg,每日1次,口服,化疗引起的恶心呕吐,对5-HT3受体拮抗剂过敏者禁用,头痛、便秘,与阿扑吗啡合用禁忌,5-HT3受体拮抗剂,B,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,强效止吐药
GI111,CA364-62-5,0002-3475-01,,A03FA01,RX4001011,V1V1W1W1,CHEMBL511,4168,DB01233,D00726,Metoclopramide,Metoclopramide,MCP,甲氧氯普胺,胃复安,康恩贝,国药准字H33020829,19,消化系统药物/多巴胺受体拮抗剂,5mg;10mg/片,10mg,每日3次,口服,恶心呕吐、功能性消化不良,嗜铬细胞瘤、胃肠梗阻禁用,锥体外系反应、迟发性运动障碍,与左旋多巴拮抗,促胃肠动力,B,CrCl<40需减量,肝功能不全需减量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,促动力+止吐药
GI114,CA1302-78-9,0173-0465-40,,A07BC05,RX4001014,Y4Y4Z4Z4,CHEMBL514,56841936,DB06771,D01384,Montmorillonite,Montmorillonite,MMT,蒙脱石,思密达,博福-益普生,国药准字J20171094,20,消化系统药物/肠道吸附剂,3g/袋,3g,每日3次,口服,急慢性腹泻、肠道炎症,肠梗阻禁用,便秘,影响其他药物吸收,肠道黏膜保护剂,B,正常剂量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,肠道吸附剂
GI115,CA53179-11-6,0062-1470-01,,A07DA03,RX4001015,Z5Z5A6A6,CHEMBL515,3955,DB00836,D00119,Loperamide,Loperamide,LOP,洛哌丁胺,易蒙停,西安杨森,国药准字H10940123,20,消化系统药物/阿片受体激动剂,2mg/粒,"4mg首剂,后2mg",腹泻后服用,口服,急慢性腹泻,伪膜性肠炎、细菌性腹泻禁用,便秘、腹痛,与奎尼丁合用增加心脏毒性,外周阿片受体激动剂,B,正常剂量,肝功能不全慎用,mg,口服,prn,2025-09-30,NMPA/国家基本药物目录,verified,止泻药
GI116,CA81110-73-8,0173-0466-50,,A07DA04,RX4001016,A6A6B7B7,CHEMBL516,151171,DB06770,D07237,Racecadotril,Racecadotril,RAC,消旋卡多曲,卡多曲颗粒,施维雅,国药准字J20171095,20,消化系统药物/脑啡肽酶抑制剂,10mg;30mg/袋,100mg,每日3次,口服,急性腹泻,对消旋卡多曲过敏者禁用,皮疹、头痛,无明显药物相互作用,减少肠道分泌,B,正常剂量,肝功能不全慎用,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗分泌性止泻药
GI117,CA4618-18-2,0173-0467-60,,A06AD11,RX4001017,B7B7C8C8,CHEMBL517,11333,DB00581,D00352,Lactulose,Lactulose,LAC,乳果糖,杜密克,雅培,国药准字J20171096,21,消化系统药物/渗透性泻药,10g/15ml,15-30ml,每日1-2次,口服,便秘、肝性脑病,半乳糖血症禁用,腹胀、腹泻,与抗生素合用降低疗效,在结肠分解产酸,B,正常剂量,正常剂量,ml,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,渗透性泻药
GI118,CA25322-68-3,0173-0468-70,,A06AD15,RX4001018,C8C8D9D9,CHEMBL518,6254,DB09325,D03961,Polyethylene_glycol,Polyethylene Glycol 4000,PEG,聚乙二醇,福松,鲁南,国药准字H20040629,21,消化系统药物/渗透性泻药,10g/袋,10-20g,每日1-2次,口服,便秘,肠梗阻禁用,腹胀、腹泻,无明显药物相互作用,高分子渗透性泻药,C,正常剂量,正常剂量,g,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,渗透性泻药
HE101,CA299-27-4,0069-1100-10,,B03AA02,RX4001019,D9D9E0E0,CHEMBL519,6093,DB13251,D00375,Ferrous_gluconate,Ferrous Gluconate,FeGlu,葡萄糖酸亚铁,葡萄糖酸亚铁片,华北制药,国药准字H11020297,26,血液系统药物/铁剂,0.3g/片(含铁35mg),0.3g,每日3次,口服,缺铁性贫血,溶血性贫血、铁负荷过重禁用,胃肠道反应较硫酸亚铁轻,与抗酸药间隔服用,"有机铁,吸收好",A,正常剂量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,有机铁剂
HE102,CA9004-66-4,0069-1101-20,,B03AC06,RX4001020,E0E0F1F1,CHEMBL520,16129622,DB08875,D04489,Iron_dextran,Iron Dextran,FeDex,右旋糖酐铁,右旋糖酐铁注射液,正大丰海,国药准字H10950029,26,血液系统药物/注射铁剂,50mg/ml,100-200mg,每周1-2次,肌肉注射/静脉注射,口服铁剂无效或不耐受的缺铁性贫血,急性感染、铁负荷过重禁用,过敏反应、注射部位疼痛,首剂试验剂量,静推需缓慢,C,CrCl<30慎用,正常剂量,mg,静脉注射,QW,2025-09-30,NMPA/国家基本药物目录,verified,注射铁剂
HE103,CA8047-67-4,0069-1102-30,,B03AC02,RX4001021,F1F1G2G2,CHEMBL521,16129623,DB09146,D08566,Iron_sucrose,Iron Sucrose,FeSuc,蔗糖铁,维乐福,日本化药,国药准字J20171097,26,血液系统药物/注射铁剂,100mg/支,100-200mg,每周1-3次,静脉注射,血液透析患者缺铁性贫血,铁负荷过重禁用,低血压、过敏反应,较右旋糖酐铁过敏反应少,透析患者首选,B,CrCl<30可用,正常剂量,mg,静脉注射,QW,2025-09-30,NMPA/国家基本药物目录,verified,新型注射铁剂
HE104,CA59-30-3,0069-1103-40,,B03BB01,RX4001022,G2G2H3H3,CHEMBL522,6037,DB00163,D00070,Folic_acid,Folic Acid,FA,叶酸,叶酸片,北京华素,国药准字H11020518,41,血液系统药物/维生素,5mg/片,5-15mg,每日1次,口服,巨幼红细胞性贫血、孕期预防神经管畸形,对叶酸过敏者禁用,过敏反应(罕见),与甲氨蝶呤拮抗,孕前3个月至孕早期补充,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,叶酸
HE105,CA13422-55-4,0069-1104-50,,B03BA03,RX4001023,H3H3I4I4,CHEMBL523,25095,DB00200,D00742,Methylcobalamin,Mecobalamin,MeCbl,甲钴胺,弥可保,卫材,国药准字J20171098,41,血液系统药物/维生素B12,0.5mg/片,1.5mg,每日3次,口服,巨幼红细胞性贫血、周围神经病变,对钴过敏者禁用,过敏反应、胃肠道反应,与氯霉素拮抗,B12活性辅酶形式,C,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,活性维生素B12
HE106,CA11096-26-7,0069-1105-60,,B03XA01,RX4001024,I4I4J5J5,CHEMBL524,16130927,DB00016,D03231,Erythropoietin,Epoetin alfa,EPO,重组人促红素,益比奥,沈阳三生,国药准字S20030085,26,血液系统药物/造血生长因子,3000IU/支,3000-10000IU,每周2-3次,皮下注射,肾性贫血、化疗相关性贫血,未控制的高血压、对EPO过敏者禁用,高血压、血栓、纯红细胞再生障碍,铁剂联用增强疗效,监测血红蛋白,C,CKD患者可用,正常剂量,IU,皮下注射,TIW,2025-09-30,NMPA/国家基本药物目录,verified,促红细胞生成素
HE108,CA9005-49-6,0069-1107-80,,B01AB01,RX4001026,K6K6L7L7,CHEMBL526,772,DB01109,D00999,Heparin,Heparin,UFH,普通肝素,肝素钠注射液,常州千红,国药准字H20023461,13,血液系统药物/抗凝药,12500IU/支,5000-10000IU,每8-12小时1次,皮下注射/静脉注射,血栓栓塞性疾病、DIC,活动性出血、血小板减少症禁用,出血、肝素诱导的血小板减少症,监测APTT,静脉血栓首选,C,正常剂量,正常剂量,IU,静脉注射,q8-12h,2025-09-30,NMPA/国家基本药物目录,verified,抗凝药
HE109,CA9041-08-1,0069-1108-90,,B01AB05,RX4001027,L7L7M8M8,CHEMBL527,772,DB01109,D07510,Enoxaparin,Enoxaparin,LMWH,依诺肝素,克赛,赛诺菲,国药准字J20171099,13,血液系统药物/抗凝药,4000IU/0.4ml,4000-6000IU,每日1-2次,皮下注射,深静脉血栓、肺栓塞、急性冠脉综合征,活动性出血、血小板减少禁用,出血、HIT风险较普通肝素低,监测抗Xa活性,低分子肝素,B,CrCl<30需减量,正常剂量,IU,皮下注射,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,低分子肝素
HE110,CA82419-36-1,0069-1109-01,,B01AB10,RX4001028,M8M8N9N9,CHEMBL528,5311419,DB14726,D07510,Fondaparinux,Fondaparinux,FPX,磺达肝癸钠,安卓,葛兰素史克,国药准字J20171100,13,血液系统药物/抗凝药,2.5mg/0.5ml,2.5mg,每日1次,皮下注射,深静脉血栓预防和治疗,活动性出血、CrCl<30禁用,出血、血小板减少,无需监测凝血功能,合成Xa因子抑制剂,B,CrCl<30禁用,正常剂量,mg,皮下注射,QD,2025-09-30,NMPA/国家基本药物目录,verified,合成抗凝药
AV101,CA36791-04-5,0173-0550-00,,J05AB01,RX5001001,N1N1O1O1,CHEMBL601,37542,DB00811,D00429,Ribavirin,Ribavirin,RBV,利巴韦林,病毒唑,东阳光,国药准字H20103520,22,抗感染药/抗病毒药,0.15g;0.25g/片,0.8-1.2g,每日2-3次,口服,呼吸道合胞病毒感染、慢性丙型肝炎,孕妇、严重贫血禁用,溶血性贫血、畸胎,与核苷类逆转录酶抑制剂拮抗,广谱抗病毒药,X,正常剂量,正常剂量,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,广谱抗病毒药
AV102,CA196618-13-0,0049-0520-30,,J05AH02,RX5001002,O2O2P2P2,CHEMBL602,65028,DB00198,D08491,Oseltamivir,Oseltamivir,OSE,奥司他韦,达菲,罗氏,国药准字J20171101,22,抗感染药/神经氨酸酶抑制剂,75mg/粒,75mg,每日2次,口服,甲型和乙型流感,对奥司他韦过敏者禁用,恶心、呕吐、神经精神症状,无明显药物相互作用,发病48小时内使用,C,CrCl<30需减量,正常剂量,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,抗流感病毒药
AV103,CA107007-99-8,0173-0551-10,,J05AB06,RX5001003,P3P3Q3Q3,CHEMBL603,3415,DB00811,D00333,Ganciclovir,Ganciclovir,GCV,更昔洛韦,丽科伟,罗氏,国药准字J20171102,22,抗感染药/抗疱疹病毒药,0.25g/片,1g,每日3次,口服,巨细胞病毒感染,中性粒细胞<500禁用,骨髓抑制、生殖毒性,与AZT合用增加血液毒性,治疗CMV视网膜炎,C,CrCl<70需减量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗CMV药物
AV104,CA134678-17-4,0173-0552-20,,J05AB14,RX5001004,Q4Q4R4R4,CHEMBL604,73339,DB00811,D00333,Valganciclovir,Valganciclovir,VGCV,缬更昔洛韦,万赛维,罗氏,国药准字J20171103,22,抗感染药/抗疱疹病毒药,450mg/片,900mg,每日2次,口服,CMV视网膜炎、器官移植CMV预防,中性粒细胞<500禁用,骨髓抑制、腹泻,与肾毒性药物合用需监测,更昔洛韦前体药,C,CrCl<60需减量,正常剂量,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,更昔洛韦前体药
AV105,CA137862-53-4,0173-0553-30,,J05AF05,RX5001005,R5R5S5S5,CHEMBL605,73339,DB00811,D01425,Lamivudine,Lamivudine,3TC,拉米夫定,贺普丁,葛兰素史克,国药准字J20171104,22,抗感染药/核苷类逆转录酶抑制剂,100mg/片,100mg,每日1次,口服,慢性乙型肝炎、HIV感染,对拉米夫定过敏者禁用,头痛、恶心、耐药性,与干扰素联用增强疗效,抗HBV和HIV,C,CrCl<50需减量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,核苷类似物
AV106,CA106941-25-7,0173-0554-40,,J05AF08,RX5001006,S6S6T6T6,CHEMBL606,60871,DB00718,D01690,Adefovir,Adefovir Dipivoxil,ADV,阿德福韦酯,贺维力,葛兰素史克,国药准字J20171105,22,抗感染药/核苷(酸)类逆转录酶抑制剂,10mg/片,10mg,每日1次,口服,慢性乙型肝炎,对阿德福韦过敏者禁用,肾毒性、骨软化症,与肾毒性药物合用需监测,耐药率较低,C,CrCl<50需减量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,核苷酸类似物
AV108,CA284461-73-0,0173-0556-60,,J05AF11,RX5001008,U8U8V8V8,CHEMBL608,159269,DB00930,D06677,Tenofovir,Tenofovir Disoproxil Fumarate,TDF,富马酸替诺福韦酯,韦瑞德,吉利德,国药准字J20171107,22,抗感染药/核苷酸类逆转录酶抑制剂,300mg/片,300mg,每日1次,口服,慢性乙型肝炎、HIV感染,对替诺福韦过敏者禁用,肾毒性、骨密度降低,与二去羟肌苷合用增加毒性,高耐药屏障,B,CrCl<50需减量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,核苷酸类似物
AP101,CA16773-42-5,0173-0600-10,,P02CA01,RX5001009,V9V9W9W9,CHEMBL609,2244,DB00518,D00134,Albendazole,Albendazole,ABZ,阿苯达唑,肠虫清,中美史克,国药准字H10920211,22,抗感染药/抗蠕虫药,0.2g/片,0.4g,单次或每日1-2次,口服,蛔虫、蛲虫、钩虫、鞭虫、囊虫病,孕妇、活动性溃疡禁用,胃肠道反应、肝毒性,与西咪替丁合用增加血药浓度,广谱驱虫药,C,正常剂量,肝功能不全慎用,g,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,广谱驱虫药
AP102,CA31431-39-7,0173-0601-20,,P02CC01,RX5001010,W0W0X0X0,CHEMBL610,4173,DB00518,D00134,Mebendazole,Mebendazole,MBZ,甲苯咪唑,安乐士,西安杨森,国药准字H10930213,22,抗感染药/抗蠕虫药,0.1g/片,0.2g,每日2次,口服,蛔虫、蛲虫、钩虫、鞭虫,孕妇禁用,腹痛、腹泻,与抗癫痫药合用降低血药浓度,驱肠道线虫,C,正常剂量,肝功能不全慎用,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,驱肠道线虫药
AP103,CA22204-24-6,0173-0602-30,,P02CB02,RX5001011,X1X1Y1Y1,CHEMBL611,16219,DB00518,D00134,Praziquantel,Praziquantel,PZQ,吡喹酮,吡喹酮片,南京制药,国药准字H32020796,22,抗感染药/抗吸虫和绦虫药,0.2g;0.6g/片,20mg/kg,每日3次,口服,血吸虫病、华支睾吸虫病、绦虫病,眼囊虫病禁用,头晕、恶心、腹痛,与氯喹合用降低血药浓度,广谱抗吸虫药,B,正常剂量,肝功能不全慎用,mg/kg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗血吸虫病药
AP104,CA443-48-1,0173-0603-40,,P01AB01,RX5001012,Y2Y2Z2Z2,CHEMBL612,2723601,DB00518,D00134,Metronidazole,Metronidazole,MNZ,甲硝唑,灭滴灵,华北制药,国药准字H11020298,22,抗感染药/抗原虫药,0.2g;0.4g/片,0.4-0.6g,每日3次,口服,阿米巴病、滴虫病、厌氧菌感染,活动性中枢神经系统疾病禁用,恶心、金属味、双硫仑反应,避免饮酒,抗厌氧菌和原虫,B,正常剂量,肝功能不全需减量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗厌氧菌+原虫
AP105,CA19387-91-8,0173-0604-50,,P01AB02,RX5001013,Z3Z3A4A4,CHEMBL613,5479,DB00518,D00134,Tinidazole,Tinidazole,TNZ,替硝唑,替硝唑片,扬子江药业,国药准字H32024165,22,抗感染药/抗原虫药,0.5g/片,1-2g,每日1次,口服,阿米巴病、滴虫病、厌氧菌感染,妊娠早期、中枢神经系统疾病禁用,恶心、金属味、双硫仑反应,避免饮酒,半衰期长,C,正常剂量,肝功能不全需减量,g,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,长效硝基咪唑类
UR101,CA153559-49-0,0173-0650-10,,G04BD08,RX5001014,A4A4B5B5,CHEMBL614,132999,DB01591,D01972,Solifenacin,Solifenacin,SOL,索利那新,卫喜康,安斯泰来,国药准字J20171108,23,泌尿系统药物/抗胆碱药,5mg;10mg/片,5-10mg,每日1次,口服,膀胱过度活动症,尿潴留、胃潴留、未控制的闭角型青光眼禁用,口干、便秘、视力模糊,与CYP3A4抑制剂合用需减量,M3受体选择性,C,CrCl<30需监测,肝功能不全需减量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,治疗OAB
UR102,CA124937-51-5,0173-0651-20,,G04BD07,RX5001015,B5B5C6C6,CHEMBL615,77991,DB01036,D01973,Tolterodine,Tolterodine,TOL,托特罗定,托特罗定片,辉瑞,国药准字J20171109,23,泌尿系统药物/抗胆碱药,2mg;4mg/片,2-4mg,每日2次,口服,膀胱过度活动症,尿潴留、胃潴留禁用,口干、便秘、头痛,CYP3A4和2D6底物,缓释制剂每日1次,C,正常剂量,肝功能不全需减量,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,治疗OAB
UR103,CA106463-17-6,0597-0210-30,,G04CA02,RX5001016,C6C6D7D7,CHEMBL616,5281037,DB01120,D00521,Tamsulosin,Tamsulosin,TAM,坦索罗辛,哈乐,安斯泰来,国药准字J20171110,24,泌尿系统药物/α1受体阻滞剂,0.2mg/粒,0.2mg,每日1次,口服,良性前列腺增生,体位性低血压禁用,头晕、直立性低血压、逆行射精,与PDE5抑制剂合用需谨慎,α1A受体选择性,C,正常剂量,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,治疗BPH
UR104,CA77-28-1,0173-0652-40,,G04CA03,RX5001017,D7D7E8E8,CHEMBL617,2913,DB01120,D00521,Terazosin,Terazosin,TER,特拉唑嗪,高特灵,雅培,国药准字J20171111,24,泌尿系统药物/α1受体阻滞剂,2mg;5mg/片,5-10mg,每日1次,口服,良性前列腺增生、高血压,对喹唑啉类过敏者禁用,头晕、乏力、直立性低血压,与PDE5抑制剂合用需谨慎,α1受体阻滞剂,C,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,治疗BPH+高血压
UR105,CA98319-26-7,0006-0050-31,,G04CB01,RX5001018,E8E8F9F9,CHEMBL618,47936,DB01120,D00321,Finasteride,Finasteride,FIN,非那雄胺,保法止,默沙东,国药准字J20171112,24,泌尿系统药物/5α还原酶抑制剂,5mg/片,5mg,每日1次,口服,良性前列腺增生,孕妇禁用,性功能障碍、男性乳房发育,与α受体阻滞剂联用协同作用,抑制睾酮转化为DHT,X,正常剂量,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,治疗BPH
UR106,CA164656-23-9,0173-0653-50,,G04CB02,RX5001019,F9F9G0G0,CHEMBL619,6918296,DB01120,D00321,Dutasteride,Dutasteride,DUT,度他雄胺,适尿通,葛兰素史克,国药准字J20171113,24,泌尿系统药物/5α还原酶抑制剂,0.5mg/粒,0.5mg,每日1次,口服,良性前列腺增生,孕妇、儿童禁用,性功能障碍、男性乳房发育,与CYP3A4抑制剂合用增加血药浓度,双重5α还原酶抑制,X,正常剂量,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,I型和II型抑制剂
UR107,CA67-20-9,0173-0654-60,,J01XE01,RX5001020,G0G0H1H1,CHEMBL620,6604200,DB00698,D00137,Nitrofurantoin,Nitrofurantoin,NIT,呋喃妥因,呋喃妥因片,东北制药,国药准字H21022287,22,抗感染药/硝基呋喃类,0.1g/片,0.1g,每日4次,口服,尿路感染,CrCl<60、G6PD缺乏禁用,恶心、肺毒性、周围神经病变,与镁铝制酸剂合用降低吸收,尿路消毒药,B,CrCl<60禁用,正常剂量,g,口服,QID,2025-09-30,NMPA/国家基本药物目录,verified,尿路消毒药
EY101,CA26839-75-8,0173-0700-10,,S01ED01,RX5001021,H1H1I2I2,CHEMBL621,33624,DB00373,D00237,Timolol,Timolol,TIM,噻吗洛尔,噻吗洛尔滴眼液,参天,国药准字J20171114,47,眼科用药/β受体阻滞剂,0.5%/5ml,1滴,每日2次,滴眼,青光眼、高眼压症,哮喘、心动过缓禁用,眼部刺激、心动过缓,与全身β受体阻滞剂合用增强作用,降眼压,C,正常剂量,正常剂量,ml,滴眼,BID,2025-09-30,NMPA/国家基本药物目录,verified,降眼压药
EY102,CA130209-82-4,0013-8303-06,,S01EE01,RX5001022,I2I2J3J3,CHEMBL622,5311221,DB00654,D00350,Latanoprost,Latanoprost,LAT,拉坦前列素,适利达,辉瑞,国药准字J20171115,47,眼科用药/前列腺素类似物,50μg/ml,1滴,每日1次,滴眼,开角型青光眼、高眼压症,对拉坦前列素过敏者禁用,虹膜色素沉着、睫毛生长,与含硫柳汞眼药水间隔15分钟,增加房水流出,C,正常剂量,正常剂量,ml,滴眼,qhs,2025-09-30,NMPA/国家基本药物目录,verified,前列腺素类降眼压药
EY103,CA59803-98-4,0013-8304-06,,S01EC03,RX5001023,J3J3K4K4,CHEMBL623,5284514,DB00819,D00628,Brinzolamide,Brinzolamide,BRZ,布林佐胺,派立明,爱尔康,国药准字J20171116,47,眼科用药/碳酸酐酶抑制剂,1%/5ml,1滴,每日2次,滴眼,开角型青光眼、高眼压症,严重肾功能不全、高氯性酸中毒禁用,苦味、视物模糊,与口服碳酸酐酶抑制剂合用增强作用,减少房水生成,C,CrCl<30禁用,正常剂量,ml,滴眼,BID,2025-09-30,NMPA/国家基本药物目录,verified,CAI类降眼压药
EY104,CA120279-96-1,0013-8305-06,,S01EC04,RX5001024,K4K4L5L5,CHEMBL624,5284549,DB00869,D01008,Dorzolamide,Dorzolamide,DOR,多佐胺,多佐胺滴眼液,默沙东,国药准字J20171117,47,眼科用药/碳酸酐酶抑制剂,2%/5ml,1滴,每日3次,滴眼,开角型青光眼、高眼压症,严重肾功能不全禁用,苦味、眼部刺激,与口服CAI合用增强作用,减少房水生成,C,CrCl<30禁用,正常剂量,ml,滴眼,TID,2025-09-30,NMPA/国家基本药物目录,verified,CAI类降眼压药
EY105,CA87-00-3,0173-0701-20,,S01FA06,RX5001025,L5L5M6M6,CHEMBL625,1234,DB00373,D00237,Tropicamide,Tropicamide,TRP,托吡卡胺,美多丽,参天,国药准字J20171118,47,眼科用药/散瞳药,0.5%;1%/5ml,1-2滴,检查前给药,滴眼,散瞳验光、眼底检查,闭角型青光眼禁用,视物模糊、畏光,与抗胆碱药合用增强作用,短效散瞳药,C,正常剂量,正常剂量,ml,滴眼,prn,2025-09-30,NMPA/国家基本药物目录,verified,短效散瞳药
EY106,CA51-45-6,0173-0702-30,,S01FA01,RX5001026,M6M6N7N7,CHEMBL626,174174,DB00477,D00129,Atropine,Atropine,ATR,阿托品,硫酸阿托品滴眼液,沈阳兴齐,国药准字H21022287,47,眼科用药/散瞳药,1%/5ml,1滴,每日1-2次,滴眼,散瞳验光、虹膜睫状体炎,闭角型青光眼禁用,视物模糊、畏光持续1-2周,与抗胆碱药合用增强作用,长效散瞳药,C,正常剂量,正常剂量,ml,滴眼,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,长效散瞳药
CV205,CA75330-75-5,0078-0357-15,,C10AA04,RX6001005,T5T5U5U5,CHEMBL705,53232,DB00175,D00434,Fluvastatin,Fluvastatin,FLU,氟伐他汀,来适可,诺华,国药准字J20171125,18,心血管系统药物/HMG-CoA还原酶抑制剂,20mg;40mg/片,20-80mg,每日1-2次,口服,高胆固醇血症,活动性肝病、孕妇禁用,肌病、胃肠道反应,CYP2C9底物,中等强度他汀,X,正常剂量,肝功能不全慎用,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,中等强度他汀
CV209,CA107-43-7,0006-0747-01,,C10AC01,RX6001009,X9X9Y9Y9,CHEMBL709,444972,DB00930,D00565,Colesevelam,Colesevelam,COL,考来维仑,考来维仑片,第一三共,国药准字J20171129,18,心血管系统药物/胆汁酸螯合剂,625mg/片,3.75g,每日1-2次,口服,高胆固醇血症,肠梗阻、血清TG>500mg/dl禁用,便秘、腹胀、胃肠道不适,影响脂溶性维生素吸收,不吸收入血,B,正常剂量,正常剂量,g,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,胆汁酸螯合剂
CV211,CA113665-84-2,0024-4162-34,,B01AC04,RX6001011,Z1Z1A2A2,CHEMBL711,2806,DB00758,D07729,Clopidogrel,Clopidogrel,CLO,氯吡格雷,波立维,赛诺菲,国药准字J20171131,14,心血管系统药物/抗血小板药,75mg/片,75mg,每日1次,口服,急性冠脉综合征、PCI术后,活动性出血禁用,出血、血栓性血小板减少性紫癜,"CYP2C19代谢,PPI降低疗效",P2Y12受体拮抗剂,B,正常剂量,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,P2Y12受体拮抗剂
CV212,CA180970-78-5,0186-0860-54,,B01AC24,RX6001012,A2A2B3B3,CHEMBL712,9871419,DB08816,D09030,Ticagrelor,Ticagrelor,TIC,替格瑞洛,倍林达,阿斯利康,国药准字J20171132,14,心血管系统药物/抗血小板药,90mg/片,90mg,每日2次,口服,急性冠脉综合征,活动性出血、颅内出血史禁用,呼吸困难、出血,与强效CYP3A4抑制剂合用禁忌,可逆性P2Y12抑制,C,正常剂量,肝功能不全慎用,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,可逆性P2Y12抑制剂
CV213,CA58-32-2,0597-0087-59,,B01AC07,RX6001013,B3B3C4C4,CHEMBL713,3108,DB00266,D00302,Dipyridamole,Dipyridamole,DIP,双嘧达莫,潘生丁,勃林格殷格翰,国药准字J20171133,14,心血管系统药物/抗血小板药,25mg/片,75-100mg,每日3次,口服,缺血性脑血管病、冠心病,严重冠心病急性期禁用,头痛、头晕、胃肠道反应,与阿司匹林协同作用,磷酸二酯酶抑制剂,B,正常剂量,肝功能不全慎用,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,抗血小板药
PA104,CA53-39-4,0069-5003-90,,M01AC06,RX6001017,F7F7G8G8,CHEMBL717,23663637,DB00814,D00126,Meloxicam,Meloxicam,MEL,美洛昔康,莫比可,勃林格殷格翰,国药准字J20171135,31,解热镇痛药/NSAIDs,7.5mg;15mg/片,7.5-15mg,每日1次,口服,骨关节炎、类风湿关节炎,活动性消化性溃疡禁用,胃肠道不适,与阿司匹林合用增加溃疡风险,COX-2选择性,C/D,CrCl<30慎用,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,COX-2选择性NSAIDs
PA105,CA76-57-3,0069-5004-01,,N02AA01,RX6001018,G8G8H9H9,CHEMBL718,5288826,DB00295,D08233,Morphine,Morphine,MOR,吗啡,硫酸吗啡片,东北制药,国药准字H21022288,32,麻醉性镇痛药/阿片类,10mg;30mg/片,10-30mg,每4小时1次,口服,中重度疼痛,呼吸抑制、麻痹性肠梗阻禁用,便秘、恶心、呼吸抑制、成瘾,与CNS抑制剂合用增加呼吸抑制,阿片受体激动剂,C,正常剂量,肝功能不全需减量,mg,口服,q4h,2025-09-30,NMPA/国家基本药物目录,verified,强阿片类镇痛药
PA106,CA467-85-6,0069-5005-10,,N02AA03,RX6001019,H9H9I0I0,CHEMBL719,5460517,DB00327,D08233,Hydromorphone,Hydromorphone,HYD,氢吗啡酮,氢吗啡酮注射液,西安杨森,国药准字J20171136,32,麻醉性镇痛药/阿片类,2mg/ml,1-2mg,每4-6小时1次,皮下注射/静脉注射,中重度急性疼痛,呼吸抑制、麻痹性肠梗阻禁用,便秘、恶心、呼吸抑制、成瘾,与CNS抑制剂合用增加呼吸抑制,半合成阿片类,C,CrCl<30需减量,肝功能不全需减量,mg,静脉注射,q4-6h,2025-09-30,NMPA/国家基本药物目录,verified,强阿片类镇痛药
PA107,CA76-42-6,0069-5006-20,,N02AA55,RX6001020,I0I0J1J1,CHEMBL720,5360621,DB00497,D08233,Oxycodone,Oxycodone,OXY,羟考酮,奥施康定,普渡制药,国药准字J20171137,32,麻醉性镇痛药/阿片类,5mg;10mg;20mg/片,10-40mg,每12小时1次,口服,中重度疼痛,呼吸抑制、麻痹性肠梗阻禁用,便秘、恶心、呼吸抑制、成瘾,与CYP3A4抑制剂合用增加血药浓度,半合成阿片类,C,CrCl<60需减量,肝功能不全需减量,mg,口服,q12h,2025-09-30,NMPA/国家基本药物目录,verified,缓释阿片类镇痛药
ON102,CA50-24-8,0009-0720-10,,L01AA06,RX7001002,P2P2Q2Q2,CHEMBL802,3890,DB00562,D00287,Ifosfamide,Ifosfamide,IFO,异环磷酰胺,异环磷酰胺注射液,江苏恒瑞,国药准字H32020858,36,抗肿瘤药/烷化剂,1g/支,1.2-2.4g/m²,每日1-5天,静脉注射,睾丸癌、肺癌、淋巴瘤,严重骨髓抑制禁用,骨髓抑制、出血性膀胱炎、CNS毒性,与美司钠合用预防膀胱炎,需与美司钠联用,D,CrCl<60需减量,肝功能不全需减量,g/m²,静脉注射,QD×5d,2025-09-30,NMPA/国家基本药物目录,verified,烷化剂类
ON106,CA71-30-7,0009-0724-50,,L01CA02,RX7001006,T6T6U6U6,CHEMBL806,31703,DB00570,D00419,Vincristine,Vincristine,VCR,长春新碱,硫酸长春新碱注射液,江苏恒瑞,国药准字H32020859,36,抗肿瘤药/长春碱类,1mg/支,1.4mg/m²,每周1次,静脉注射,急性淋巴细胞白血病、淋巴瘤,神经肌肉疾病、肠梗阻禁用,周围神经病变、便秘、SIADH,避免外渗,神经毒性剂量限制,D,正常剂量,肝功能不全需减量,mg/m²,静脉注射,QW,2025-09-30,NMPA/国家基本药物目录,verified,长春碱类抗肿瘤药
ON107,CA57-22-7,0009-0725-60,,L01CA01,RX7001007,U7U7V7V7,CHEMBL807,5978,DB00570,D00750,Vinblastine,Vinblastine,VLB,长春碱,硫酸长春碱注射液,江苏恒瑞,国药准字H32020860,36,抗肿瘤药/长春碱类,10mg/支,6mg/m²,每周1次,静脉注射,霍奇金淋巴瘤、睾丸癌,严重骨髓抑制、感染禁用,骨髓抑制、周围神经病变,避免外渗,骨髓毒性剂量限制,D,正常剂量,肝功能不全需减量,mg/m²,静脉注射,QW,2025-09-30,NMPA/国家基本药物目录,verified,长春碱类抗肿瘤药
ON108,CA33069-62-4,0009-0726-70,,L01CD01,RX7001008,V8V8W8W8,CHEMBL808,36462,DB00997,D00750,Paclitaxel,Paclitaxel,PTX,紫杉醇,泰素,施贵宝,国药准字J20171144,36,抗肿瘤药/紫杉类,30mg/支,135-175mg/m²,每3周1次,静脉注射,卵巢癌、乳腺癌、肺癌,严重骨髓抑制、基线中性粒细胞<1500禁用,骨髓抑制、周围神经病变、过敏反应,预防用地塞米松+抗组胺药,微管稳定剂,D,正常剂量,肝功能不全需减量,mg/m²,静脉注射,q3w,2025-09-30,NMPA/国家基本药物目录,verified,紫杉类抗肿瘤药
ON113,CA120511-73-1,0009-0731-20,,L02BB03,RX7001013,A3A3B4B4,CHEMBL813,60198,DB00675,D00966,Bicalutamide,Bicalutamide,BIC,比卡鲁胺,康士得,阿斯利康,国药准字J20171148,36,抗肿瘤药/抗雄激素药,50mg/片,50mg,每日1次,口服,前列腺癌,女性禁用,男性乳房发育、肝毒性、潮热,与华法林合用增加INR,非甾体抗雄激素,X,正常剂量,肝功能不全禁用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,抗雄激素药
IM101,CA59865-13-3,0078-0109-01,,L04AA01,RX7001014,B4B4C5C5,CHEMBL814,5284373,DB00091,D00184,Ciclosporin,Cyclosporine,CsA,环孢素,新山地明,诺华,国药准字J20171149,36,免疫抑制剂/钙调磷酸酶抑制剂,25mg;50mg;100mg/粒,3-5mg/kg,每日2次,口服,器官移植排斥反应、自身免疫性疾病,未控制的高血压、未控制的感染禁用,肾毒性、高血压、多毛症,"CYP3A4底物,与葡萄柚汁相互作用",监测血药浓度,C,肾功能不全需监测,肝功能不全需减量,mg/kg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,钙调磷酸酶抑制剂
IM102,CA104987-11-3,0069-0110-30,,L04AA06,RX7001015,C5C5D6D6,CHEMBL815,445643,DB00108,D08556,Mycophenolate,Mycophenolate Mofetil,MMF,吗替麦考酚酯,骁悉,罗氏,国药准字J20171150,36,免疫抑制剂/嘌呤合成抑制剂,0.25g;0.5g/片,1-1.5g,每日2次,口服,器官移植排斥反应,妊娠、严重胃肠道疾病禁用,胃肠道反应、白细胞减少、感染,与抗酸药间隔服用,嘌呤合成抑制,D,CrCl<25需监测,肝功能不全慎用,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,嘌呤合成抑制剂
IM103,CA53123-88-9,0069-0111-40,,L04AA05,RX7001016,D6D6E7E7,CHEMBL816,6473,DB00108,D08556,Tacrolimus,Tacrolimus,TAC,他克莫司,普乐可复,安斯泰来,国药准字J20171151,36,免疫抑制剂/钙调磷酸酶抑制剂,0.5mg;1mg/粒,0.1-0.2mg/kg,每日2次,口服,器官移植排斥反应,对他克莫司过敏者禁用,肾毒性、神经毒性、高血糖,CYP3A4底物,监测血药浓度,C,肾功能不全需监测,肝功能不全需减量,mg/kg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,钙调磷酸酶抑制剂
IM104,CA53-06-5,0009-0050-01,,H02AB09,RX7001017,E7E7F8F8,CHEMBL817,5743,DB00741,D00165,Cortisone,Cortisone,COR,可的松,醋酸可的松片,天津天药,国药准字H12020181,30,免疫抑制剂/糖皮质激素,25mg/片,25-300mg,每日1-4次,口服,肾上腺皮质功能不全、严重过敏,全身真菌感染禁用,库欣综合征、骨质疏松、高血糖,与NSAIDs合用增加胃肠道风险,需转化为氢化可的松,C,正常剂量,肝功能不全需监测,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,糖皮质激素
IM105,CA446-86-6,0069-0112-50,,L04AX01,RX7001018,F8F8G9G9,CHEMBL818,5743,DB00993,D00238,Azathioprine,Azathioprine,AZA,硫唑嘌呤,硫唑嘌呤片,葛兰素史克,国药准字J20171152,36,免疫抑制剂/嘌呤类似物,50mg/片,1-3mg/kg,每日1次,口服,器官移植、自身免疫性疾病,孕妇、严重肝功能不全禁用,骨髓抑制、肝毒性、感染,与别嘌醇合用需减量75%,监测血常规,D,CrCl<10需减量,肝功能不全需减量,mg/kg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,嘌呤类似物
IM106,CA53-19-0,0069-0113-60,,L04AX03,RX7001019,G9G9H0H0,CHEMBL819,2537,DB00631,D00111,Clofarabine,Clofarabine,CLO,氯法拉滨,氯法拉滨注射液,赛诺菲,国药准字J20171153,36,免疫抑制剂/嘌呤类似物,20mg/支,52mg/m²,每日1次×5天,静脉注射,儿童急性淋巴细胞白血病,严重肝肾功能不全禁用,骨髓抑制、感染、肝肾毒性,监测肝肾功能,嘌呤核苷类似物,D,CrCl<30需减量,肝功能不全需减量,mg/m²,静脉注射,QD×5d,2025-09-30,NMPA/国家基本药物目录,verified,抗代谢药
DE101,CA65277-42-1,0173-0800-10,,D01AC08,RX7001021,I1I1J2J2,CHEMBL821,55283,DB00224,D00168,Ketoconazole,Ketoconazole,KTZ,酮康唑,酮康唑乳膏,西安杨森,国药准字H10940155,44,皮肤科用药/抗真菌药,2%/10g,外用,每日1-2次,外用,皮肤真菌感染、脂溢性皮炎,对咪唑类过敏者禁用,局部刺激、过敏反应,无明显药物相互作用(外用),外用抗真菌药,C,正常剂量,正常剂量,次,外用,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,外用抗真菌药
DE102,CA23593-75-1,0173-0801-20,,D01AE13,RX7001022,J2J2K3K3,CHEMBL822,1549008,DB00257,D00107,Clotrimazole,Clotrimazole,CLO,克霉唑,克霉唑乳膏,拜耳,国药准字H20000080,44,皮肤科用药/抗真菌药,1%/10g,外用,每日2-3次,外用,皮肤真菌感染、念珠菌感染,对咪唑类过敏者禁用,局部刺激、过敏反应,无明显药物相互作用(外用),广谱抗真菌,B,正常剂量,正常剂量,次,外用,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,广谱外用抗真菌药
DE103,CA91161-71-6,0173-0802-30,,D01AE15,RX7001023,K3K3L4L4,CHEMBL823,5282,DB00393,D00307,Terbinafine,Terbinafine,TRB,特比萘芬,兰美抒,诺华,国药准字J20171154,44,皮肤科用药/抗真菌药,1%/10g,外用,每日1-2次,外用,皮肤真菌感染、甲真菌病,对特比萘芬过敏者禁用,局部刺激、皮疹,无明显药物相互作用(外用),烯丙胺类抗真菌药,B,正常剂量,正常剂量,次,外用,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,烯丙胺类抗真菌药
DE104,CA5373-11-5,0173-0803-40,,D01AE16,RX7001024,L4L4M5M5,CHEMBL824,3318,DB00224,D00308,Amorolfine,Amorolfine,AMO,阿莫罗芬,罗每乐,赛诺菲,国药准字J20171155,44,皮肤科用药/抗真菌药,5%/搽剂,外用,每周1-2次,外用,甲真菌病,对阿莫罗芬过敏者禁用,局部刺激,指甲穿透力强,治疗甲真菌病,B,正常剂量,正常剂量,次,外用,QW-BIW,2025-09-30,NMPA/国家基本药物目录,verified,治疗甲真菌病
DE106,CA2193-99-1,0173-0805-60,,D07AC13,RX7001026,N6N6O7O7,CHEMBL826,441335,DB00443,D01253,Mometasone,Mometasone Furoate,MOM,糠酸莫米松,艾洛松,先灵葆雅,国药准字J20171156,45,皮肤科用药/糖皮质激素,0.1%/10g,外用,每日1次,外用,皮炎、湿疹、银屑病,病毒性皮肤病、痤疮禁用,皮肤萎缩、毛细血管扩张,长期使用需注意HPA轴抑制,强效糖皮质激素,C,正常剂量,正常剂量,次,外用,QD,2025-09-30,NMPA/国家基本药物目录,verified,强效外用激素
DE107,CA2438-72-4,0173-0806-70,,D06AX09,RX7001027,O7O7P8P8,CHEMBL827,16130923,DB00410,D01076,Mupirocin,Mupirocin,MUP,莫匹罗星,百多邦,葛兰素史克,国药准字J20171157,46,皮肤科用药/抗菌药,2%/5g,外用,每日3次,外用,皮肤细菌感染、鼻腔金葡菌定植,对莫匹罗星过敏者禁用,局部刺激、过敏反应,无明显药物相互作用,抗MRSA外用药,B,正常剂量,正常剂量,次,外用,TID,2025-09-30,NMPA/国家基本药物目录,verified,外用抗MRSA药
AI302,CA1336-21-6,0069-3300-10,,J01CR05,RX8001002,R2R2S2S2,CHEMBL902,43672,DB00319,D00341,Piperacillin_Tazobactam,Piperacillin/Tazobactam,TZP,哌拉西林他唑巴坦,特治星,辉瑞,国药准字J20171159,22,抗感染药/β-内酰胺类/青霉素+β-内酰胺酶抑制剂,4.5g/支,4.5g,每6-8小时一次,静脉注射,严重腹腔感染、医院获得性肺炎,青霉素过敏者禁用,腹泻、皮疹,与氨基糖苷类协同,抗假单胞菌,B,CrCl<40需减量,无需调整,g,静脉注射,q6-8h,2025-09-30,NMPA/国家基本药物目录,verified,抗假单胞菌复方制剂
AI303,CA74469-00-4,0062-3337-01,,J01CR04,RX8001003,S3S3T3T3,CHEMBL903,5742673,DB00303,D07660,Cefoperazone_Sulbactam,Cefoperazone/Sulbactam,SCF,头孢哌酮舒巴坦,舒普深,辉瑞,国药准字H20023133,22,抗感染药/β-内酰胺类/头孢+β-内酰胺酶抑制剂,2g/支,2-4g,每12小时一次,静脉注射,严重细菌感染,头孢过敏者禁用,腹泻、出血倾向,避免饮酒(双硫仑反应),胆道排泄,B,无需调整,肝功能不全需减量,g,静脉注射,q12h,2025-09-30,NMPA/国家基本药物目录,verified,复方头孢类
AI305,CA80214-83-1,0173-0551-30,,J01AA08,RX8001005,U5U5V5V5,CHEMBL905,54675779,DB00759,D07659,Tetracycline,Tetracycline,TET,四环素,盐酸四环素片,华北制药,国药准字H11020299,22,抗感染药/四环素类,0.25g/片,0.25-0.5g,每6小时一次,口服,支原体、衣原体、立克次体感染,孕妇、8岁以下儿童禁用,牙齿变色、光敏反应、胃肠道反应,与奶制品、抗酸药间隔服用,四环素类抗生素,D,正常剂量,肝功能不全慎用,g,口服,q6h,2025-09-30,NMPA/国家基本药物目录,verified,四环素类抗生素
EN203,CA1491-59-4,0173-0902-30,,R01AA07,RX8001008,X8X8Y8Y8,CHEMBL908,5282230,DB00935,D00125,Oxymetazoline,Oxymetazoline,OXY,羟甲唑啉,达芬林,先灵葆雅,国药准字J20171162,50,耳鼻喉科用药/鼻减充血剂,0.05%/喷,1-2喷,每12小时一次,鼻喷,鼻充血、鼻炎,长期使用禁忌,反跳性充血、鼻黏膜干燥,不超过3-5天连续使用,α受体激动剂,C,正常剂量,正常剂量,喷,鼻喷,q12h,2025-09-30,NMPA/国家基本药物目录,verified,鼻减充血剂
EN204,CA2338-37-6,0173-0903-40,,R01AA09,RX8001009,Y9Y9Z9Z9,CHEMBL909,31269,DB00966,D07516,Xylometazoline,Xylometazoline,XYL,赛洛唑啉,诺通,先灵葆雅,国药准字J20171163,50,耳鼻喉科用药/鼻减充血剂,0.1%/喷,1-2喷,每8-12小时一次,鼻喷,鼻充血,长期使用禁忌,反跳性充血、鼻黏膜干燥,不超过3-5天连续使用,α受体激动剂,C,正常剂量,正常剂量,喷,鼻喷,q8-12h,2025-09-30,NMPA/国家基本药物目录,verified,鼻减充血剂
EN205,CA3380-34-5,0173-0904-50,,S02AA07,RX8001010,Z0Z0A1A1,CHEMBL910,33613,DB00759,D00223,Triamcinolone,Triamcinolone,TRI,曲安奈德,曲安奈德鼻喷雾剂,上海医药,国药准字H31021270,50,耳鼻喉科用药/鼻用糖皮质激素,55μg/喷,220μg,每日1次,鼻喷,过敏性鼻炎,鼻腔感染禁用,鼻出血、头痛,长期使用需监测,中效糖皮质激素,C,正常剂量,正常剂量,μg,鼻喷,QD,2025-09-30,NMPA/国家基本药物目录,verified,鼻用激素
AN101,CA57-43-2,0069-6100-01,,N01AX03,RX8001011,A1A1B2B2,CHEMBL911,2771,DB00474,D00537,Ketamine,Ketamine,KET,氯胺酮,盐酸氯胺酮注射液,江苏恒瑞,国药准字H32020861,32,麻醉药/解离性麻醉药,50mg/ml,1-2mg/kg,单次给药,静脉注射/肌肉注射,诱导麻醉、镇痛,高血压、颅内压增高禁用,幻觉、恶梦、血压升高,与苯二氮䓬类合用减少幻觉,NMDA受体拮抗剂,B,正常剂量,肝功能不全慎用,mg/kg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,解离性麻醉药
AN102,CA71-43-2,0069-6101-10,,N05CD08,RX8001012,B2B2C3C3,CHEMBL912,3672,DB01435,D00293,Midazolam,Midazolam,MDZ,咪达唑仑,咪达唑仑注射液,江苏恒瑞,国药准字H32020862,32,麻醉药/苯二氮䓬类,5mg/ml,0.05-0.1mg/kg,单次给药,静脉注射,麻醉前用药、镇静,重症肌无力、急性闭角型青光眼禁用,呼吸抑制、低血压,与阿片类合用增加呼吸抑制,短效镇静药,D,正常剂量,肝功能不全需减量,mg/kg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,麻醉前用药
AN103,CA2078-54-8,0069-6102-20,,N01AH01,RX8001013,C3C3D4D4,CHEMBL913,47936,DB00797,D00549,Propofol,Propofol,PRO,丙泊酚,得普利麻,阿斯利康,国药准字J20171164,32,麻醉药/静脉麻醉药,10mg/ml,2-2.5mg/kg,单次给药,静脉注射,全身麻醉诱导和维持,对大豆或鸡蛋过敏者禁用,低血压、呼吸抑制、注射痛,与阿片类合用增强麻醉效果,短效静脉麻醉药,B,正常剂量,肝功能不全慎用,mg/kg,静脉注射,continuous,2025-09-30,NMPA/国家基本药物目录,verified,静脉麻醉药
AN104,CA76-75-5,0069-6103-30,,N01AH06,RX8001014,D4D4E5E5,CHEMBL914,3286,DB00474,D00537,Sevoflurane,Sevoflurane,SEV,七氟烷,舒更,雅培,国药准字J20171165,32,麻醉药/吸入麻醉药,吸入,2-3%,持续吸入,吸入,全身麻醉,恶性高热家族史禁用,恶心、呼吸抑制,与肌松药合用增强肌松作用,吸入麻醉药,B,正常剂量,肝功能不全慎用,%,吸入,continuous,2025-09-30,NMPA/国家基本药物目录,verified,吸入麻醉药
AN105,CA13838-16-9,0069-6104-40,,N01AB08,RX8001015,E5E5F6F6,CHEMBL915,42113,DB00802,D00546,Enflurane,Enflurane,ENF,恩氟烷,恩氟烷,雅培,国药准字J20171166,32,麻醉药/吸入麻醉药,吸入,1.5-3%,持续吸入,吸入,全身麻醉,癫痫患者慎用,肝毒性、肾毒性,与肌松药合用增强肌松作用,吸入麻醉药,B,正常剂量,肝功能不全慎用,%,吸入,continuous,2025-09-30,NMPA/国家基本药物目录,verified,吸入麻醉药
AN106,CA15442-64-5,0069-6105-50,,N01AX10,RX8001016,F6F6G7G7,CHEMBL916,5282445,DB00708,D08687,Rocuronium,Rocuronium,ROC,罗库溴铵,罗库溴铵注射液,华东医药,国药准字H20093272,32,麻醉药/非去极化肌松药,10mg/ml,0.6mg/kg,单次给药,静脉注射,气管插管、手术肌松,重症肌无力禁用,过敏反应、延长肌松,与氨基糖苷类合用增强肌松,非去极化肌松药,B,正常剂量,肝功能不全需监测,mg/kg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,中时效肌松药
AN107,CA15376-43-1,0069-6106-60,,N01AX03,RX8001017,G7G7H8H8,CHEMBL917,5282452,DB00728,D08687,Atracurium,Atracurium,ATR,阿曲库铵,阿曲库铵注射液,江苏恒瑞,国药准字H32020863,32,麻醉药/非去极化肌松药,10mg/ml,0.5mg/kg,单次给药,静脉注射,气管插管、手术肌松,重症肌无力禁用,组胺释放、低血压,Hofmann消除,适用于肝肾功能不全,C,正常剂量,正常剂量,mg/kg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,中时效肌松药
AN108,CA71195-58-9,0069-6107-70,,N01AX11,RX8001018,H8H8I9I9,CHEMBL918,5282343,DB00899,D05041,Vecuronium,Vecuronium,VEC,维库溴铵,维库溴铵注射液,江苏恒瑞,国药准字H32020864,32,麻醉药/非去极化肌松药,4mg/支,0.08-0.1mg/kg,单次给药,静脉注射,气管插管、手术肌松,重症肌无力禁用,延长肌松,与氨基糖苷类合用增强肌松,中时效肌松药,C,正常剂量,肝功能不全需监测,mg/kg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,中时效肌松药
EM101,CA51-43-4,0069-7100-01,,C01CA24,RX8001019,I9I9J0J0,CHEMBL919,5816,DB00668,D00095,Epinephrine,Adrenaline,EPI,肾上腺素,盐酸肾上腺素注射液,上海禾丰,国药准字H31020587,32,急救药/拟肾上腺素药,1mg/ml,1mg,必要时重复,静脉注射/肌肉注射,心脏骤停、过敏性休克,高血压危象、心动过速禁用,心律失常、高血压,与β受体阻滞剂拮抗,α和β受体激动剂,C,正常剂量,正常剂量,mg,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,急救首选药物
EM104,CA298-46-4,0069-7103-30,,V03AB15,RX8001022,L2L2M3M3,CHEMBL922,3878,DB00555,D00555,Naloxone,Naloxone,NAL,纳洛酮,盐酸纳洛酮注射液,北京四环,国药准字H11020964,32,急救药/阿片受体拮抗剂,0.4mg/ml,0.4-2mg,必要时重复,静脉注射/肌肉注射,阿片类药物过量、中毒,对纳洛酮过敏者禁用,戒断综合征、恶心,拮抗阿片类药物作用,阿片类解毒剂,C,正常剂量,正常剂量,mg,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,阿片中毒解救
EM105,CA59-26-7,0069-7104-40,,C01CA26,RX8001023,M3M3N4N4,CHEMBL923,439260,DB00368,D00095,Norepinephrine,Noradrenaline,NE,去甲肾上腺素,重酒石酸去甲肾上腺素注射液,上海禾丰,国药准字H31020588,32,急救药/拟肾上腺素药,2mg/ml,0.1-0.5μg/kg/min,持续静滴,静脉滴注,休克、低血压,高血压、甲亢禁用,心律失常、外渗坏死,与MAOIs合用禁忌,α受体激动剂,C,正常剂量,正常剂量,μg/kg/min,静脉滴注,continuous,2025-09-30,NMPA/国家基本药物目录,verified,升压药
EM106,CA51-48-9,0069-7105-50,,V03AB23,RX8001024,N4N4O5O5,CHEMBL924,16222096,DB00157,D00111,Flumazenil,Flumazenil,FLU,氟马西尼,氟马西尼注射液,罗氏,国药准字J20171168,32,急救药/苯二氮䓬拮抗剂,0.1mg/ml,0.2mg,必要时重复,静脉注射,苯二氮䓬类药物过量,癫痫患者禁用,癫痫发作、恶心,拮抗苯二氮䓬类作用,苯二氮䓬解毒剂,C,正常剂量,肝功能不全需减量,mg,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,苯二氮䓬中毒解救
EM107,CA56-75-7,0069-7106-60,,D06BA01,RX8001025,O5O5P6P6,CHEMBL925,5743,DB00446,D00104,Chloramphenicol,Chloramphenicol,CHL,氯霉素,氯霉素注射液,华北制药,国药准字H11020300,22,抗感染药/氯霉素类,0.5g/支,0.5-1g,每6小时一次,静脉注射,伤寒、脑膜炎,骨髓抑制、新生儿禁用,骨髓抑制、灰婴综合征,抑制CYP450,监测血常规,C,正常剂量,肝功能不全需减量,g,静脉注射,q6h,2025-09-30,NMPA/国家基本药物目录,verified,氯霉素类抗生素
CV215,CA52-53-9,0069-5411-70,,C01CA03,RX9001007,V7V7W7W7,CHEMBL1007,5826,DB00752,D00095,Dopamine,Dopamine,DA,多巴胺,盐酸多巴胺注射液,上海禾丰,国药准字H31020589,17,心血管系统药物/拟肾上腺素药,20mg/ml,2-10μg/kg/min,持续静滴,静脉滴注,休克、心力衰竭,嗜铬细胞瘤禁用,心律失常、外渗坏死,与MAOIs合用禁忌,剂量依赖性作用,C,正常剂量,正常剂量,μg/kg/min,静脉滴注,continuous,2025-09-30,NMPA/国家基本药物目录,verified,正性肌力药
CV216,CA51-48-9,0069-5412-80,,C01CA06,RX9001008,W8W8X8X8,CHEMBL1008,31268,DB00280,D00095,Dobutamine,Dobutamine,DOB,多巴酚丁胺,多巴酚丁胺注射液,上海禾丰,国药准字H31020590,17,心血管系统药物/拟肾上腺素药,20mg/ml,2.5-10μg/kg/min,持续静滴,静脉滴注,心力衰竭、心源性休克,肥厚梗阻型心肌病禁用,心律失常、心动过速,与β受体阻滞剂拮抗,β1受体激动剂,B,正常剂量,正常剂量,μg/kg/min,静脉滴注,continuous,2025-09-30,NMPA/国家基本药物目录,verified,正性肌力药
CV217,CA58-32-2,0069-5413-90,,C01DA14,RX9001009,X9X9Y9Y9,CHEMBL1009,3108,DB00266,D00302,Isosorbide_Dinitrate,Isosorbide Dinitrate,ISDN,硝酸异山梨酯,消心痛,阿斯利康,国药准字H20033416,17,心血管系统药物/硝酸酯类,5mg;10mg/片,10-40mg,每日2-3次,口服,心绞痛、心力衰竭,低血压、严重贫血禁用,头痛、低血压、耐受性,与西地那非合用禁忌,硝酸酯类,C,正常剂量,正常剂量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,硝酸酯类抗心绞痛药
CV218,CA16051-77-7,0069-5414-01,,C01DA08,RX9001010,Y0Y0Z0Z0,CHEMBL1010,27661,DB00883,D00516,Isosorbide_Mononitrate,Isosorbide Mononitrate,ISMN,单硝酸异山梨酯,依姆多,阿斯利康,国药准字H20033417,17,心血管系统药物/硝酸酯类,20mg;40mg/片,20-60mg,每日1-2次,口服,心绞痛,低血压、严重贫血禁用,头痛、低血压,与西地那非合用禁忌,长效硝酸酯,C,正常剂量,正常剂量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,长效硝酸酯类
CV219,CA35898-87-4,0069-5415-10,,C01DA02,RX9001011,Z1Z1A2A2,CHEMBL1011,4510,DB01015,D00515,Nitroglycerin,Glyceryl Trinitrate,NTG,硝酸甘油,硝酸甘油片,北京益民,国药准字H11020517,17,心血管系统药物/硝酸酯类,0.5mg/片,0.3-0.6mg,心绞痛发作时,舌下含服,心绞痛急性发作,低血压、颅内压增高禁用,头痛、低血压、耐受性,与西地那非合用禁忌,短效硝酸酯,C,正常剂量,正常剂量,mg,舌下含服,prn,2025-09-30,NMPA/国家基本药物目录,verified,短效硝酸酯类
CV220,CA35700-23-3,0069-5416-20,,C01DA13,RX9001012,A2A2B3B3,CHEMBL1012,5464343,DB00820,D07449,Trimetazidine,Trimetazidine,TMZ,曲美他嗪,万爽力,施维雅,国药准字J20171174,17,心血管系统药物/抗心绞痛药,20mg/片,20mg,每日3次,口服,心绞痛,帕金森病、震颤禁用,震颤、步态不稳,无明显药物相互作用,代谢性抗心绞痛药,C,正常剂量,肝肾功能不全慎用,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,代谢性抗心绞痛药
CV223,CA66722-44-9,0069-5419-50,,C07AG02,RX9001015,D5D5E6E6,CHEMBL1015,9524,DB00612,D00593,Bisoprolol,Bisoprolol,BIS,比索洛尔,康忻,默克,国药准字J20171175,17,心血管系统药物/β受体阻滞剂,2.5mg;5mg/片,2.5-10mg,每日1次,口服,高血压、心力衰竭,哮喘、二度以上传导阻滞禁用,心动过缓、乏力,与地尔硫䓬合用增加心动过缓,高选择性β1受体阻滞剂,C,正常剂量,肝功能不全需减量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,高选择性β受体阻滞剂
RS115,CA54239-37-1,0173-0405-60,,R03DC03,RX9001022,K2K2L3L3,CHEMBL1022,5282230,DB00588,D07949,Montelukast,Montelukast,MON,孟鲁司特,顺尔宁,默沙东,国药准字J20171182,23,呼吸系统药物/白三烯受体拮抗剂,4mg;5mg;10mg/片,10mg,每日1次,口服,支气管哮喘、过敏性鼻炎,对孟鲁司特过敏者禁用,头痛、腹痛、神经精神症状,无明显药物相互作用,白三烯受体拮抗剂,B,正常剂量,肝功能不全慎用,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,白三烯受体拮抗剂
RS116,CA119355-06-1,0173-0406-70,,R05CB13,RX9001023,L3L3M4M4,CHEMBL1023,5282230,DB00588,D03850,Erdosteine,Erdosteine,ERD,厄多司坦,厄多司坦胶囊,苏州东瑞,国药准字H20093601,23,呼吸系统药物/祛痰药,0.3g/粒,0.6g,每日2次,口服,慢性支气管炎、COPD,对厄多司坦过敏者禁用,胃肠道反应,无明显药物相互作用,黏液溶解剂,C,正常剂量,肝功能不全慎用,g,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,祛痰药
RS117,CA90-03-9,0173-0407-80,,R05DA09,RX9001024,M4M4N5N5,CHEMBL1024,5282230,DB00588,D02106,Dextromethorphan,Dextromethorphan,DEX,右美沙芬,美沙芬片,扬子江药业,国药准字H32024166,23,呼吸系统药物/中枢性镇咳药,15mg/片,15-30mg,每4-6小时,口服,干咳,与MAOIs合用禁忌,嗜睡、头晕,与5-HT能药物合用增加5-HT综合征风险,中枢性镇咳药,C,正常剂量,正常剂量,mg,口服,q4-6h,2025-09-30,NMPA/国家基本药物目录,verified,中枢性镇咳药
RS118,CA486-56-6,0173-0408-90,,R05DA04,RX9001025,N5N5O6O6,CHEMBL1025,5282230,DB00588,D08138,Codeine,Codeine,COD,可待因,磷酸可待因片,东北制药,国药准字H21022289,23,呼吸系统药物/中枢性镇咳药,15mg;30mg/片,15-30mg,每4-6小时,口服,中度干咳,哮喘急性发作、呼吸抑制禁用,便秘、嗜睡、成瘾,与CNS抑制剂合用增强作用,阿片类镇咳药,C,正常剂量,肝功能不全需减量,mg,口服,q4-6h,2025-09-30,NMPA/国家基本药物目录,verified,阿片类镇咳药
GI119,CA73590-85-9,0186-0886-10,,A02BC06,RX9002001,P1P1Q1Q1,CHEMBL1101,9579578,DB00736,D01984,Dexlansoprazole,Dexlansoprazole,DEX,右兰索拉唑,康彼身,武田,国药准字J20171183,20,消化系统药物/质子泵抑制剂,30mg;60mg/片,30-60mg,每日1次,口服,反流性食管炎,对PPI过敏者禁用,腹泻、恶心,CYP2C19和3A4底物,兰索拉唑R-对映体,B,正常剂量,肝功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,R-兰索拉唑
GI121,CA56786-63-1,0186-0888-30,,A03AX12,RX9002003,R3R3S3S3,CHEMBL1103,60826,DB00755,D00726,Trimebutine,Trimebutine,TRI,曲美布汀,舒丽启能,雅培,国药准字J20171185,19,消化系统药物/解痉药,0.1g;0.2g/片,0.3-0.6g,每日3次,口服,肠易激综合征,对曲美布汀过敏者禁用,便秘、腹泻,无明显药物相互作用,胃肠解痉药,B,正常剂量,肝功能不全慎用,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,解痉药
GI122,CA90729-43-4,0186-0889-40,,A07AA11,RX9002004,S4S4T4T4,CHEMBL1104,73178,DB01369,D07139,Rifaximin,Rifaximin,RIF,利福昔明,诺尔曼,阿尔法韦士曼,国药准字J20171186,20,消化系统药物/肠道抗感染药,0.2g/片,0.6-1.2g,每日2-3次,口服,肝性脑病、旅行者腹泻,肠梗阻禁用,腹胀、恶心,不吸收入血,肠道选择性抗生素,C,正常剂量,正常剂量,g,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,肠道抗生素
GI123,CA80843-82-1,0186-0890-50,,A06AB08,RX9002005,T5T5U5U5,CHEMBL1105,5281093,DB00826,D03961,Sodium_picosulfate,Sodium Picosulfate,PIC,匹可硫酸钠,匹可硫酸钠滴剂,费森尤斯卡比,国药准字J20171187,21,消化系统药物/刺激性泻药,10mg/ml,5-10mg,睡前服用,口服,便秘、肠道准备,肠梗阻、急腹症禁用,腹痛、腹泻,与抗生素间隔服用,刺激性泻药,B,正常剂量,正常剂量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,刺激性泻药
GI124,CA73857-20-2,0186-0891-60,,A07FA01,RX9002006,U6U6V6V6,CHEMBL1106,104741,DB09279,D03961,Saccharomyces_boulardii,Saccharomyces boulardii,S.b,布拉氏酵母菌,亿活,法国百科达,国药准字J20171188,20,消化系统药物/微生态制剂,250mg/袋,250-500mg,每日2-4次,口服,急慢性腹泻、抗生素相关性腹泻,中心静脉置管患者慎用,腹胀、皮疹,与抗真菌药间隔服用,益生菌,C,正常剂量,正常剂量,mg,口服,BID-QID,2025-09-30,NMPA/国家基本药物目录,verified,益生菌制剂
GI125,CA99-20-7,0186-0892-70,,A06AG04,RX9002007,V7V7W7W7,CHEMBL1107,5353800,DB09279,D03961,Glycerin,Glycerol,GLY,开塞露,开塞露,福元药业,国药准字H20003410,21,消化系统药物/栓剂泻药,10ml;20ml/支,10-20ml,必要时使用,直肠给药,便秘,肠梗阻禁用,肛门刺激,无明显药物相互作用,润滑性泻药,C,正常剂量,正常剂量,ml,直肠给药,prn,2025-09-30,NMPA/国家基本药物目录,verified,栓剂泻药
GI126,CA90-82-4,0186-0893-80,,A07DA02,RX9002008,W8W8X8X8,CHEMBL1108,6408,DB01213,D00854,Diphenoxylate,Diphenoxylate,DIP,地芬诺酯,地芬诺酯片,沈阳绿洲,国药准字H21020840,20,消化系统药物/止泻药,2.5mg/片,5mg,每日4次,口服,急慢性腹泻,伪膜性肠炎、婴幼儿禁用,便秘、腹痛,与MAOIs合用禁忌,阿片类止泻药,C,正常剂量,肝功能不全慎用,mg,口服,QID,2025-09-30,NMPA/国家基本药物目录,verified,阿片类止泻药
GI127,CA17676-29-2,0186-0894-90,,A07XA01,RX9002009,X9X9Y9Y9,CHEMBL1109,444036,DB09279,D03961,Activated_charcoal,Activated Charcoal,AC,活性炭,活性炭片,海南制药,国药准字H46020158,20,消化系统药物/肠道吸附剂,0.25g/片,1-2g,每日3-4次,口服,腹泻、中毒解毒,肠梗阻禁用,便秘、黑便,影响其他药物吸收,吸附剂,C,正常剂量,正常剂量,g,口服,TID-QID,2025-09-30,NMPA/国家基本药物目录,verified,吸附剂
GI128,CA467-43-6,0186-0895-01,,A02AD01,RX9002010,Y0Y0Z0Z0,CHEMBL1110,13387,DB00586,D00455,Sucralfate,Sucralfate,SUC,硫糖铝,硫糖铝片,扬子江药业,国药准字H32024167,20,消化系统药物/胃黏膜保护剂,0.5g;1g/片,1g,每日4次,口服,消化性溃疡,肾功能不全禁用,便秘,与其他药物间隔2小时服用,胃黏膜保护剂,B,CrCl<30禁用,正常剂量,g,口服,QID,2025-09-30,NMPA/国家基本药物目录,verified,胃黏膜保护剂
GI129,CA57-53-4,0186-0896-10,,A02AD02,RX9002011,Z1Z1A2A2,CHEMBL1111,3032,DB00586,D00455,Misoprostol,Misoprostol,MIS,米索前列醇,喜克溃,辉瑞,国药准字J20171189,20,消化系统药物/前列腺素类,0.2mg/片,0.2mg,每日4次,口服,NSAIDs相关性溃疡预防,孕妇禁用,腹泻、腹痛,与镁制抗酸药合用增加腹泻,前列腺素E1类似物,X,正常剂量,正常剂量,mg,口服,QID,2025-09-30,NMPA/国家基本药物目录,verified,前列腺素类
GI130,CA54143-56-5,0186-0897-20,,A02BA06,RX9002012,A2A2B3B3,CHEMBL1112,4135,DB00863,D00422,Roxatidine,Roxatidine,ROX,罗沙替丁,罗沙替丁醋酸酯胶囊,阿斯利康,国药准字J20171190,20,消化系统药物/H2受体拮抗剂,75mg/粒,75mg,每日2次,口服,消化性溃疡,对H2受体拮抗剂过敏者禁用,头痛、便秘,无明显药物相互作用,H2受体拮抗剂,B,CrCl<50需减量,正常剂量,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,H2受体拮抗剂
GI131,CA90-05-1,0186-0898-30,,A07EA06,RX9002013,B3B3C4C4,CHEMBL1113,3811,DB00365,D00455,Smectite,Smectite,SME,思密达,蒙脱石散,博福-益普生,国药准字J20171191,20,消化系统药物/肠道吸附剂,3g/袋,3g,每日3次,口服,急慢性腹泻,肠梗阻禁用,便秘,影响其他药物吸收,肠道黏膜保护剂,B,正常剂量,正常剂量,g,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,肠道保护剂
GI132,CA99-20-7,0186-0899-40,,A06AX01,RX9002014,C4C4D5D5,CHEMBL1114,753,DB09279,D03961,Paraffin,Liquid Paraffin,PAR,石蜡油,液状石蜡,天津金耀,国药准字H12020184,21,消化系统药物/润滑性泻药,15ml/次,15-30ml,睡前服用,口服,便秘,肠梗阻禁用,肛门漏油、脂溶性维生素吸收障碍,影响脂溶性维生素吸收,润滑性泻药,C,正常剂量,正常剂量,ml,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,润滑性泻药
GI133,CA76-25-5,0186-0900-50,,A07DA01,RX9002015,D5D5E6E6,CHEMBL1115,5284517,DB09279,D03961,Trisilicate,Magnesium Trisilicate,MAG,三硅酸镁,三硅酸镁片,浙江莎普爱思,国药准字H33021207,20,消化系统药物/抗酸药,0.3g/片,0.6-1.2g,每日3-4次,口服,胃酸过多,肾功能不全禁用,便秘、镁蓄积,影响其他药物吸收,抗酸药,C,CrCl<30禁用,正常剂量,g,口服,TID-QID,2025-09-30,NMPA/国家基本药物目录,verified,抗酸药
HE111,CA102-76-1,0069-1110-10,,B03AA08,RX9002016,E6E6F7F7,CHEMBL1116,6093,DB13251,D00375,Ferric_citrate,Ferric Citrate,FeCit,枸橼酸铁,枸橼酸铁片,卫材,国药准字J20171192,26,血液系统药物/铁剂,210mg/片,210mg,每日3次,口服,缺铁性贫血、高磷血症,铁负荷过重禁用,便秘、腹泻,与抗酸药间隔服用,有机铁,A,正常剂量,正常剂量,mg,口服,TID,2025-09-30,NMPA/国家基本药物目录,verified,有机铁剂
HE112,CA9004-34-6,0069-1111-20,,B03AC05,RX9002017,F7F7G8G8,CHEMBL1117,16129622,DB08875,D04489,Ferric_carboxymaltose,Ferric Carboxymaltose,FCM,羧基麦芽糖铁,菲普利,威法,国药准字J20171193,26,血液系统药物/注射铁剂,500mg/支,500-1000mg,每周1次,静脉注射,口服铁剂无效的缺铁性贫血,铁负荷过重禁用,低血压、过敏反应,较右旋糖酐铁安全,新型注射铁剂,C,CrCl<30可用,正常剂量,mg,静脉注射,QW,2025-09-30,NMPA/国家基本药物目录,verified,新型注射铁剂
HE113,CA62-54-4,0069-1112-30,,B03BB01,RX9002018,G8G8H9H9,CHEMBL1118,6037,DB00163,D00258,Calcium_folinate,Leucovorin,LV,亚叶酸钙,亚叶酸钙注射液,辉瑞,国药准字H20033319,41,血液系统药物/叶酸类,50mg;100mg/支,10-15mg/m²,必要时给药,静脉注射,大剂量甲氨蝶呤解救,对亚叶酸过敏者禁用,过敏反应,与5-FU合用增强疗效,叶酸解救剂,C,正常剂量,正常剂量,mg/m²,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,叶酸解救剂
HE115,CA68-19-9,0069-1114-50,,B03BA01,RX9002020,I0I0J1J1,CHEMBL1120,6037,DB00163,D00166,Cyanocobalamin,Vitamin B12,VB12,氰钴胺,维生素B12注射液,华北制药,国药准字H11020302,41,血液系统药物/维生素B12,0.5mg/ml,0.1-0.5mg,每日1次,肌肉注射,巨幼红细胞性贫血,对钴过敏者禁用,过敏反应,与氯霉素拮抗,维生素B12,A/C,正常剂量,正常剂量,mg,肌肉注射,QD,2025-09-30,NMPA/国家基本药物目录,verified,维生素B12
HE116,CA63-74-1,0069-1115-60,,B02BD01,RX9002021,J1J1K2K2,CHEMBL1121,5281078,DB00166,D00071,Tranexamic_acid,Tranexamic Acid,TXA,氨甲环酸,氨甲环酸注射液,第一三共,国药准字J20171194,27,血液系统药物/抗纤溶药,0.5g/支,1g,每8小时一次,静脉注射,外伤出血、手术出血,血栓形成倾向禁用,血栓形成,与凝血酶合用协同,抗纤溶药,B,CrCl<50需减量,正常剂量,g,静脉注射,q8h,2025-09-30,NMPA/国家基本药物目录,verified,抗纤溶药
HE117,CA3546-10-9,0069-1116-70,,B02BD08,RX9002022,K2K2L3L3,CHEMBL1122,5282452,DB00166,D00071,Aminocaproic_acid,Aminocaproic Acid,EACA,氨基己酸,氨基己酸注射液,上海禾丰,国药准字H31020591,27,血液系统药物/抗纤溶药,2g/支,4-5g,首剂后1g/h,静脉注射,纤溶亢进性出血,血栓形成倾向、DIC禁用,血栓形成、肌病,与雌激素合用增加血栓风险,抗纤溶药,C,CrCl<30需减量,正常剂量,g,静脉注射,loading+continuous,2025-09-30,NMPA/国家基本药物目录,verified,抗纤溶药
HE118,CA6009-70-7,0069-1117-80,,B02BD03,RX9002023,L3L3M4M4,CHEMBL1123,5282452,DB00166,D00326,Aprotinin,Aprotinin,APR,抑肽酶,抑肽酶注射液,拜耳,国药准字J20171195,27,血液系统药物/蛋白酶抑制剂,10000KIU/ml,200万KIU,单次给药,静脉注射,心脏手术出血预防,对抑肽酶过敏者禁用,过敏反应、血栓形成,首次使用需做过敏试验,丝氨酸蛋白酶抑制剂,B,正常剂量,正常剂量,KIU,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,蛋白酶抑制剂
HE119,CA382-67-2,0069-1118-90,,B02BD02,RX9002024,M4M4N5N5,CHEMBL1124,5282452,DB00166,D00326,Carbazochrome,Carbazochrome,CAR,卡巴克洛,安络血注射液,山东鲁抗,国药准字H37021654,27,血液系统药物/止血药,10mg/ml,10-20mg,每日2-3次,肌肉注射,毛细血管性出血,血栓性疾病禁用,局部刺激,与其他止血药合用协同,降低毛细血管通透性,C,正常剂量,正常剂量,mg,肌肉注射,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,毛细血管止血药
HE120,CA305-03-3,0069-1119-01,,B02BA02,RX9002025,N5N5O6O6,CHEMBL1125,5282452,DB00166,D00071,Etamsylate,Etamsylate,ETA,酚磺乙胺,止血敏注射液,武汉远大,国药准字H42020514,27,血液系统药物/止血药,0.25g/ml,0.25-0.5g,每日2-3次,肌肉注射/静脉注射,毛细血管性出血,血栓性疾病禁用,头痛、皮疹,与其他止血药合用协同,降低毛细血管通透性,C,正常剂量,正常剂量,g,静脉注射,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,毛细血管止血药
EN207,CA64-86-8,0009-0029-20,,A11CC04,RX9002027,P7P7Q8Q8,CHEMBL1127,5280969,DB00162,D00071,Vitamin_D3,Cholecalciferol,VD3,维生素D3,维生素D3软胶囊,星鲨,国药准字H44024189,41,内分泌系统药物/维生素D,400IU;800IU/粒,400-800IU,每日1次,口服,维生素D缺乏、佝偻病,高钙血症禁用,高钙血症,与噻嗪类利尿剂合用增加高钙风险,促进钙吸收,A/C,正常剂量,正常剂量,IU,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,维生素D3
EN208,CA50906-05-3,0009-0030-30,,A11CC05,RX9002028,Q8Q8R9R9,CHEMBL1128,5280795,DB00146,D00187,Calcitriol,Calcitriol,CAL,骨化三醇,罗钙全,罗氏,国药准字J20171196,41,内分泌系统药物/维生素D类似物,0.25μg/粒,0.25-1μg,每日1次,口服,慢性肾病矿物质代谢紊乱、骨质疏松,高钙血症禁用,高钙血症,监测血钙,活性维生素D,C,CrCl<15需监测,正常剂量,μg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,活性维生素D
EN209,CA66376-36-1,0009-0031-40,,H05AA03,RX9002029,R9R9S0S0,CHEMBL1129,60764,DB00710,D00942,Alfacalcidol,Alfacalcidol,ALF,阿法骨化醇,阿法迪三,正大丰海,国药准字H20010716,41,内分泌系统药物/维生素D类似物,0.25μg;0.5μg/粒,0.5-1μg,每日1次,口服,慢性肾病矿物质代谢紊乱,高钙血症禁用,高钙血症,监测血钙,1α-羟基维生素D3,C,CrCl<15需监测,正常剂量,μg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,维生素D类似物
EN210,CA9002-72-6,0009-0032-50,,H01AC01,RX9002030,S0S0T1T1,CHEMBL1130,16130927,DB00067,D02691,Somatropin,Growth Hormone,GH,重组人生长激素,安苏萌,安科生物,国药准字S20050051,28,内分泌系统药物/生长激素,4IU/支,0.1-0.15IU/kg,每日1次,皮下注射,生长激素缺乏症,肿瘤、严重疾病急性期禁用,头痛、关节痛、水钠潴留,与糖皮质激素合用降低疗效,睡前注射,C,正常剂量,正常剂量,IU/kg,皮下注射,qhs,2025-09-30,NMPA/国家基本药物目录,verified,生长激素
EN211,CA16679-58-6,0009-0033-60,,H01BB01,RX9002031,T1T1U2U2,CHEMBL1131,439302,DB00107,D00089,Vasopressin,Vasopressin,AVP,垂体后叶素,垂体后叶素注射液,上海禾丰,国药准字H31020592,32,内分泌系统药物/垂体激素,5U/ml,5-10U,必要时重复,静脉注射/肌肉注射,消化道出血、尿崩症,冠心病、高血压禁用,血压升高、心绞痛,与硝酸甘油合用降低血压升高,血管加压素,C,正常剂量,正常剂量,IU,静脉注射,prn,2025-09-30,NMPA/国家基本药物目录,verified,垂体后叶激素
EN212,CA6533-00-2,0009-0034-70,,H02AB06,RX9002032,U2U2V3V3,CHEMBL1132,31263,DB00860,D00292,Prednisolone_acetate,Prednisolone Acetate,PDA,醋酸泼尼松龙,醋酸泼尼松龙片,天津天药,国药准字H12020185,30,内分泌系统药物/糖皮质激素,5mg/片,5-60mg,每日1-4次,口服,自身免疫性疾病,全身真菌感染禁用,库欣综合征、骨质疏松,与NSAIDs合用增加胃肠道风险,中效糖皮质激素,C,正常剂量,肝功能不全时监测,mg,口服,QD-QID,2025-09-30,NMPA/国家基本药物目录,verified,中效糖皮质激素
EN213,CA50-24-8,0009-0035-80,,H02AB09,RX9002033,V3V3W4W4,CHEMBL1133,5754,DB00741,D00165,Hydrocortisone_sodium,Hydrocortisone Sodium Succinate,HCS,琥珀酸氢化可的松,氢化可的松注射液,天津金耀,国药准字H12020186,30,内分泌系统药物/糖皮质激素,0.1g/支,100-300mg,每6-8小时,静脉注射,肾上腺危象、严重过敏,全身真菌感染禁用,水钠潴留、高血糖,与NSAIDs合用增加胃肠道风险,短效糖皮质激素,C,正常剂量,正常剂量,mg,静脉注射,q6-8h,2025-09-30,NMPA/国家基本药物目录,verified,短效糖皮质激素注射剂
PS106,CA604-75-1,0008-0732-10,,N05AA02,RX9002036,Y6Y6Z7Z7,CHEMBL1136,4216,DB00477,D00238,Chlorpromazine,Chlorpromazine,CPZ,氯丙嗪,盐酸氯丙嗪片,上海信谊,国药准字H31020834,33,神经系统药物/典型抗精神病药,25mg;50mg;100mg/片,200-600mg,每日2-3次,口服,精神分裂症、躁狂症,昏迷、帕金森病禁用,锥体外系反应、直立性低血压,与CNS抑制剂合用增强作用,典型抗精神病药,C,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,典型抗精神病药
PS107,CA50-53-3,0008-0733-20,,N05AH04,RX9002037,Z7Z7A8A8,CHEMBL1137,3559,DB00734,D00563,Haloperidol,Haloperidol,HAL,氟哌啶醇,氟哌啶醇片,西安杨森,国药准字H10940156,33,神经系统药物/典型抗精神病药,1.5mg;5mg/片,5-20mg,每日2-3次,口服,精神分裂症、躁狂症,昏迷、帕金森病禁用,锥体外系反应、QT延长,CYP2D6和3A4底物,监测QTc间期,C,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,典型抗精神病药
PS108,CA53-60-1,0008-0734-30,,N05AH03,RX9002038,A8A8B9B9,CHEMBL1138,4762,DB00850,D00238,Perphenazine,Perphenazine,PPZ,奋乃静,奋乃静片,上海信谊,国药准字H31020835,33,神经系统药物/典型抗精神病药,2mg;4mg/片,12-24mg,每日2-3次,口服,精神分裂症,昏迷、帕金森病禁用,锥体外系反应、直立性低血压,与CNS抑制剂合用增强作用,典型抗精神病药,C,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,典型抗精神病药
PS109,CA84-97-9,0008-0735-40,,N06AA09,RX9002039,B9B9C0C0,CHEMBL1139,2160,DB00543,D00823,Amitriptyline,Amitriptyline,AMI,阿米替林,盐酸阿米替林片,常州四药,国药准字H32020837,33,神经系统药物/三环类抗抑郁药,25mg/片,75-150mg,每日1-3次,口服,抑郁症、神经病理性疼痛,急性心肌梗死、青光眼、与MAOIs合用禁忌,口干、便秘、心律失常,CYP2D6底物,三环类抗抑郁药,C,正常剂量,肝功能不全需减量,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,三环类抗抑郁药
PS110,CA50-47-5,0008-0736-50,,N06AA02,RX9002040,C0C0D1D1,CHEMBL1140,2396,DB00458,D00809,Imipramine,Imipramine,IMI,丙米嗪,盐酸丙米嗪片,常州四药,国药准字H32020838,33,神经系统药物/三环类抗抑郁药,25mg/片,75-150mg,每日1-3次,口服,抑郁症,急性心肌梗死、与MAOIs合用禁忌,口干、便秘、心律失常、体位性低血压,CYP2D6底物,三环类抗抑郁药,D,正常剂量,肝功能不全需减量,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,三环类抗抑郁药
PS111,CA438-41-5,0008-0737-60,,N05CF,RX9002041,D1D1E2E2,CHEMBL1141,4386,DB00334,D08690,Zaleplon,Zaleplon,ZAL,扎来普隆,扎来普隆胶囊,卫材,国药准字J20171198,34,神经系统药物/非苯二氮䓬类催眠药,5mg;10mg/粒,5-10mg,睡前服用,口服,失眠,重症肌无力禁用,头晕、嗜睡,CYP3A4底物,"Z药物,超短效",C,正常剂量,肝功能不全需减量,mg,口服,qhs,2025-09-30,NMPA/国家基本药物目录,verified,Z药物
PS114,CA13655-52-2,0008-0740-90,,N05BA12,RX9002044,G4G4H5H5,CHEMBL1144,2704,DB00404,D00365,Alprazolam,Alprazolam,ALP,阿普唑仑,佳静安定,辉瑞,国药准字H20033075,34,神经系统药物/苯二氮䓬类,0.4mg;0.8mg/片,0.4-2.4mg,每日2-3次,口服,焦虑症、惊恐障碍,急性闭角型青光眼、重症肌无力禁用,嗜睡、依赖性,与CYP3A4抑制剂合用增加血药浓度,短中效苯二氮䓬类,D,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,抗焦虑药
PS115,CA59467-70-8,0008-0741-01,,N05BA08,RX9002045,H5H5I6I6,CHEMBL1145,2997,DB00186,D00366,Lorazepam,Lorazepam,LOR,劳拉西泮,罗拉,惠氏,国药准字J20171201,34,神经系统药物/苯二氮䓬类,1mg;2mg/片,2-6mg,每日2-3次,口服,焦虑症,急性闭角型青光眼、重症肌无力禁用,嗜睡、依赖性,与CNS抑制剂合用增强作用,中效苯二氮䓬类,D,正常剂量,肝功能不全需减量,mg,口服,BID-TID,2025-09-30,NMPA/国家基本药物目录,verified,抗焦虑药
AL101,CA154-69-8,0173-0500-10,,R06AX27,RX9002046,I6I6J7J7,CHEMBL1146,3957,DB00283,D00238,Cetirizine,Cetirizine,CET,西替利嗪,仙特明,优时比,国药准字J20171202,25,抗过敏药/第二代抗组胺药,10mg/片,10mg,每日1次,口服,过敏性鼻炎、荨麻疹,对西替利嗪过敏者禁用,嗜睡、头痛,与CNS抑制剂合用增强作用,第二代抗组胺药,B,CrCl<30需减量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,第二代抗组胺药
AL102,CA83799-24-0,0173-0501-20,,R06AX13,RX9002047,J7J7K8K8,CHEMBL1147,3957,DB00341,D07402,Loratadine,Loratadine,LOR,氯雷他定,克敏能,先灵葆雅,国药准字J20171203,25,抗过敏药/第二代抗组胺药,10mg/片,10mg,每日1次,口服,过敏性鼻炎、荨麻疹,对氯雷他定过敏者禁用,头痛、嗜睡,CYP3A4和2D6底物,第二代抗组胺药,B,正常剂量,肝功能不全需减量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,第二代抗组胺药
AL103,CA100643-71-8,0173-0502-30,,R06AX29,RX9002048,K8K8L9L9,CHEMBL1148,1549000,DB00967,D07662,Desloratadine,Desloratadine,DES,地氯雷他定,芙必叮,先灵葆雅,国药准字J20171204,25,抗过敏药/第二代抗组胺药,5mg/片,5mg,每日1次,口服,过敏性鼻炎、荨麻疹,对地氯雷他定过敏者禁用,头痛、口干,无明显药物相互作用,氯雷他定活性代谢物,C,正常剂量,肝肾功能不全慎用,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,第二代抗组胺药
AL104,CA83881-52-1,0173-0503-40,,R06AX26,RX9002049,L9L9M0M0,CHEMBL1149,3348,DB00950,D07956,Fexofenadine,Fexofenadine,FEX,非索非那定,艾来,赛诺菲,国药准字J20171205,25,抗过敏药/第二代抗组胺药,60mg;120mg;180mg/片,60-180mg,每日1-2次,口服,过敏性鼻炎、荨麻疹,对非索非那定过敏者禁用,头痛、恶心,与果汁同服降低吸收,第二代抗组胺药,C,正常剂量,正常剂量,mg,口服,QD-BID,2025-09-30,NMPA/国家基本药物目录,verified,第二代抗组胺药
AL105,CA73-48-3,0173-0504-50,,R06AX17,RX9002050,M0M0N1N1,CHEMBL1150,667490,DB01620,D00238,Ketotifen,Ketotifen,KET,酮替芬,酮替芬片,北京双鹤,国药准字H11020519,25,抗过敏药/抗组胺药,1mg/片,2mg,每日2次,口服,过敏性鼻炎、哮喘预防,对酮替芬过敏者禁用,嗜睡、体重增加,与CNS抑制剂合用增强作用,抗组胺+肥大细胞稳定,C,正常剂量,正常剂量,mg,口服,BID,2025-09-30,NMPA/国家基本药物目录,verified,抗组胺药
NU103,CA79-81-2,0069-1202-30,,A11HA05,RX9002053,P3P3Q4Q4,CHEMBL1153,135,DB00141,D00068,Pantothenic_acid,Pantothenic Acid (Vitamin B5),VB5,泛酸钙,泛酸钙片,华北制药,国药准字H11020305,41,维生素/水溶性维生素,10mg/片,10-20mg,每日1-3次,口服,泛酸缺乏,无禁忌症,罕见不良反应,无明显药物相互作用,辅酶A前体,A,正常剂量,正常剂量,mg,口服,QD-TID,2025-09-30,NMPA/国家基本药物目录,verified,维生素B5
NU104,CA7439-89-6,0069-1203-40,,B05XA03,RX9002054,Q4Q4R5R5,CHEMBL1154,23925,DB01592,D00166,Iron,Elemental Iron,Fe,铁,复合维生素铁片,惠氏,国药准字H10950023,26,矿物质/铁剂,60mg元素铁/片,60mg,每日1次,口服,缺铁性贫血,铁负荷过重禁用,胃肠道反应,与抗酸药间隔服用,元素铁,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,铁剂
NU105,CA7440-66-6,0069-1204-50,,A12AA01,RX9002055,R5R5S6S6,CHEMBL1155,23978,DB01593,D00166,Zinc,Zinc,Zn,锌,葡萄糖酸锌片,华北制药,国药准字H11020306,42,矿物质/锌剂,10mg元素锌/片,10-30mg,每日1次,口服,锌缺乏,无禁忌症,胃肠道反应,与铁剂、钙剂间隔服用,微量元素,A,正常剂量,正常剂量,mg,口服,QD,2025-09-30,NMPA/国家基本药物目录,verified,锌剂
AN201,CA91-64-5,0069-7200-10,,V03AB06,RX9002056,S6S6T7T7,CHEMBL1156,2812,DB00537,D00166,Sodium_thiosulfate,Sodium Thiosulfate,STS,硫代硫酸钠,硫代硫酸钠注射液,上海禾丰,国药准字H31020593,32,解毒药/氰化物解毒剂,10g/支,12.5g,单次给药,静脉注射,氰化物中毒,无禁忌症,恶心、低血压,与亚硝酸盐联用,氰化物解毒,C,正常剂量,正常剂量,g,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,氰化物解毒剂
AN203,CA62-74-8,0069-7202-30,,V03AB31,RX9002058,U8U8V9V9,CHEMBL1158,2566,DB00531,D00166,Sodium_nitrite,Sodium Nitrite,NaNO2,亚硝酸钠,亚硝酸钠注射液,上海禾丰,国药准字H31020594,32,解毒药/氰化物解毒剂,0.3g/支,300mg,单次给药,静脉注射,氰化物中毒,高铁血红蛋白血症禁用,高铁血红蛋白血症、低血压,与硫代硫酸钠联用,氰化物解毒,C,正常剂量,正常剂量,mg,静脉注射,single,2025-09-30,NMPA/国家基本药物目录,verified,氰化物解毒剂
AN205,CA51-15-0,0069-7204-50,,V03AB04,RX9002060,W0W0X1X1,CHEMBL1160,6011,DB00668,D00166,Pralidoxime,Pralidoxime,PAM,氯解磷定,氯解磷定注射液,上海禾丰,国药准字H31020596,32,解毒药/胆碱酯酶复活剂,0.5g/支,0.5-1g,每4-6小时,静脉注射/肌肉注射,有机磷农药中毒,对氯解磷定过敏者禁用,头晕、心动过速,与阿托品联用,胆碱酯酶复活剂,C,肾功能不全需减量,正常剂量,g,静脉注射,q4-6h,2025-09-30,NMPA/国家基本药物目录,verified,胆碱酯酶复活剂
DI101,CA73-48-3,0173-0600-10,,V04CL,RX9002061,X1X1Y2Y2,CHEMBL1161,667490,DB01620,D00238,Tuberculin,Tuberculin PPD,PPD,结核菌素,结核菌素纯蛋白衍生物,成都生物,国药准字S19993001,48,诊断用药/皮试抗原,5TU/0.1ml,0.1ml,单次皮试,皮内注射,结核病筛查,活动性结核禁用,局部红肿,48-72小时读取结果,结核筛查,C,正常剂量,正常剂量,ml,皮内注射,single,2025-09-30,NMPA/国家基本药物目录,verified,结核菌素试验
FL101,CA7647-14-5,0069-8100-10,,B05XA03,RX9002062,Y2Y2Z3Z3,CHEMBL1162,5234,DB09153,D00166,Sodium_chloride,Sodium Chloride,NaCl,氯化钠,氯化钠注射液,石药集团,国药准字H13022064,32,电解质补充剂/钠盐,0.9%/100ml;0.9%/250ml;0.9%/500ml,按需,持续输注,静脉注射,脱水、电解质紊乱,高钠血症、水肿禁用,高钠血症、水钠潴留,与强心苷合用需监测,生理盐水,C,肾功能不全需监测,正常剂量,ml,静脉注射,continuous,2025-09-30,NMPA/国家基本药物目录,verified,生理盐水
FL103,CA7447-40-7,0069-8102-30,,B05XA01,RX9002064,A4A4B5B5,CHEMBL1164,24393,DB00761,D00166,Potassium_chloride,Potassium Chloride,KCl,氯化钾,氯化钾注射液,石药集团,国药准字H13022066,32,电解质补充剂/钾盐,10%/10ml,10-40mEq,缓慢输注,静脉注射,低钾血症,高钾血症、肾衰竭禁用,高钾血症、心律失常,输注速度<20mEq/h,补钾,C,CrCl<30禁用,正常剂量,mEq,静脉注射,slow infusion,2025-09-30,NMPA/国家基本药物目录,verified,氯化钾注射液
FL104,CA7487-88-9,0069-8103-40,,B05XA10,RX9002065,B5B5C6C6,CHEMBL1165,24844,DB01378,D00166,Magnesium_sulfate,Magnesium Sulfate,MgSO4,硫酸镁,硫酸镁注射液,石药集团,国药准字H13022067,32,电解质补充剂/镁盐,10%/10ml;25%/10ml,1-2g,缓慢输注,静脉注射,低镁血症、子痫前期,肾功能不全、心脏传导阻滞禁用,潮红、低血压、呼吸抑制,监测镁浓度,补镁+抗惊厥,B,CrCl<30禁用,正常剂量,g,静脉注射,slow infusion,2025-09-30,NMPA/国家基本药物目录,verified,硫酸镁注射液
FL105,CA144-55-8,0069-8104-50,,B05XA02,RX9002066,C6C6D7D7,CHEMBL1166,5460341,DB01390,D00166,Sodium_bicarbonate,Sodium Bicarbonate,NaHCO3,碳酸氢钠,碳酸氢钠注射液,石药集团,国药准字H13022068,32,电解质补充剂/碱性药,5%/100ml;5%/250ml,按需,持续输注,静脉注射,代谢性酸中毒,代谢性碱中毒、低钙血症禁用,代谢性碱中毒、高钠血症,监测血气和电解质,纠正酸中毒,C,肾功能不全需监测,正常剂量,ml,静脉注射,continuous,2025-09-30,NMPA/国家基本药物目录,verified,碳酸氢钠注射液
